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ABSTRACT 
 
 
The cell cycle theory of Alzheimer’s Disease (AD) states that neurodegeneration is 
secondary to aberrant cell cycle activity in neurons.  Previous studies suggest that this may 
be partly attributed to alterations in the mTOR pathway, which promotes cell growth and 
division, and partly to genetic variants on genes responsible for cell cycle control.    
 
In this study we perform a systematic analysis of the rapamycin-regulated genes that are 
differentially regulated in brain affected by AD compared to control.  These genes may serve 
as novel therapeutic targets or biomarkers of AD.  Secondly, we investigate the association 
of a cancer-associated variant of p21
cip1
, and a variant of p57
kip2
, with AD.  These cyclin 
dependent kinase inhibitors are crucial cell cycle regulatory components that function 
downstream of mTOR.  We confirm the association of the p21
cip1
 SNPs with AD, and inform 
on the mechanisms by which they cause loss of function.  We also show a weak association 
between variant p57
kip2
 and AD.  Furthermore, we demonstrate that p57
kip2
 is differentially 
imprinted in the frontal and occipital lobe; and suggest that AD may be associated with 
change in the imprinting status of p57
kip2
 in the brain.   
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1. INTRODUCTION 
 
Late-onset Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects 
primarily the limbic and cortical brain regions responsible for memory, learning and emotion 
(for review see
1
).  Risk factors include increasing age, poor diet, high homocysteine, low 
educational level and head trauma.  There is a strong genetic component to AD, as indicated 
by studies suggesting a heritability of 60-80%
2, 3
.  However, few associated genes are 
currently established.  The reality of today’s ageing population is adding to the financial and 
social burden of AD, with an estimated 15% of the population above the age of 65 affected: 
this figure increasing to ~50% of the population over the age of 85
4
.     
 
1.1. PATHOLOGICAL HALLMARKS OF AD 
 
The pathological hallmarks of AD are the extracellular beta-amyloid plaques and 
intracellular neurofibrillary tangles (NFT) that accumulate in the brain, accompanied by 
extensive neuronal cell death
5
.  Beta-amyloid is a 39 to 43 amino acid cleavage product of 
the amyloid precursor protein (APP)
1
.  The function of APP is poorly understood, although it 
has been implicated in neuronal and synaptic function
6, 7
.  In healthy brain it is processed by 
secretases to produce various soluble cleavage products.  However, pathological processing 
by beta- and gamma-secretases results in the production of insoluble beta-amyloid that 
accumulates in the brain in AD.  Interestingly, whilst extracellular beta-amyloid plaques are 
one of the hallmarks of AD, plaques may also accumulate in the brain of subjects with no 
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symptoms of AD, although generally at low levels.  Studies show that there is a relatively 
poor correlation between the number of plaques and severity of AD
8
. 
  
NFT are composed of paired helical filaments (PHF) of hyperphosphorylated tau, and 
accumulate inside neurons in AD.  Tau is an intracellular scaffolding protein that stabilises 
microtubules in neurons
9
.  The microtubule structure is dependent on the phosphorylation 
status of tau: with sequential phosphorylation and dephosphorylation driving the structural 
changes required for activities such as axonal transport and neurite outgrowth.  In AD, tau is 
pathologically hyperphosphorylated, resulting in the formation of the PHF that aggregate to 
form insoluble intracellular NFTs
10
.   
 
1.2. DIAGNOSIS  
 
Currently, there is no definitive diagnostic test for AD.  Diagnosis is based on clinical 
examination, and can be confirmed at post-mortem by the presence of AD-related brain 
pathology
11
.  The Cambridge Cognitive Examination (CAMCOG) is a standardised 
cognitive performance test that is used to estimate severity of dementia, and forms part of the 
Cambridge Examination for Mental Disorders of the Elderly
12, 13
.  On post-mortem, the 
Consortium to Establish a Registry for Alzheimer’s disease (CERAD) Neuropathology 
Assessment
14
 is a standardised system for diagnosing AD, and relies on the presence and 
location of senile plaques (beta-amyloid deposits associated with diseased neurites) in the 
brain, and the age of the patient at death.   
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The Braak staging system
15
 is used to estimate the severity and progression of AD.  It relies 
on the fact that tau pathology has a characteristic distribution in AD; and that the spread and 
density of NFTs correlates well with disease severity
16, 17
.  The accumulation of tau 
pathology in the entorhinal cortex is defined as preclinical AD (entorhinal stage); tau 
pathology in the entorhinal and limbic regions is defined as mild AD (limbic stage); whereas 
additional spread to the neocortical areas is defined as advanced AD (neocortical stage). 
   
1.3. TREATMENT AND BIOMARKERS OF DISEASE 
 
AD is currently incurable: with the majority of treatments focused on the management of 
symptoms
1
.  Despite the identification of numerous risk factors, very little can be done to 
prevent or improve the course of the disease, highlighting the need for more research.  The 
absence of a reliable diagnostic test is hugely problematic to research, as preclinical and mild 
AD sufferers cannot be reliably identified, making early targeted clinical drug trials 
impossible.  The search is on to identify biomarkers of AD that could be used to diagnose 
pre-clinical AD and monitor AD progression
18
.  An ideal biomarker would be a reliable 
predictor of disease, and easily measurable (for example, from blood).   
 
1.4. AD PATHOGENESIS 
 
The reasons neurons degenerate in AD are not fully understood.  Numerous theories exist; 
mainly focusing on the hallmarks of AD.  The amyloid cascade hypothesis suggests that 
neurodegeneration is secondary to beta-amyloid deposition
19
, based on the finding that 
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aggregates of beta-amyloid accumulate in the brain in AD, often in close proximity to areas 
of neurodegeneration
20
.  Furthermore, mutations of APP and the presenilin genes (involved 
in APP processing) that result in rapid accumulation of beta-amyloid in the brain are 
associated with early-onset AD
20
.  Similarly, the tau hypothesis states that neurodegeneration 
is secondary to NFT accumulation in neurons, based on the finding that spread of tau 
pathology is closely related to disease severity
15
.  
 
Whether the hallmarks are a cause or consequence of AD remains controversial.  Neither the 
amyloid nor tau hypotheses
10, 19
 satisfactorily explain the accumulation of the other hallmark.  
Whilst they may partially explain the progressive character of the disease (for example, beta-
amyloid peptides have been found to be neurotoxic in the presence of tau pathology
21
), there 
is no explanation for how or why AD initiates. 
 
Studies show that the heritability of late-onset AD is 60-80%
2, 3
, indicating that there is a 
strong genetic component to AD.  However, despite extensive research, few associated genes 
are currently known.  The Apolipoprotein E (ApoE) gene is the main established risk factor 
for late-onset AD
22, 23
, with the ApoE 4 allele significantly associated with increased risk 
and earlier age of onset
24
.  The ApoE 3 allele has no effect on AD risk, whereas the ApoE 
2 allele may be protective.  The mechanism by which the ApoE 4 allele is detrimental to 
brain function remain unclear, although the ApoE gene is known to be involved in lipid 
transport during synaptic remodelling and mitochondrial metabolism in the central nervous 
system
25
.   
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Oxidative stress has also been implicated in AD pathogenesis
11, 26-28
; as has neuronal cell 
cycle activity.  The cell cycle hypothesis of AD postulates that neurodegeneration in AD is 
secondary to aberrant neuronal cell cycle activity
29, 30
.   
 
1.5. ROLE OF THE CELL CYCLE IN AD 
 
1.5.1 The cell cycle 
 
The cell cycle is a sequence of four defined phases, namely: first gap phase (G1), DNA 
synthesis phase (S), second gap phase (G2) and mitosis phase (M).  The entry into the cell 
cycle is driven by signalling from various growth factors, cytokines and other mitogenic 
factors, resulting in the expression of Cyclin D, an activator of cyclin dependent kinase-4 
(CDK4) and CDK6.  The kinase activity of CDK4/6 is required for progression through the 
G1 phase.  At each phase of the cell cycle, progression is driven by the activity of a specific 
cyclin/CDK complex: with progression through the G1/S, S/G2 and G2/M checkpoints 
requiring the activity of cyclin E/CDK2, cyclin A/CDK2 and cyclin A or B/CDK1 
respectively (Figure 1).  
 
Chapter 1  Introduction                     
6 
 
 
Figure 1 Overview of cyclin/CDK interactions required for progression through 
G1, S, G2 and M phase of the cell cycle.  
    
Cell cycle activity is tightly regulated: with the cyclin dependent kinase inhibitors (CDKI) 
largely responsible for the checkpoints that regulate progression, by directly inhibiting the 
activity of cyclin/CDK complexes.  They are turned on in response to intra- and extra-
cellular signals to prevent cell division.  The CDKI: p21
cip1 
inhibits CDK2 activation by 
cyclin A and cyclin E, and inhibits various other cyclin/CDK complexes to some extent
31
.  
Its expression is regulated on a transcriptional level by the p53 tumour suppressor pathway: 
with DNA damage triggering up-regulation.  The activity of CDK2 is necessary for cell 
cycle progression through the G1/S and S/G2 checkpoints, so p21
cip1
 is an inhibitor at 
several cell cycle stages
32
.   P21
cip1
 is also involved in regulating apoptosis, and directly 
inhibits DNA replication by interacting with proliferating cell nuclear antigen (PCNA) 
(reviewed in
31
).   
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Similarly, the CDKI: p57
kip2
 inhibits CDK2 activation by cyclin A and E; and CDK4/6 
activation by cyclin D, thereby inhibiting cell cycle progression at several cell cycle phases.  
It has a number of additional functions, including involvement in the regulation of apoptosis 
and cytoskeleton dynamics
33
.  It is the only member of the cip/kip family of CDKI found to 
be essential during development: with knock-out mice suffering severe developmental 
abnormalities and premature death.  p57
kip2
 is also the only cip/kip family member that is 
imprinted: with the maternal allele preferentially expressed (reviewed in
33
).         
 
1.6. CELL CYCLE REGULATORY FAILURE IN AD 
 
Whilst neurons were historically thought to be terminally differentiated, there is now 
considerable evidence to indicate that this is not the case and that neurons can in fact re-enter 
the cell cycle
34, 35
.  Whether re-entry is part of the lifespan of a healthy neuron, or restricted 
to diseased neuronal states, remains unclear.  It is possible that the re-entry into the early G1 
phase may be a necessary step for synaptic plasticity and brain remodelling, as suggested by 
Arendt
36-38
.  However, healthy neurons are not thought to pass the G1/S checkpoint, but 
instead return to resting phase when remodelling is complete.   
 
The association of AD with neuronal cell cycle activity prompted the cell cycle theory of AD 
that states that neurodegeneration is secondary to aberrant neuronal cell cycle re-entry and 
subsequent G1/S checkpoint failure
29, 30
.   Neurons do not possess the machinery necessary 
for successful division or apoptosis, so are forced into a prolonged period of inappropriate 
activity, culminating in cell death.  This is supported by the observation that levels of various 
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growth and mitogenic factors are raised in the brain of patients with mild AD
39-43
.  
Furthermore, AD neurons express proteins involved in the cell cycle (e.g. cell cycle 
markers): including proteins involved beyond G1 phase
44-52
.   In addition, a number of 
studies demonstrate that a small proportion of neurons in AD brain (up to 10%) have 
replicated their DNA
53, 54
.  It appears that cell cycle regulation may be defective in AD.  For 
example, cell cycle regulators are expressed at high levels in AD brain, but may be 
inappropriately located in the cytoplasm rather than in the nucleus 
45, 48, 52
.  The nature of cell 
death in AD is also not fully understood
55
, although the slow course of the disease suggests 
that cells do not die simply by apoptosis. 
 
The cell cycle hypothesis goes further than the other theories in providing a link between the 
pathological hallmarks of AD.  The entry and progression of a cell through the cell cycle is 
driven by the activity of numerous kinases.  The microtubule associated protein: tau is one of 
the proteins involved in the re-organisation of the cytoskeleton during the cell cycle, and is 
also tightly regulated by phosphorylation
10
.  The aberrant re-entry into the cell cycle and 
inappropriate progression beyond the G1/S checkpoint may lead to inappropriate kinase 
activity, inappropriate phosphorylation of tau, and ultimately NFT formation
10
.  Cell cycle 
kinases are also involved in the processing of APP, potentially leadings to beta-amyloid 
deposition
43
.  Interestingly, beta-amyloid is a mitogen in vitro, which may contribute to the 
self-perpetuating nature of the disease
56, 57
.  Assuming Arendt’s theory36-38 is correct, the cell 
cycle hypothesis also fits with the overall picture of AD, as pathology characteristically 
spreads from more to less plastic areas of the brain
15
. 
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There is considerable evidence to suggest that the cell cycle regulatory failure that takes 
place in neurons in AD also occurs in other cell types of these patients
58-63
.  For example, 
there is an association between AD and some cancers
64-66
: with Burke and co-workers
67
 
demonstrating that AD patients have a higher risk of developing certain cancers than 
controls.  Furthermore, there is evidence to suggest that lymphocytes from AD patients 
respond inappropriately to mitogenic stimuli compared to lymphocytes from controls
11, 61, 68, 
69
.  In particular, the mammalian target of rapamycin (mTOR) signalling pathway that 
promotes cell growth, division and differentiation seems to be altered.  A study found altered 
expression of mTOR pathway component in lymphocytes from AD patients compared to 
controls
70
.  Furthermore, two studies have shown that peripheral lymphocytes from AD and 
mild cognitive impairment (MCI) patients have a reduced response to rapamycin: a potent 
upstream inhibitor of mTOR, compared to lymphocytes from controls
71, 72
.   
 
1.7. MTOR PATHWAY 
 
mTOR is a highly conserved serine-threonine kinase that is essential to the co-ordination of 
intra and extra-cellular signals concerning cell growth, division and differentiation.  It is 
found in two complexes within the cell: mTOR complex (mTORC) 1 and mTORC2
73
 that 
act upstream of the hugely complex mTOR pathway (Figure 2).    
 
The mTOR complexes are turned on in response to various upstream signals that promote 
cell division (for example, growth factors and hypoxia).  mTORC1 activates two translation 
initiation factors (4E-BP1 and p70S6K) that are needed for the synthesis of proteins required 
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for cell cycle initiation and progression
73
; whereas mTOR2 activates kinases involved in 
actin re-organisation: an integral part of the cell cycle.  Both complexes are part of an 
excitatory pathway that promotes proliferation; whereas their inactivation (by rapamycin) 
should actively inhibit proliferation.   
 
The fact that lymphocytes from AD patients have a reduced response to rapamycin (a potent 
cell cycle inhibitor) implies that the mTOR signalling pathway is inappropriately regulated 
in AD.  It is possible that the mTOR pathway components that are responsible for the cell 
cycle regulatory failure in lymphocytes may also be responsible for the cell cycle regulatory 
failure in neurons in AD.  The identification of these components is of vital importance as 
they may serve as novel drug targets for the treatment of AD, or may represent novel 
diagnostic biomarkers.   
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Figure 2 Simplified version of the mTOR signalling pathway.  The pathway 
responds to various upstream mitogenic signals, transmits the signals 
downstream, and culminates in the co-ordinated translation of various 
proteins requires for cell cycle activity. 
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1.8. CYCLIN DEPENDENT KINASE INHIBITORS (CDKI) 
 
The G1/S checkpoint is controlled by the cip/kip family of CDKIs, namely: p21
cip1
 
(CDKN1A), p27
kip1
 (CDKN1B) and p57
kip2
 (CDKN1C).  It is possible that genetic variants 
of the CDKIs, that have reduced expression or function, may contribute to the loss of G1/S 
checkpoint control that is postulated to be a cause of neurodegeneration in AD
29, 30, 74
.  
Interestingly, a common genetic variant of p21
cip1
 that is associated with an increased risk of 
cancer
75-79
 was also found to be associated with an increased risk and earlier age of onset of 
AD
74
.  The association with cancer implies that the variant has reduced function and/or 
expression: thereby limiting its ability to inhibit cyclin/CDK complexes, contributing to the 
loss of cell cycle control.  Furthermore, genetic linkage studies have identified variants of the 
6p21 loci, on which the p21
cip1 
gene is located, as associated with an increased risk of AD
80, 
80-83
.  This may indicate an association of the p21
cip1
 gene with AD.        
 
The p21
cip1
 variant has two polymorphisms: a cytosine to adenine change (SNP A) that 
induces a serine to alanine substitution at codon 31 of p21
cip175-79
, and a cytosine to thymine 
change (SNP B) in its 3-prime untranslated region (UTR)
76, 77
 (Figure 4 and 5).  It appears 
that the SNPs are only associated with cancer and AD when found together 
76, 77
.  SNP A 
triggers an amino acid change in the CDK inhibitory region of the p21
cip1
 protein, potentially 
altering its CDK binding capacity
74
.  SNP B is located within the 3’-UTR of p21cip1: a site 
involved in p21
cip1
 mRNA binding to various non-coding RNAs and proteins that regulate 
mRNA stability
84
.  This implies that SNP B may alter mRNA stability, potentially altering 
expression at the protein level.  
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The study
74
 also identified a SNP on p57
kip2 
 that may be associated with an earlier age of 
onset of AD
 
(Figure 3).  The SNP leads to an amino acid change within the central 
proline/alanine rich domain of p57
kip2
.  Currently, the SNP is not known to be associated 
with cancer.   The analysis of the SNP is complicated by the finding that p57
kip2
 is paternally 
imprinted in humans: with extent of imprinting tissue-dependent.  Its imprinting status in the 
brain is currently unknown
85
.   
 
Imprinting refers to the preferential expression of a gene of one parent of origin over 
another, and is regulated by various epigenetic mechanisms: for example, DNA methylation, 
histone modification and chromosome re-organisation.  The p57
kip2
 gene is located within a 
cluster of imprinted genes on 11p15.5: their imprinting controlled by a common imprinting 
control region (ICR) located within another gene member of the cluster.  Beckwich-
Wiederman syndrome, an overgrowth/cancer syndrome, is associated with inappropriate 
imprinting and expression of the imprinted genes within the 11p15.5 imprinted cluster
33
.  It 
is possible that inefficient imprinting of p57
kip2
 in the brain may alter p57
kip2
 expression, 
potentially contributing to the loss of cell cycle control that is postulated to be a cause of 
neurodegeneration in AD.  However, as very little is known about the imprinting status of 
p57
kip2
 in the human brain, research regarding normal imprinting status is necessary before 
conclusions can be drawn on imprinting status and disease.    
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1 MSDASLRSTS  TMERLVARGT  FPVLVRTSAC  RSLFGPVDHE  ELSRELQARL   
51 AELNAEDQNR  WDYDFQQDMP  LRGPGRLQWT  EVDSDSVPAF YRETVQVGRC  
101 RLLLAPRPVA  VAVAVSPPLE  PAAESLDGLE  EAPEQLPSVP  VPAPASTPPP  
151 VPVLAPAPAP  APAPVAAPVA  APVAVAVLAP  APAPAPAPAP  APAPVAAPAP  
201 APAPAPAPAP  APAPAPDAAP  QESAEQGANQ  GQRGQEPLAD  QLHSGISGRP  
251  AAGTAAASAN  GAAIKKLSGP  LISDFFAKRK  RSAPEKSSGD  VPAPCPSPSA  
301 APGVGSVEQT PRKRLR 
 
Figure 3 p57
kip2
 protein (316 amino acids): green represents CDK inhibitory 
domain; red represents codon 159 (altered by SNP); yellow represents 
the nuclear localisation signal. 
 
 
1 GCTGCCGAAG TCAGTTCCTT GTGGAGCCGG AGCTGGGCGC GGATTCGCCG AGGCACCGAG 
61 GCACTCAGAG GAGGTGAGAG AGCGGCGGCA GACAACAGGG GACCCCGGGC CGGCGGCCCA 
121 GAGCCGAGCC AAGCGTGCCC GCGTGTGTCC CTGCGTGTCC GCGAGGATGC GTGTTCGCGG 
181 GTGTGTGCTG CGTTCACAGG TGTTTCTGCG GCAGGCGCCA TGTCAGAACC GGCTGGGGAT 
241 GTCCGTCAGA ACCCATGCGG CAGCAAGGCC TGCCGCCGCC TCTTCGGCCC AGTGGACAGC 
301 GAGCAGCTGA GCCGCGACTG TGATGCGCTA ATGGCGGGCT GCATCCAGGA GGCCCGTGAG 
361 CGATGGAACT TCGACTTTGT CACCGAGACA CCACTGGAGG GTGACTTCGC CTGGGAGCGT 
421 GTGCGGGGCC TTGGCCTGCC CAAGCTCTAC CTTCCCACGG GGCCCCGGCG AGGCCGGGAT 
481 GAGTTGGGAG GAGGCAGGCG GCCTGGCACC TCACCTGCTC TGCTGCAGGG GACAGCAGAG 
541 GAAGACCATG TGGACCTGTC ACTGTCTTGT ACCCTTGTGC CTCGCTCAGG GGAGCAGGCT 
601 GAAGGGTCCC CAGGTGGACC TGGAGACTCT CAGGGTCGAA AACGGCGGCA GACCAGCATG 
661 ACAGATTTCT ACCACTCCAA ACGCCGGCTG ATCTTCTCCA AGAGGAAGCC CTAATCCGCC 
721 CACAGGAAGC CTGCAGTCCT GGAAGCGCGA GGGCCTCAAA GGCCCGCTCT ACATCTTCTG 
781 CCTTAGTCTC AGTTTGTGTG TCTTAATTAT TATTTGTGTT TTAATTTAAA CACCTCCTCA 
841 TGTACATACC CTGGCCGCCC CCTGCCCCCC AGCCTCTGGC ATTAGAATTA TTTAAACAAA 
901 AACTAGGCGG TTGAATGAGA GGTTCCTAAG AGTGCTGGGC ATTTTTATTT TATGAAATAC 
961 TATTTAAAGC CTCCTCATCC CGTGTTCTCC TTTTCCTCTC TCCCGGAGGT TGGGTGGGCC 
1021 GGCTTCATGC CAGCTACTTC CTCCTCCCCA CTTGTCCGCT GGGTGGTACC CTCTGGAGGG 
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1081 GTGTGGCTCC TTCCCATCGC TGTCACAGGC GGTTATGAAA TTCACCCCCT TTCCTGGACA 
1141 CTCAGACCTG AATTCTTTTT CATTTGAGAA GTAAACAGAT GGCACTTTGA AGGGGCCTCA 
1201 CCGAGTGGGG GCATCATCAA AAACTTTGGA GTCCCCTCAC CTCCTCTAAG GTTGGGCAGG 
1261 GTGACCCTGA AGTGAGCACA GCCTAGGGCT GAGCTGGGGA CCTGGTACCC TCCTGGCTCT 
1321 TGATACCCCC CTCTGTCTTG TGAAGGCAGG GGGAAGGTGG GGTCCTGGAG CAGACCACCC 
1381 CGCCTGCCCT CATGGCCCCT CTGACCTGCA CTGGGGAGCC CGTCTCAGTG TTGAGCCTTT 
1441 TCCCTCTTTG GCTCCCCTGT ACCTTTTGAG GAGCCCCAGC TACCCTTCTT CTCCAGCTGG 
1501 GCTCTGCAAT TCCCCTCTGC TGCTGTCCCT CCCCCTTGTC CTTTCCCTTC AGTACCCTCT 
1561 CAGCTCCAGG TGGCTCTGAG GTGCCTGTCC CACCCCCACC CCCAGCTCAA TGGACTGGAA 
1621 GGGGAAGGGA CACACAAGAA GAAGGGCACC CTAGTTCTAC CTCAGGCAGC TCAAGCAGCG 
1681 ACCGCCCCCT CCTCTAGCTG TGGGGGTGAG GGTCCCATGT GGTGGCACAG GCCCCCTTGA 
1741 GTGGGGTTAT CTCTGTGTTA GGGGTATATG ATGGGGGAGT AGATCTTTCT AGGAGGGAGA 
1801 CACTGGCCCC TCAAATCGTC CAGCGACCTT CCTCATCCAC CCCATCCCTC CCCAGTTCAT 
1861 TGCACTTTGA TTAGCAGCGG AACAAGGAGT CAGACATTTT AAGATGGTGG CAGTAGAGGC 
1921 TATGGACAGG GCATGCCACG TGGGCTCATA TGGGGCTGGG AGTAGTTGTC TTTCCTGGCA 
1981 CTAACGTTGA GCCCCTGGAG GCACTGAAGT GCTTAGTGTA CTTGGAGTAT TGGGGTCTGA 
2041 CCCCAAACAC CTTCCAGCTC CTGTAACATA CTGGCCTGGA CTGTTTTCTC TCGGCTCCCC 
2101 ATGTGTCCTG GTTCCCGTTT CTCCACCTAG ACTGTAAACC TCTCGAGGGC AGGGACCACA 
2161 CCCTGTACTG TTCTGTGTCT TTCACAGCTC CTCCCACAAT GCTGAATATA CAGCAGGTGC 
2221 TCAATAAATG ATTCTTAGTG ACTTTAAAAA AAAAAAAAAA AAAAA 
 
Figure 4  p21
cip1
 mRNA (2265 nucleotides): yellow represents translated region; 
red represents location of SNP A; blue represents location of SNP B. 
 
 
1 MSEPAGDVRQ  NPCGSKACRR  LFGPVDSEQL  SRDCDALMAG  CIQEARERWN   
51 FDFVTETPLE  GDFAWERVRG  LGLPKLYLPT  GPRRGRDELG  GGRRPGTSPA   
101 LLQGTAEEDH  VDLSLSCTLV  PRSGEQAEGS  PGGPGDSQGR  KRRQTSMTGK   
151 DRRRGGKILR  EAAC 
 
Figure 5 p21
cip1
 protein (164 amino acids): green represents the CDK inhibitory 
domain; red represents codon 31 (altered by SNP A); yellow represents 
the nuclear localisation signal. 
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1.9. AIMS 
 
The aims of the study were three fold.  Firstly, to identify the rapamycin-regulated genes that 
are differentially expressed in brain from AD patients compared to control.  These genes 
may play a causal role in the pathogenesis of AD, and may serve as novel drug targets or 
biomarkers of disease.  Genes were identified with a gene expression microarray: a sensitive 
tool that allows rapid screening of a large number of genes for differential expression in a 
group-of-interest compared to control.  A whole human genome microarray was used to 
identify genes that were rapamycin-regulated in lymphocytes by comparing expression in 
lymphocytes treated with rapamycin to expression in untreated lymphocytes.  A custom 
microarray was then created to include the identified rapamycin-response elements, plus 
established rapamycin-regulated genes, to allow screening for differential expression in AD 
brain compared to control.   
 
A second aim was to elucidate the effects of the p21
cip1
 SNPs on the risk of AD, the age of 
onset of AD, and the accumulation of AD-related pathology in the brain.  This was achieved 
by genotyping a cohort of AD patients for the p21
cip1
 SNPs, and quantifying various markers 
of AD-related pathology in the brain by enzyme linked immunosorbant assay (ELISA).  The 
effects of the p21
cip1
 SNPs on the function and stability of p21
cip1
 were determined by 
transient transfection of a vector containing the wild type or variant p21
cip1
 into a rapidly 
dividing cell line.  p21
cip1
 mRNA stability was determined by Q-PCR; p21
cip1
 expression 
determined by Acumen analysis after immunolabelling; and effects of the different versions 
of p21
cip1
 on cell cycle activity determined by Acumen cytometry.         
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A third aim was to investigate the imprinting status of p57
kip2
 in the brain, and the 
association of the imprinting status with AD.  Furthermore, we investigated the association 
of the p57
kip2
 SNP with AD, and the effects of the SNP on p57
kip2
 expression.  Elderly 
control and AD patients were genotyped for the p57
kip2
 SNP, and various markers of AD-
related pathology in the brain quantified by ELISA.  Individuals that were heterozygous for 
the p57
kip2
 SNP were informative in terms of imprinting status.  They were additionally 
genotyped from cDNA to establish whether there was preferential expression of one allele 
over another.  p57
kip2
 mRNA stability and p57
kip2
 expression were determined by Q-PCR and 
ELISA respectively.            
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2. MATERIALS AND METHODS 
 
2.1. PATIENTS AND BIOMATERIALS 
 
Human brain tissue collected by the Oxford Project to Investigate Memory and Aging 
(OPTIMA) was made available through the Thomas Willis brain bank.  In total, samples 
from 252 brains were available from a mix of elderly controls and patients suffering from 
preclinical, mild and severe AD at the time of death (as determined by Braak staging).  The 
number of cases included in the study was based on availability, not statistical power 
calculations, as the outcome, and hence number of patients in each group-of-interest, was 
unknown.  The tissue was snap frozen at the time of autopsy: and available from the lateral 
temporal lobe (severely affected by AD pathology), frontal lobe (affected by AD pathology) 
and occipital lobe (largely unaffected by AD pathology).  A wealth of clinical information 
was available for each subject, including: Braak stage (severity of AD); additional 
pathology; age of onset and age at death; personal and family history of cancer; plasma 
homocysteine level, and the results of annual clinical tests including test of cognitive 
performance (CAMCOG).   
 
2.2. DNA, RNA AND PROTEIN EXTRACTION 
 
RNA, DNA and protein were isolated from lateral temporal, frontal and occipital lobe tissue 
of each subject by TRI-reagent extraction.  Appendix 1 (Table 52) identifies the chemical 
manufacturers relating to this protocol.  100mg of frozen tissue was homogenised in 1ml 
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TRI-reagent, incubated at room temperature (RT) for 5 minutes, and supplemented with 
100µl 1-bromo-3-chloropropane.  Following 15 sec of vigorous mixing, the solution was 
incubated for 2 min and centifuged at 12,000 rotational centrifugal force (g) for 15 minutes 
at 4ºC to separate the RNA, DNA and protein layers.     
 
The aqueous RNA layer was supplemented with 500µl isopropanol and mixed gently by 
inversion.  After a five minute incubation, the solution was centrifuged at 12,000g for 8 
minutes at 4ºC.  The pellet was washed in 1ml 75% ethanol, centrifuged at 7,500g for 5 
minutes at 4ºC, and ethanol wash removed.  The pellet was air-dried for 30 minutes and 
rehydrated in 100µl nuclease free water by incubation at 55ºC for 15 minutes, prior to 
storage at -80ºC. 
 
RNA was converted to cDNA by reverse transcription.  10µg of RNA in a 50µl volume was 
added to 50µl of reverse transcriptase master mix (composed of 10µl 10 x reverse 
transcriptase buffer; 4 µl dNTP mix (100mM); 10µl random primers; 5µl MultiScribe 
Reverse Transcriptase (50U/µl); and 21µl nuclease free water), and incubated at 25ºC for 10 
minutes; 37ºC for 120 minutes; and 85ºC for 5 seconds in a Thermal cycler.  The cDNA was 
precipitated with isopropanol with pH correction (100µl cDNA supplemented with 20µl of 
3M sodium citrate at pH 5 and 400 µl isopropanol), centrifuged at high speed for 10 minutes, 
and the resulting pellet washed in ice cold ethanol.  Following high speed centrifugation and 
supernatant removal, the pellet was air dried overnight, rehydrated in 100µl nuclease free 
water and stored at 4ºC.  
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The remaining TRI-reagent layers were supplemented with 300µl ethanol, centrifuged at 
12,000g for 5 minutes at 4ºC, and supernatant transferred to a clean tube for subsequent 
protein extraction (see below).  The DNA pellet was washed three times, 1 hour per wash, in 
0.1M sodium citrate in 10% ethanol, with centrifugation at 12,000g for 5 minutes between 
each wash.  Following a 30 minute wash in 75% ethanol, the pellet was centrifuged at 
2,000g for 5 minutes, supernatant removed, and the pellet air dried overnight.  The pellet 
was dissolved in nuclease free water for 24 hours, centrifuged at 16,000g for 10 minutes, and 
supernatant transferred to a clean tube to separate DNA from the insoluble material.  The 
DNA was stored at 4ºC.   
 
The protein was precipitated by 15 minute incubation with 3 times its volume of acetone 
prior to centrifugation at 12,000g for 10 min at 4ºC.  The protein pellet was subjected to 
three 10 minute washes in 0.3M guanidine hydrochloride in 95% ethanol and 2.5% glycerol, 
and subsequently dissolved in radio-immunoprecipitation (RIPA) buffer (composition: 0.1M 
sodium chloride, 0.01M Tris hydrochloride, 1:500 EDTA, 400µg/ml 
phenylmethanesulfonylfluoride, 2µg/ml aprotinin and 1% sodium dodecyl sulphate).  The 
protein was stored at -20ºC. 
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2.3. GENE EXPRESSION MICROARRAY 
 
Two-colour microarray based gene expression analysis (Agilent Technologies) was used to 
identify genes that were differentially expressed in lymphocytes treated with rapamycin 
compared to lymphocytes that were left untreated (Agilent Whole Human Genome 
Microarray: 4x44K).  The identified differentially expressed genes were rapamycin-
regulated, and were screened in one-colour custom microarray based gene expression 
analysis (Agilent Technologies) for differential expression in brain affected by AD 
compared to control.  Appendix 1 (Table 53) outlines the chemical manufacturers relating to 
gene expression microarray.   
 
2.3.1 Two-colour microarray based gene expression analysis 
 
Lymphocyte cell culture and rapamycin treatment, in preparation for two-colour microarray 
based gene expression analysis, were carried out by Zsuzsanna Nagy, and are described in 
appendix 4.  RNA was extracted from the lymphocyte pellets by TRI-reagent method (as 
described in 2.2). To ensure that there was no DNA contamination, the RNA was treated 
with DNase prior to microarray analysis, by standard Qiagen protocol as described in 
appendix 2.  The RNA quality was determined by RNA nano-chip analysis on the Agilent 
2100 Bioanalyser, also by standard protocol
86
.  The RNA quality ranged from 8-10 RNA 
Integrity number
87
 (RIN): indicative of good quality RNA
88
 suitable for gene expression 
microarray. 
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2.3.1.1. Conversion of RNA to cDNA 
 
200ng of RNA was converted to cDNA with the low-input quick amplification labelling kit.  
Spike Mix A and B were prepared separately. For each, the spike mix was thawed and 
vortexed; incubated at 37ºC for 5 minutes; and diluted in the provided dilution buffer (see 
Table 1 for dilution protocol).  2µl of diluted spike mix A and spike mix B were added to 
200ng of RNA in a 1.5µl volume from the rapamycin-treated and untreated lymphocytes 
respectively.  The T7 promoter primer was prepared as shown in Table 2, and 1.8µl added 
per 3.5µl sample.  The samples were incubated at 65ºC for 10 minutes, and placed on ice for 
5 minutes.  The cDNA master mix was set up immediately prior to use as shown in Table 3.  
4.7µl of the cDNA master mix was added per sample; and samples incubated at 40ºC for 2 
hours; 70ºC for 15 minutes; and placed on ice for 5 minutes.     
 
Table 1 Preparation of Spike Mix A and Spike Mix B 
Starting amount of RNA Serial dilutions  
Total 
RNA  (ng) 
Concentration 
(ng/µl) 
First Second Third  Spike mix volume per 
labelling (µl) 
200 133.3 1:20 1:40 1:16 2 
 
Table 2 Dilution of T7 promoter primer 
Component (Agilent) Volume (µl) per reaction 
T7 promoter primer 0.8 
Nuclease free water 1 
Total volume 1.8 
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Table 3 cDNA master mix 
Components (Agilent) Volume (µl) per 
reaction 
5x first strand buffer  (pre-warmed at 80
o
C for 4 minutes prior to 
use) 
2 
0.1M DTT 1 
10mM dNTP mix  0.5 
AffinityScript RNase Block mix  1.2 
Total volume 4.7 
 
 
2.3.1.2. Conversion of cDNA to labelled cRNA 
 
The low-input quick amplification labelling kit was used to convert the cDNA to labelled 
cRNA.  The transcription master mix was set up immediately prior to use as shown in Table 
4.  Spike Mix A samples were added to transcription master mix prepared with Cyanine 3-
CTP (green); whereas Spike Mix B samples were added to transcription master mix prepared 
with Cyanine 5-CTP (red).  6µl of the transcription master mix was added per 10µl cDNA 
sample; and incubated at 40ºC for 2 hours. 
     
Chapter 2  Materials and Methods                    
24 
 
Table 4 Composition of transcription master mix 
Component (Agilent) Volume (µl) per reaction 
Nuclease free water  0.75 
5 x transcription buffer  3.2 
0.1 M DTT  0.6 
NTP mix  1 
T7 RNA polymerase Blend  
(store on ice until use) 
0.21 
Cyanine 3-CTP or Cyanine 5-CTP 0.24 
Total volume 6 
 
 
2.3.1.3. cRNA purification and quantification  
 
The cRNA was purified by standard RNeasy mini column protocol (Qiagen) as described in 
appendix 2.  The cRNA was quantified with a nanodrop spectrophotometer on the 
Microarray setting.  The yield and specific activity of the cRNA samples were calculated as 
follows: 
 
Yield    = Concentration of cRNA x remaining cRNA volume / 1000   
Specific activity  = Concentration of Cy3 or Cy5/ Concentration of cRNA x 1000    
 
The specific activity and yield of all the samples were greater than 6 and 825ng respectively, 
indicating suitability for hybridisation.   
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2.3.1.4. Hybridisation 
 
825ng of labelled cRNA was added to various fragmentation components as described in 
Table 5, incubated at 60ºC for 30 minutes, and cooled on ice for 1 minute.  55µl of GEx 
Hybridisation buffer HI-RPM was subsequently added to stop fragmentation.  The samples 
were mixed, centrifuged at 13,000 rotations per minute (RPM) for 1 minute, and placed on 
ice in preparation for microarray assembly.  The microarray of choice was the 4x44K 
Agilent Whole Human Genome Microarray.  A clean gasket slide was placed into the 
chamber base, 100µl of sample dispensed per well, and array placed onto the gasket slide to 
facilitate hybridisation.  The gasket and microarray slides were clamped together and 
incubated at 65ºC for 17 hours.   
 
Table 5 Components of Fragmentation mix 
Components (Agilent) Volume/ Mass (for 4x44K microarray) 
Cy3-labelled cRNA 825ng 
Cy5-labelled cRNA 825ng 
10 x blocking agent 11 µl 
Nuclease free water Bring total volume to 52.8 µl 
25 x fragmentation buffer 2.2 µl 
Total volume 55 µl 
 
Following hybridisation, the microarrays were washed in various wash solutions as 
described in Table 6.  To summarise, the microarrays were removed from the hybridisation 
assembly and carefully separated from the gasket slide whilst fully submersed in wash buffer 
1.  Slides were washed for 1 minute, transferred to wash buffer 2 at 37ºC for 1 minute, and 
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washed in acetonitrile for 10 seconds.  The final wash was in stabilisation and drying 
solution for 30 seconds.    The slides were air-dried and stored in a dark slide box in a 
nitrogen rich environment prior to scanning on the Agilent C Scanner.  The 
AgilentHD_GX_2color programme was used, and settings amended as shown in Table 7.   
   
Table 6 Microarray wash protocol 
Dish Wash buffer (Agilent) Temp Time 
1 GE Wash buffer 1 Room temperature 
(RT) 
 
2 GE Wash buffer 1 RT (with stir bar) 1 min 
3 GE Wash buffer 2 37ºC (with stir bar) 1 min 
4 Acetonitrile RT (with stir bar) 10 sec 
5 Stabilisation and drying solution 
(Agilent) 
RT (with stir bar) 30 sec 
 
 
Table 7 Microarray scanner settings for two-colour microarray based gene 
expression analysis (Agilent) 
 4x44K HD microarray format 
Dye Channel Red and Green 
Scan region Scan area (61 x 21.6mm) 
Scan resolution (µM) 5 
Tiff 20 bit 
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2.3.1.5. Data analysis: microarray 
 
The feature extraction programme was used to collate the Microarray layout with the output 
of the scanner.  The output was normalised to various housekeeping genes present on the 
microarray, and results processed to provide a list of genes that were differentially expressed 
in rapamycin-treated lymphocytes compared to untreated lymphocytes.  Estimates of the 
false discovery rate (FDR) were provided for each gene.  For the purpose of our study, genes 
with a FDR up to 10% were accepted as differentially expressed
89
.    
 
2.3.2 One-colour custom microarray based gene expression analysis (Agilent)  
 
8x 15K Custom Microarrays (Agilent Technologies: able to accommodate up to 15,000 
genes) were designed to include various housekeeping genes (719 genes), internal controls 
(3141 genes), and genes that were differentially expressed in AD brain relative to control 
brain based on a published dataset
90, 91
 (3718 genes).  The remaining 7422 spaces were filled 
with known rapamycin-regulated genes (based on an IPA Ingenuity search: see appendix 6, 
Table 58) and the genes that were identified as rapamycin-regulated in lymphocytes based 
on the two-colour microarray based gene expression analysis (see appendix 6, Table 56 and 
Table 57).  
 
Of the 252 subjects for whom tissue was available through the Thomas Willis brain bank, 32 
subjects were selected for one-colour custom microarray based gene expression analysis.  
They included control subjects and patients with mild and advanced AD.  The exclusion 
Chapter 2  Materials and Methods                    
28 
 
criteria were as follows: vascular disease; Parkinson’s disease; ApoE 2/2, ApoE 2/3 and 
ApoE 4/4 genotypes (not enough patients for meaningful statistical analysis); and high 
plasma homocysteine level (> 35 µM).     
 
2.3.2.1. Sample preparation 
 
RNA was extracted from the frontal lobe of each subject by TRI-reagent protocol as 
described in 2.2.  The RNA was treated with DNase as described in appendix 2.  The 
suitability of the RNA for microarray based gene expression analysis was determined by 
Agilent RNA nano-chip analysis.  RIN values ranged from 2-3 indicating relatively poor 
quality RNA.  However, this was unavoidable, as the source brain tissue had significant 
post-mortem time prior to freezing, resulting in inevitable degradation.   
 
2.3.2.2. Conversion of RNA to labelled cRNA 
 
200ng of RNA was converted to cDNA, and subsequently to labelled cRNA, with the low-
input quick amplification labelling kit.  The spike mix was incubated at 37ºC for 5 minutes, 
and diluted in the provided dilution buffer (Agilent Techologies) as shown in Table 8.  2µl of 
the diluted spike mix was added to the RNA (200ng) in a 1.5µl volume.  The next part of the 
labelling protocol was identical to that described in section 2.3.1.1 and 2.3.1.2.  Note that 
cyanine 3-CTP was used to label all samples.  The labelled and amplified cRNA samples 
were purified by standard Qiagen RNeasy mini column protocol, and quality assessed and 
quantified as described in section 2.3.1.3.    
Chapter 2  Materials and Methods                    
29 
 
Table 8 Preparation of Spike Mix 
Starting amount of RNA Serial dilutions  
Total 
RNA  
(ng) 
Concentration 
(ng/µl) 
First Second Third  Fourth Spike mix volume 
per labelling (µl) 
200 133.3 1:20 1:25 1:10  2 
 
 
2.3.2.3. Hybridisation 
 
600ng of labelled cRNA was added to various fragmentation components (Table 9), 
incubated at 60ºC for 30 minutes, and cooled on ice for 1 min.  25µl of GEx Hybridisation 
buffer HI-RPM was added to stop fragmentation.  The sample was gently mixed, centrifuged 
at 13,000 rpm for 1 min, and placed on ice in preparation for hybridisation.  The microarray 
was assembled and incubated overnight as described in section 2.3.1.4, with two alterations: 
the Custom 8x15K Microarray was used and 40µl of sample was added per 15K array.  After 
17 hour hybridisation, the microarrays were washed as described in section 2.3.1.4, and 
scanned on the Agilent C Scanner on programme AgilentHD_GX_1color, with the settings 
amended as shown in Table 10.   
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Table 9 Components of Fragmentation mix 
Components (Agilent) Volume/ Mass (for 8x15K microarray) 
Cy3-labelled cRNA 600 ng 
10 x blocking agent 5 µl 
Nuclease free water Bring total volume to 24 µl 
25 x fragmentation buffer 1 µl 
Total volume 25 µl 
 
Table 10 Microarray scanner settings for one-colour microarray based gene 
expression analysis (Agilent) 
 8x15K HD microarray format 
Dye Channel Green 
Scan region Scan area (61 x 21.6mm) 
Scan resolution (µM) 5 
Tiff 20 bit 
   
 
2.3.2.4. Data analysis: microarray  
 
The feature extraction programme was used to collate the Custom Microarray layout with 
the output of the scanner.  The results from individual patients were grouped based on 
subject diagnosis, disease severity (as defined by Braak stage) and ApoE genotype.  For the 
purposes of this study, the groups-of-interest were as follows (see Table 11): 
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Table 11 Microarray: subject groups 
Patient diagnosis ApoE genotype Number of patients 
Control (entorhinal stage) ApoE 3/3 5 
Mild AD (limbic stage) ApoE 3/3 5 
Advanced AD (neocortical stage) ApoE 3/3 4 
Advanced AD (neocortical stage) ApoE 3/4 18 
 
Statistical Analysis of Microarray (SAM)
92
 was used to carry out unpaired, two-sample T 
tests for each gene in a group-of-interest compared to control.  SAM identifies genes that are 
differentially expressed at RNA level in the group-of-interest compared to control group; the 
direction of expression; fold change; and an estimate of the false discovery rate (FDR).  For 
the purpose of our study, we selected an estimated FDR of 10% as acceptable for identifying 
differentially expressed genes
89
.  SAM was carried out with 1000 permutations, and the 
output processed to remove duplicates.  The output was analysed with the IPA Ingenuity 
software (www.ingenuity.com). 
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2.4. Q-PCR VALIDATION OF MICROARRAY RESULTS 
 
Real-time PCR (Q-PCR) measures the expression of a gene-of-interest relative to a 
housekeeping gene such as beta-actin, thereby allowing relative quantification of the gene-
of-interest.  Validation was carried out on cDNA obtained from the same subjects and brain 
regions used for the microarray study (see Table 6).  The genes-of-interest were selected as 
they were shown to be either significantly up- or down- regulated in advanced AD 
(neocortical stage) compared to control in the microarray study.   
 
The Universal probe library design centre (Roche Diagnostic Website) was used to design 
Q-PCR systems (Table 12); and primers and probes ordered from Sigma Genosys and Roche 
respectively.  For the composition of each 20µl Q-PCR mix see Table 13.  Two negative 
controls (water) and a cDNA standard curve (five serial dilutions starting with neat cDNA) 
were included per Q-PCR run.  The samples were denatured at 96
o
C for 15 minutes and 
amplified by 40 cycles of 96
o
C for 15 seconds, optimal annealing temperature (Table 12) for 
30 seconds and 72
o
C for 30 seconds.  FAM output was read in the annealing phase.  
 
Chapter 2  Materials and Methods                    
33 
 
Table 12 Q-PCR: Probe, primer sequences, and annealing temperature 
corresponding to each gene-of-interest 
Gene Roche 
Probe 
Forward primer  Backward primer  Optimal 
annealing temp 
(ºC) 
Beta actin 24 
5’-TCAGCTGTGG 
GGTCCTGT-3’ 
5’-GAAGGGGACA 
GGCAGTGAG-3’ 62 
EIF4E 
(Variant 1/ 2) 35 
5’-GATGGCGAC 
TGTCGAACC-3’ 
5’-TGGGTTAGCAA 
CCTCCTGAT-3’ 60 
EIF4E 
(Variant 3) 35 
5’-GTGTAGCGCA 
CACTTTCTGG-3’ 
5’-TGGGTTAGCA 
ACCTCCTGAT-3’ 60 
MAPK1 
(Variant 1/ 2) 62 
5’-CCGTGACCT 
CAAGCCTTC-3’ 
5’-GCCAGGCCA 
AAGTCACAG-3’ 58 
GABBR2 
 3 
5’-GCGAAGGAC 
AGTGGAGAAGT-3’ 
5’-GAGAGGGCG 
GATGGAGATA-3’ 62 
SEMA4C 14 
5’-TTGTGCCGC 
GTAAGACAGT-3’ 
5’-CAGCGTCA 
GTGTCAGGAAGT-3’ 60 
DZIP3 39 
5’-TGCCCAAGAT 
CTGATACAAGG-3’ 
5’-CTCCAACAC 
ACCACCGTACA-3’ 60 
SERPINE1 80 
5’-CTCCTGGTTC 
TGCCCAAGT-3’ 
5’-CAGGTTCT 
CTAGGGGCTTCC-3’ 58 
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Table 13 Q-PCR reaction for validation of microarray  
Composition of Q-PCR reaction Manufacturer 
0.5µl Universal probe (10µM) Roche 
10µl Absolute Q-PCR mix  
(Compositition: 0.625 Units ThermoPrime Taq DNA polymerase, 75mM Tris 
HCl (pH 8.8 at 25ºC), 20mM (NH4) 2SO4, 1.5mM MgCl2, 0.01% (v/v) tween 
20, 0.2mM each of dATP, dCTP, dGTP, dTTP). 
ThermoScientific 
0.5µl forward primer (20µM) Sigma Genosys 
0.5µl backward primer (20µM) Sigma Genosys 
6.5µl nuclease free water Qiagen 
2µl cDNA (neat, 1:4 and 1:16) Prepared as in 
section 2.2 
 
 
2.4.1 Data analysis: Q-PCR 
 
Each of the cDNA standard curve serial dilutions were assigned an arbitrary copy number 
(1:1 = 10,000; 1:2 = 5,000; 1:4 = 2500; 1:8 = 1250; 1:16 = 625).  The Rotor gene-6 
programme automatically identifies the optimal threshold and determines the copy number 
of the gene-of-interest relative to the standard curve for each sample. The Q-PCR was 
considered fully optimised when the calculated standard curve copy number varied less than 
10% from the assigned copy number.  The values obtained for each gene were normalised to 
the corresponding beta-actin values to allow quantitative comparison of samples.   
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2.5. P21CIP1 AND P57KIP2 GENOTYPING 
 
Of the 252 brains made available for the study, those with rare additional pathologies were 
excluded from the analysis (for example: motor neurone disease, Huntington’s disease and 
frontal lobe dementia).  Brains from AD patients with common additional pathologies 
(Parkinson’s disease, vascular disease and Lewy bodies) were included in the study to boost 
patient numbers.  The subjects were genotyped for SNP A and SNP B on p21
cip1
 and for the 
p57
kip2
 SNP (refer to section 1.8).   
 
2.5.1 p21cip1 genotyping: SNP A 
 
p21
cip1
 was genotyped for SNP A by standard PCR/ restriction digest protocol.  PCR was set 
up as described in Table 14, and amplified on a thermal cycler with an initial denaturation 
step of 95
o
C for 5 minutes, followed by 40 cycles of 95
o
C for 60 seconds, 65
o
C for 60 
seconds and 72
o
C for 60 seconds.  17µl of the PCR product was digested with 1µl BsmA1 
(5000U/ml) and 2µl of NEbuffer 3 (both New England Biolabs) at 55
o
C for 18 hours.     
 
Restriction digest products were separated on a 3% Metaphor agarose (Lonza) and 0.5% 
Multipurpose agarose (Roche) gel prepared with 1x Tris-borate-EDTA (TBE) buffer 
(Invitrogen), and supplemented with Sybr safe to a final concentration of 1:10,000 (Sybr 
safe).  The gel was run at 150 volts for 3 hours in 0.5x TBE buffer.  Gels were viewed and 
photographed in an Uvitec ultraviolet light box and results interpreted as shown (Figure 6). 
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Table 14 Composition of PCR mix (p21
cip1
 genotyping: SNP A) 
Composition of PCR reaction Volume 
(µl) 
Concentration Manufacturer 
DNA  2 25ng/µl See section 2.2 
Forward primer  
(5'-CGGGATCCGGCGCCATGTC 
AGAACCGGC-3') 
0.1 100µM Sigma Genosys 
Backward primer  
(5'-CCAGACAGGTCAGCCCTTGG-3') 
0.1 100µM Sigma Genosys 
Nuclease free water 5.3  Qiagen 
Polyethylene glycol 2.5 40% w/w Sigma 
Reddymix PCR master mix (Composition: 
0.625 units ThermoPrime Taq DNA 
polymerase, 75mM Tris-HCl (pH 8.8 at 
25ºC), 20mM (NH
4
)
2
SO
4
, 1.5M MgCl, 
0.01% (v/v) Tween 20, 0.2mM each of 
dATP, dCTP, dGTP and dTTP).   
10 2 x Thermoscientific 
 
1        2        3      L 
 
Figure 6 p21
cip1
 SNP A: restriction digest banding pattern: 1 = wild type for SNP 
A on p21
cip1
; 2 = heterozygous for SNP A on p21
cip1
; 3 = homozygous for 
SNP A on p21
cip1
; L = ladder (molecular weight marker V, Roche). 
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2.5.2   p21cip1 genotyping: SNP B 
 
p21
cip1
 was genotyped for SNP B by standard PCR/ restriction digest protocol.  PCR was set 
up as described in Table 15, and amplified on a thermal cycler with an initial denaturation 
step of 95
o
C for 5 minutes, followed by 40 cycles of 95
o
C for 30 seconds, 56
o
C for 30 
seconds and 72
o
C for 30 seconds.  17μl of PCR product was digested with 1.25μl Pst1 
(20,000U/ml), 2.5μl NE buffer 3, 4μl nuclease free water and 0.25μl bovine serum albumin 
(all New England Biolabs) at 37ºC for 18 hours.  The restriction digest products were 
separated on a 2% Multipurpose agarose (Roche) gel prepared with 1 x TBE buffer and 
1:10,000 Sybr safe.  The gel was run in 0.5 x TBE buffer at 150 volts for 3 hours.  The 
results were interpreted as shown (Figure 7).   
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Table 15 Composition of PCR mix (p21
cip1
 genotyping: SNP B) 
Composition of PCR reaction Volume 
(µl) 
Concentration Manufacturer 
DNA  2 25ng/µl See section 2.2 
Forward primer  
5'-CCCAGGGAAGGGTGTCCTG-3' 
0.11 100µM Sigma Genosys 
Backward primer  
5'-GGGCGGCCAGGGTATGTAC-3' 
0.11 100µM Sigma Genosys 
Nuclease free water 7.68  Qiagen 
Gelatin 1.1 2% Sigma 
Reddymix PCR master mix (composition 
outlined in Table 14)  
11 2 x Thermoscientific 
 
 
          1         2        3        L 
 
Figure 7 p21
cip1
 SNP B: restriction digest banding pattern: 1 = wild type for SNP 
B on p21
cip1
; 2 = heterozygous for SNP B on p21
cip1
; 3 = homozygous for 
SNP B on p21
cip1
; L= ladder (molecular weight marker V, Roche).   
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2.5.3 p57kip2 genotyping  
 
p57
kip2
 was genotyped by standard PCR/ restriction digest protocol (see section 1.8 for SNP 
description).  PCR was set up as described in Table 16, and amplified on a thermal cycler on 
the following programme: 95ºC for 5 minutes; 35 cycles of 95ºC for 30 seconds, 60ºC for 1 
minute and 72ºC for 30 seconds.  17µl PCR product was digested with 1μl AvaII (10,000 
units/ml) and 2μl NE buffer 4 (both New England biolabs) at 37ºC for 18 hours.  The 
restriction digest products were resolved on a gel composed of 3% Metaphor agarose 
(Lonza), 0.5% Multipurpose agarose (Roche), 1x TBE buffer and 1:10,000 Sybr Safe by 
running at 150 volts for 3 hours.  The gels were interpreted as shown in Figure 8.    
  
Table 16 Composition of PCR mix (p57
kip2
 genotyping) 
Composition of PCR reaction Volume 
(µl) 
Concentration Manufacturer 
DNA or cDNA 2 25ng/µl See section 2.2 
5´-CCGGAGCAGCTGCCTAGTG-3´ 0.075 100µM Sigma Genosys 
Backward primer  
5´-AATCCCCGAGTGCAGCTG-3´ 
0.075 100µM Sigma Genosys 
Nuclease free water 6.05  Qiagen 
DMSO 2.05  Sigma 
Reddymix PCR master mix (composition 
outlined in Table 14)  
10.25 2 x Thermoscientific 
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           1        2         3        L 
 
Figure 8 Restriction digest banding pattern for p57
kip2
 SNP: 1 = wild type for SNP 
on p57
kip2
; 2 = heterozygous for SNP on p57
kip2
; 3 = homozygous for SNP 
on p57
kip2
; L = molecular weight marker V, Roche).   
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2.5.4  p57kip2 imprinting status 
 
The patients that were heterozygous for the p57
kip2
 SNP were informative in terms of 
imprinting status.  They were genotyped from frontal and occipital lobe cDNA and results 
analysed with the National Institute of Health (NIH) imaging software: Image J.  We 
measured the mean intensity of the wild type and variant bands (72 and 54 base pair bands 
respectively) of the DNA and cDNA results, and calculated the ratio of intensity of the wild 
type band to variant band for each as shown below: 
 
Ratio  =  wild type band intensity 
  variant band intensity     
 
For heterozygous samples, the ratios calculated from DNA represent equal wild type and 
variant content.  cDNA samples with a ratio greater than the DNA ratio were interpreted as 
having greater p57
kip2
 wild type expression than p57
kip2
 variant expression; whereas samples 
with a ratio below the DNA ratio were interpreted as having more p57
kip2
 variant expression 
than p57
kip2
 wild type expression.  For more detailed description of analysis refer to 
appendix 3.   
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2.6. ELISA: QUANTIFICATION OF AD-RELATED PATHOLOGY 
 
Enzyme linked immunosorbant assay (ELISA) is a technique that allows relative 
quantification of a protein-of-interest.  Amen Zafar (research technician) quantified the 
proteins described in Table 17 in the temporal, frontal and occipital lobe of each subject 
prior to the start of this MPhil.  As part of this MPhil, p21
cip1
, p57
kip2
 and beta-actin were 
quantified in the temporal, frontal and occipital lobe of each subject.  All data analysis and 
interpretation were carried out as part of this study.   
   
Table 17 AD-related pathology markers 
Marker Description  
Beta-amyloid 39-43 amino acid cleavage product of APP that accumulates 
in the brain of AD patients.   One of the hallmarks of AD. 
Amyloid precursor protein- 
C terminal (APP-C) 
Beta-amyloid is contained within the C-terminal of APP-C, so 
APP-C presence is indicative of abnormal APP-C processing. 
Phospho-tau (AT8) Hyperphoshorylated (Ser 202/Thr 205) version of tau found in 
neurofibrillary tangles
93
: one of the hallmarks of AD.  The 
antibody detects hyperphosphorylated tau both prior to 
incorporation into tangles and within tangles. 
PHF tangles (DC11) Antibody recognises a conformational epitope of the 
neurofibrillary tangle that is highly AD specific
94
.  DC11 is 
therefore a measure of tangles only.   
Synaptophysin 38kDa glycoprotein located on neuronal synapses that can be 
used as a marker of synaptic density
95
.   
Growth associated protein 
43 (GAP-43) 
Neuron specific protein expressed on axonal growth cones 
during synaptic remodelling (synaptic remodelling marker)
96
.   
Neuronal nuclei (NeuN) A neuron specific protein: a measure of neuronal density
97
. 
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2.6.1 Method: ELISA 
 
A protein sample with a high quantity of the protein-of-interest was selected for each 
standard curve.  The standard curve samples and samples-of-interest were included on each 
plate in triplicates.  100µl of protein (diluted in 0.1M Carbonate Buffer, pH 9.6 to 
concentration shown in Table 18) was loaded per well and incubated overnight at 4ºC.  
Following liquid aspiration, the wells were incubated with 200µl phosphate buffered saline 
(PBS) (Sigma) with 1% Bovine Serum Albumin (BSA) (Sigma) for 2 hours.  The samples 
were incubated with 100µl of primary antibody (Table 18) diluted in PBS with 1% BSA and 
0.1% tween-20.  Following the overnight incubation at 4ºC, the wells were washed with PBS 
with 0.1% tween-20, and incubated with 100µl secondary antibody (Table 18) at room 
temperature for 2 hours.  The wells were washed and incubated with 100µl of Streptavidin-
horseradish peroxidate (1:200, R&D Systems) for 2 hours at RT.  The reaction was 
visualised with o-phenylenediamine dihydrochloride (Sigma fast OPD), and reaction stopped 
with 25µl of 4M H2SO4 when colour was appropriately developed.  The absorbance was read 
at 490nm with a plate reader.    
 
Table 18 ELISA 
Protein Protein loading 
concentration (µm/ml) 
Primary antibody Secondary antibody 
Beta-
amyloid 
2 Mouse monoclonal to 
amyloid-β (1:5000, 
Dako) 
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
(1:2000, Dako) 
AT8 2.5 Mouse monoclonal to 
AT8  
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
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Protein Protein loading 
concentration (µm/ml) 
Primary antibody Secondary antibody 
(1:1000, Innogenetics) (1:2000, Dako) 
DC11 4 Mouse monoclonal 
Alzheimer’s disease 
tau, DCII (1:500, 
Sigma) 
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
(1:2000, Dako) 
GAP-43 2 Rabbit polyclonal to 
growth associated 
protein, GAP43  
(1:1000, Chemicon) 
Polyclonal Swine anti-rabbit 
Immunoglobulin biotinylated 
(1:2000, Dako) 
APP-C 4 Rabbit monoclonal to 
APP-C-terminal  
(1:1000, Sigma) 
Polyclonal Swine anti-rabbit 
Immunoglobulin biotinylated 
(1:2000, Dako) 
Synapto-
physin 
2 Mouse monoclonal to 
synaptophysin (1:1000, 
Dako) 
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
(1:2000, Dako) 
NeuN 2.5 Mouse monoclonal to 
neuronal nuclei (NeuN)  
(1:1000, Chemicon) 
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
(1:2000, Dako) 
P57
kip2
 4 Mouse monoclonal to 
p57
kip2
 (1:500, BD) 
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
(1:2000, Dako) 
Beta-
actin 
4 Mouse monoclonal to 
beta-actin (1:2000, 
ABcam) 
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
(1:1000, Dako) 
P21
cip1
 4 Rabbit polyclonal to 
p21
cip1
  
(1:500, ABcam) 
Polyclonal Rabbit anti-mouse 
Immunoglobulin biotinylated  
(1:2000, Dako) 
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2.6.2 Data analysis: ELISA 
 
The calibration curve, obtained from the serial dilution of the standard curve sample, was 
used to estimate concentration of the protein-of-interest in the samples based on their optical 
density readings.  The ELISA results were normalised for protein content. 
 
 
2.7. SNP DEPENDENT Q-PCR  
 
The Amplifluor SNPs genotyping system for assay development (Millipore) is a Q-PCR 
based technique that allows quantification of two alleles of a gene-of-interest in a sample at 
RNA level
98
.  The kit is most commonly used for genotyping DNA, but can be used to 
determine ratio of mRNA corresponding to two gene variants in cDNA.  The kit was used to 
determine the ratio of wild type p21
cip1
 mRNA relative to variant p21
cip1
 mRNA in the brain 
of patients that were heterozygous for both SNP A and B on p21
cip1
.  Of the 252 AD patients 
available for the study, all individuals that were heterozygous for SNP A and B were 
included in the analysis (28 subjects).     
 
The Amplifluor AssayArchitect Software available through the Millipore website allowed 
the design of p21
cip1
 allele specific primers (specific for SNP A).  The sequences are given in 
Table 20.  Note that green represents the sequence corresponding to the Amplifluor SNP 
FAM primer, whereas red represents the sequence corresponding to the Amplifluor SNP SR 
primer.   Q-PCR was set up as described in Table 19 and subjected to an initial denaturation 
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step of 96ºC for 5 minutes, followed by 50 cycles of 96
o
C for 30 seconds, 55
o
C for 30 
seconds, and 72
o
C for 30 seconds.  The FAM and SR fluorescent signals were acquired in 
the annealing and elongation step.        
 
Table 19 Composition of SNP dependent Q-PCR mix (p21
cip1
: SNP A) 
Q-PCR mix composition Volume Concentration Manufacturer 
cDNA 4 (unknown concentration: 
prepared as described in 
section 2.2 
 
Nuclease free water 9.2  Qiagen 
dNTP mix 1.6 2.5mM per dNTP Millipore kit 
Amplifluor SNP FAM primer 1.0 5µM Millipore kit 
Amplifluor SNP SR Primer 1.0 5µM Millipore kit 
Reaction buffer S 2.0 10x Millipore kit 
SNP specific primer mix 
(Composed of 0.5µM wild type 
allele-specific forward primer, 
0.5µM variant-specific forward 
primer and 7.5µM common reverse 
primer  
1.0 20x Sigma Genosys 
Taq DNA polymerase 0.2 5 U/ml Promega 
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Table 20 Primer sequences for SNP dependent Q-PCR 
Primer Sequence 
P21
cip1
 allele 1 (wild type) 
forward primer 
5’GAAGGTGACCAAGTTCATGCTATTAGCGCATCAC
AGTCGCGG -3’ 
 
P21
cip1
 allele 2 (variant) 
forward primer 
5’-
GAAGGTCGGAGTCAACGGATTAGCGCATCACAGT
CGCGT-3’ 
P21
cip1
 common reverse 
primer 
5’-CTCTTCGGCCCAGTGGA -3’   
 
 
 
2.7.1 Data analysis: SNP dependent Q-PCR 
 
A calibration curve was constructed by assigning each of the DNA standard curve serial 
dilutions with an arbitrary copy number (1:1 = 10,000; 1:2 = 5,000; 1:4 = 2500; 1:8 = 1250; 
1:16 = 625).  The calibration curve was used to estimate the relative copy number of the wild 
type mRNA to variant mRNA in each sample, and ratio of wild type allele to variant allele 
calculated.   
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2.8. P21CIP1 AND P57KIP2 Q-PCR 
 
The relative amount of p21
cip
 and p57
kip2
 mRNA in the temporal, frontal and occipital lobe 
of the 252 individuals in our cohort was determined by Q-PCR and normalised to beta-actin 
content.  The Q-PCR systems (p21
cip1
, p57
kip2
 and beta-actin) were developed using the 
primer design programme available on the Roche Diagnostic website in combination with 
the Universal probe library (Roche).  The primers were designed to amplify irrespective of 
p21
cip1
 and p57
kip2
 genotype. 
     
Q-PCR was set up as described in Table 21, and amplified on the Rotor Gene-6 Q-PCR 
machine with a initial denaturation step of 95ºC for 15 minutes, followed by 50 cycles of 
96ºC for 15 seconds, optimal annealing temperature for 30 seconds, and 72ºC for 30 
seconds.  See Table 22 for the probe, primers, and optimal annealing temperature that 
correspond to each gene.  The results were analysed as described in section 2.4: with p21
cip1
 
and p57
kip2
 values normalised to the corresponding beta-actin values, to allow sample to 
sample comparisons. 
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Table 21 Composition of Q-PCR mix  
Q-PCR mix composition Volume Concentration Manufacturer 
cDNA 2 Neat (prepared as in section 2.2) 
Nuclease free water 6.5  Qiagen 
Forward primer 0.5 100 µM Sigma Genosys 
Backward primer 0.5 100 µM Sigma Genosys 
Universal probe 0.5 10 µM Roche 
Absolute Q-PCR mix 10 Neat Thermoscientific 
 
 
Table 22 Primer sequences for Q-PCR 
Gene Roche 
Probe 
Forward primer (Sigma 
Genosys) 
Backward primer (Sigma 
Genosys) 
Optimised 
annealing 
temp (
o
C) 
Beta-
actin 24 
5’-TCAGCTGTGGGGTCC 
TGT-3’ 
5’-GAAGGGGACAGG 
CAGTGAG-3’ 62 
p21
cip1
 12 
5’-TGGGTGGTACCCTC 
TGGA-3’  
5’TGAATTTCATA 
ACCGCCTGTG-3’ 58 
p57
kip2
 18 
5’-AACCGCTGGGATT 
ACGACT-3’ 
5’-TCCACTTCGGTC 
CACTGC-3’ 58 
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2.9. CELL CULTURE AND TRANSFECTION 
 
The effect of the p21
cip1
 SNPs on the function and expression of p21
cip1
 was investigated by 
transient transfection of wild type p21
cip1
 or variant p21
cip1 
(with SNP A and B) into the 
rapidly dividing Flp-In-T-Rex-293 (human embryonic kidney) cell line.  The cell cycle 
activity of the cells was determined by Acumen Cytometry after propidium iodide staining; 
the expression of p21
cip1
 mRNA determined by Q-PCR; and p21
cip1
 protein expression 
determined by Acumen analysis after immunolabelling with p21
cip1 
and beta-actin antibody.  
The transient transfection was carried out by Erzsebet Rabai (Research Associate) and the 
immunolabelling and propidium iodide staining carried out by Sheila Nagy (Research 
Technician).  The procotols are described in appendix 5.  The Q-PCR and data analysis were 
carried out as part of this MPhil.     
 
2.9.1 p21cip1 Q-PCR  
 
RNA was extracted from pellets of cells transfected with wild type, variant, or no p21
cip1
; 
and RNA converted to cDNA as described in 2.2.  The p21
cip1
 and beta-actin mRNA content 
was determined by Q-PCR as described in 2.8.  The p21
cip1
 content was normalised to beta-
actin content to allow sample to sample comparisons.   
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2.9.2 Data analysis 
 
The Acumen Explorer Cytometer scans cell cultures in situ and combines image analysis 
with the measurement of fluorescence: thereby allowing quantification of fluorescence 
within a defined area of the image.  The propidium iodide stained cultures provided 
measurements of DNA content and cell size, and were analysed by standard flow Cytometry 
method
99
 to determine cell cycle phase of the individual cells in the sample.  The 
immunolabelled cell cultures provided measurements of p21
cip1
 and beta-actin protein 
content per cell and per cell nucleus.   
 
2.10. STATISTICAL ANALYSIS 
 
A description of the data analysis methods relating to each technique can be found in the 
methods section.  All statistical analysis was carried out with the MedCalc statistical package 
unless specified.  The distribution of all data sets was investigated prior to statistical analysis 
to allow selection of the most appropriate test.  For data that was normally distributed, one-
way ANOVA, multi-factorial ANOVA, regression or multiple-regression was used as 
appropriate.  Logarithmic transformation was carried out if suitable.  The non-parametric 
test: Kruskall Wallis was used for data that did not follow a normal distribution.  The chosen 
statistical test for each analysis can be found in the accompanying figure legend.  
 
The accumulation of AD-related pathology in the brain is highly dependent on the severity 
of AD.  Therefore, the analysis of the effect of the p21
cip1
 and p57
kip2
 genotype on the 
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accumulation of AD-related pathology had to take into account the severity of AD of the 
individual.  Two-way ANOVA was used to analyse parametric data (entering genotype and 
severity of AD as independent variables), whereas the Kruskal-Wallis test was used to 
analyse non-parametric data (analysing data in subgroups defined by severity of AD, and 
entering genotype as the independent variable).  Note that subjects with rare additional 
pathologies were excluded from the analysis (for example: motor neurone disease, 
Huntington’s disease and frontal lobe dementia), whereas subjects with common pathologies 
in addition to AD (Parkison’s disease, vascular disease, Lewy bodies and tumours) were 
included in the analysis to boost patient numbers.       
 
For the purpose of the p21
cip1
 study, individuals that were heterozygous or homozygous for 
SNPs A and B on p21
cip1
 were classed as having the p21
cip1
 variant, whereas individuals that 
were wild type for p21
cip1
, or had only one of the SNPs were classed as being wild type for 
p21
cip1
.  Analysis of the effect of the p21
cip1
 genotype on AD-related pathology was impeded 
by the small number of cases in the p21
cip1
 variant subgroups defined by the severity of AD. 
Z-scores were calculated for each variable, taking into account the severity of AD (Braak 
staging), to eliminate the need for subgroups.  The z-score is a measure of the deviation of a 
variable from the group mean.  Patients were sorted into three groups depending on the 
severity of AD (entorhinal, limbic and neocortical), and group means calculated for each 
variable.  For each variable, the individual patient measurements were compared to the 
relevant mean, to eliminate the severity of AD from the analysis.   
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3. RESULTS 
 
3.1. ALTERED RAPAMYCIN RESPONSE ELEMENTS IN THE BRAIN 
OF ALZHEIMER’S DISEASE PATIENTS 
 
Two previous studies
71, 72
 have shown that lymphocytes from AD patients have a reduced 
response to rapamycin compared to lymphocytes from control subjects.  As rapamycin is an 
upstream inhibitor of the mTOR pathway, a pathway that promotes cell cycle activity, these 
studies suggest that lymphocytes from AD patients have a deficiency downstream of mTOR 
that impedes appropriate cell cycle control.  The fact that the cell cycle regulatory failure is 
not restricted to lymphocytes in AD
58, 59, 63, 100
, and that the deficit is present in lymphocytes 
obtained from advanced AD patients and MCI sufferers
71
, implies that the failure is 
systemic.   
 
The cell cycle theory of AD postulates that neurodegeneration is secondary to inappropriate 
cell cycle re-entry of neurons with subsequent progression beyond the G1/S checkpoint
30
.  
We hypothesise that the defective components of the mTOR pathway that are responsible for 
the loss of cell cycle control in AD lymphocytes are also responsible for the loss of 
appropriate cell cycle control in AD neurons.  Despite extensive research, ApoE 4 is the 
only established genetic risk factor for AD.  This suggests that the cause of the regulatory 
failure in AD may differ from patient to patient: with different mTOR pathway components 
involved in each case.     
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To identify these components, rapamycin-regulated genes were revealed by two-colour 
microarray based gene expression analysis (comparison between rapamycin-treated 
lymphocytes and untreated lymphocytes from subjects with appropriate rapamycin-response, 
identified by flow cytometry).  The identified rapamycin-regulated genes were screened for 
differential expression in the frontal lobe of brain affected by AD compared to frontal lobe 
unaffected by AD using a custom-made gene expression microarray.  The identified genes 
act downstream of mTOR, and are differentially regulated in brain affected by AD, 
suggesting that they may have a role in the development of the disease.  They may severe as 
new therapeutic targets for AD or novel diagnostic biomarkers.  The genes were further 
analysed with the IPA Ingenuity software to identify associated networks and pathways.  As 
the list contained both positive and negative pathway regulators, it was decided that the up- 
and down- regulated genes should be analysed together to give the best overview of 
networks and pathways involved. 
 
3.1.1 Rapamycin-regulated genes  
 
The two-colour gene expression microarray identified 1138 genes that were rapamycin-
regulated in lymphocytes.  1043 of the genes were up-regulated in response to rapamycin 
treatment and 95 genes downregulated in response to rapamycin.  The full list of rapamycin-
regulated genes in lymphocytes can be found in appendix 6 (Table 56 and Table 57).   
 
Genes that are functionally controlled by rapamycin in human brain are not necessarily 
functionally controlled by rapamycin in lymphocytes. Therefore, genes that were known to 
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be rapamycin-regulated (identified with IPA Ingenuity), which were not identified as 
rapamycin-regulated in lymphocytes, were added to the list for screening for differential 
expression in AD brain compared to control (34 additional genes: appendix 6, Table 58). 
 
3.1.2 Altered rapamycin-response elements as a result of mild AD  
 
The rapamycin-regulated genes were analysed with SAM (see 2.3.2.4) for altered expression 
in the frontal lobe of mild (limbic) AD patients with the ApoE 3/3 genotype relative to 
frontal lobe of control subjects with the ApoE 3/3 genotype.  Only ApoE 3/3 patients 
were included in the analysis to eliminate the effect of the ApoE genotype from the 
analysis
22
.      
 
Of the 1172 rapamycin-regulated genes, SAM analysis identified 18 that were differentially 
expressed (Appendix 7, Table 59) in brain affected by mild AD relative to control (all up-
regulated).  Genes for enzymes, growth factors, ion channels, receptors and transporters were 
marked as possible therapeutic targets; whereas genes for cytokines and proteins located in 
the extracellular space were marked as possible biomarkers of AD.  Of the 18 genes: 9 were 
identified as possible drug targets, and 6 identified as possible biomarkers of disease 
(Appendix 7, Table 59).  The IPA software identified existing drugs to two of the 
differentially expressed gene (Appendix 7, Table 59). 
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3.1.2.1. Associated pathways, networks and functions 
 
The list of 18 differentially expressed genes included transcriptional regulators (HDAC5, 
POU4F2, RUNX1T1); genes involved in nucleic acid metabolism (ENTPD8); genes 
involved in post-translational modification of proteins (FN3K, TGM4, ADAMTS2, 
PRODH2); the neuronal guidance molecule SEMA4C; genes involved in cytoskeletal re-
organisation (ADAMTS2) and inflammatory pathways (CCL2, IL6, FCGBP). 
 
The differentially expressed genes were further analysed with IPA to identify associated 
molecular and cellular functions (Table 23), known diseases and disorders (Table 24), and 
physiological systems (Table 25).  The differentially expressed transcripts were significantly 
enriched for involved in cellular development, cellular growth and proliferation, cellular 
movement, cell cycle, and antigen presentation (Table 23).  IPA also identified networks 
associated with the differentially expressed genes: with 9 of the genes shown to be part of a 
network involved in connective tissue disorders, inflammatory disease, and skeletal and 
muscular disorders.  The network was given a highly significant score of 22:  based on the 
right-tailed Fisher’s exact test, a score of 22 indicates that there was a 1x10-22 chance of the 
network being randomly identified.  The only pathways significantly associated with the 
differentially expressed genes were the inflammatory pathways (data not shown).   
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Table 23 Molecular and cellular functions significantly associated with the genes 
identified to be differentially expressed as a result of mild AD only 
Molecular and cellular functions p-value Number of genes 
Cellular Development  <0.05 5 
Cellular Growth and Proliferation  <0.05 8 
Cellular Movement  <0.05 3 
Cell Cycle  <0.05 2 
Antigen Presentation  <0.05 2 
 
 
Table 24 Diseases and disorders significantly associated with the genes identified 
to be differentially expressed as a result of mild AD only 
Diseases and disorders p-value Number of genes 
Connective Tissue Disorders  <0.05 3 
Inflammatory Disease <0.05 5 
Skeletal and Muscular Disorders  <0.05 3 
Infectious Disease  <0.05 2 
Hematological Disease  <0.05 4 
 
 
Table 25 Physiological systems significantly associated with the genes identified to 
be differentially expressed as a result of mild AD only 
Physiological system development and function p-value Number of genes 
Lymphoid tissue structure and development <0.001-  0.0213 3 
Nervous system development and function <0.001- 0.0323 5 
Skeletal muscle system development and function <0.001- 0.0279 4 
Connective tissue development and function <0.001- 0.0290 2 
Hematological system development and function <0.001- 0.0301 4 
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3.1.3 Altered rapamycin-response elements as a result of advanced AD 
 
To identify rapamycin-regulated genes whose transcription are altered as a consequence of 
advanced AD only, gene transcripts in the frontal lobe of advanced AD patients (neocortical 
stage) with ApoE 3/3 genotype were compared to gene transcripts in the frontal lobe of 
elderly controls with ApoE 3/3 genotype.  Inclusion of only ApoE 3/3 subjects in this 
analysis eliminated the effect of ApoE 
22
.  Of the 1172 rapamycin-regulated genes, SAM 
analysis identified 203 that were differentially transcribed in brain affected by advanced AD 
compared to control (see Appendix 8, Table 60 for full list).      
 
To identify rapamycin-regulated genes whose transcription are altered as a result of 
advanced AD (neocortical stage) in subjects carrying the ApoE 4 allele, gene transcripts in 
the frontal lobe of advanced AD patients with ApoE 3/4 genotype were compared to gene 
transcripts in control subjects with ApoE 3/3 genotype.  Of the 1172 rapamycin-regulated 
genes, SAM analysis identified 168 that were differentially transcribed as a result of 
advanced AD and the ApoE 4 allele (See Appendix 9, Table 68).     
  
The rapamycin-regulated genes whose transcription were altered in brain of advanced AD 
patients with the ApoE 3/3 genotype (203 genes) were compared to the rapamycin-
regulated genes whose transcription were altered in brain of advanced AD patients with the 
ApoE 3/4 genotype (168 genes).  As we only had a small number of subjects in each 
group, the rapamycin-regulated genes that were differentially transcribed as a consequence 
of advanced AD only, and advanced AD in combination with the ApoE 4 allele (i.e. the 
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overlapping genes), were likely to represent the most accurate picture of altered rapamycin-
regulated genes as a result of advanced AD (i.e. the overlapping genes).  The analysis 
identified 104 such genes (62% overlap) (Appendix 10, Table 76).     
 
Genes for enzymes, growth factors, ion channels, receptors and transporters were marked as 
possible drug targets; whereas genes for cytokines and proteins located in the extracellular 
space were marked as possible biomarkers of disease. Of the 104 differentially expressed 
genes, 43 were identified as possible drug targets, and 19 identified as possible biomarkers 
of disease (Appendix 10, Table 76).  The IPA software identified existing drugs to 5 of the 
possible drug targets (Appendix 10, Table 77).   
 
3.1.3.1. Associated pathways, networks and functions 
 
The 104 genes that were differentially transcribed as a result of advanced AD, irrespective of 
ApoE genotype, represent 8.9% (104/1172) of the total number of rapamycin-regulated 
genes; and includes transcriptional regulators, genes involved in post-translational 
modification, genes involved in nucleic acid metabolism, growth factors, various receptors 
and channels, inflammatory genes, genes involved in cytoskeleton reorganisation; tumour 
suppressors, and cell signalling genes.   
 
The list was analysed with IPA to identify molecular and cellular functions (Table 26), 
diseases and disorders (Table 27) and physiological systems (Table 28) that were 
significantly associated with the differentially expressed genes.  The genes were enriched for 
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involved in cellular development, cellular movement, protein synthesis, cell morphology and 
cellular growth and proliferation.  IPA also identified a number of networks (Table 29) and 
pathways (Table 30) that were significantly associated with the differentially expressed 
genes.  Note that the score (x) in Table 29 is based on the right-tailed Fisher’s exact test and 
represents a 1x10
x
 chance of the network having been randomly identified.  
 
Table 26 Molecular and cellular functions significantly associated with the genes 
identified to be differentially expressed as a result of advanced AD  
Molecular and cellular functions p-value Number of 
Genes 
Cellular development <0.05 12 
Cellular movement <0.05 14 
Protein synthesis <0.05 5 
Cell morphology <0.05 13 
Cellular growth and proliferation <0.05 14 
 
 
Table 27 Diseases and disorders significantly associated with the genes identified 
to be differentially expressed as a result of advanced AD  
Diseases and disorders p-value Number of 
genes 
Cardiovascular disease <0.05 30 
Genetic disorders <0.05 59 
Cancer <0.05 31 
Renal and urological disorders <0.05 9 
Infectious disease <0.05 16 
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Table 28 Physiological systems significantly associated with the genes identified to 
be differentially expressed as a result of advanced AD 
Physiological system development and 
function 
p-value Number of 
Genes 
Skeletal and muscular system development 
and function 
<0.05 9 
Tissue development <0.05 13 
Hematological system development and 
function 
<0.05 13 
Immune cell trafficking <0.05 8 
Nervous system development and function <0.05 13 
 
 
Table 29 Top networks associated with the genes identified to be differentially 
expressed as a result of advanced AD 
Network Score Focus 
Molecules 
Top Functions 
 1 33 17 Cellular growth and proliferation, cancer 
 2 22 13 
Connective tissue development, skeletal and muscular 
system development and function, Tissue morphology 
 3 19 11 
Cellular function and maintenance, cell-to-cell signalling 
and interaction, Nervous system development and function 
 4 15 9 
Decreased levels of albumin, gene expression, post-
translational modifications 
 5 13 9 Cellular development, genetic disorders, metabolic disease 
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Table 30 Top pathways associated with the genes identified as differentially 
expressed as a result of advanced AD 
Canonical pathway p-value 
 mTOR Signaling <0.001 
 Corticotropin Releasing Hormone Signaling <0.001 
 Insulin Receptor Signaling <0.001 
 IL-17 Signaling <0.001 
 TGF-β Signaling <0.05 
 
 
Note that identical analyses to the one shown above were carried out for the differentially 
regulated genes in subjects with advanced AD, who were ApoE 3 carriers only; and in 
subjects with advanced AD, who were ApoE 4 carriers (see appendix 8 and 9 respectively).   
 
3.1.4 Altered rapamycin-response elements as a result of the ApoE 4 allele  
 
Rapamycin-regulated transcripts that were differentially expressed in advanced AD 
(neocortical stage, ApoE 3/4) compared to control (ApoE 3/3), but not differentially 
expressed in advanced AD (neocortical stage: ApoE 3/3) compared to control (ApoE 
3/3), were differentially expressed as a result of the ApoE 4 allele only.  The analysis 
identified 64 such genes (Appendix 11, Table 78).   
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3.1.4.1. Associated pathways, networks and functions 
 
The 64 genes represent 5.4% (64/1172) of the total number of genes regulated by mTOR.  
Their altered expression can be attributed to the ApoE 4 allele only.  They included genes 
involved in energy metabolism (mitochondrial activity), fatty acid metabolism, synaptic 
activity, cell motility (adhesion and cytoskeleton structure), and cell signalling (receptors, 
channels and signalling molecules).  Analysis with IPA identified associated molecular and 
cellular functions (Table 31), diseases and disorders (Table 32), and physiological systems 
(Table 33).  The differentially expressed transcripts were significantly enriched for genes 
involved in cell death, cellular development, cellular growth and proliferation, drug 
metabolism and lipid metabolism. 
 
IPA identified a number of networks associated with the differentially expressed genes 
(Table 34).  The score is based on the right-tailed Fisher’s exact test and represents a  
1x10
-score
 chance of the network having been randomly identified.  The genes were strongly 
associated with all the networks shown.   
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Table 31  Molecular and cellular functions significantly associated with the genes 
identified to be differentially expressed as a result of the ApoE 4 allele  
Molecular and cellular functions p-value Number of 
Genes 
Cell death <0.05 4 
Cellular development <0.05 7 
Cellular growth and proliferation <0.05 7 
Drug metabolism <0.05 2 
Lipid metabolism <0.05 2 
 
 
Table 32 Diseases and disorders significantly associated with the genes identified 
to be differentially expressed as a result of the ApoE 4 allele 
Diseases and disorders p-value Number of 
genes 
Neurological disease <0.05 25 
Psychological disease <0.05 16 
Skeletal and muscular disorders <0.05 23 
Genetic disorders <0.05 34 
Reproductive system disease <0.05 12 
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Table 33 Physiological systems significantly associated with the genes identified to 
be differentially expressed as a result of the ApoE 4 allele  
Physiological system development and function p-value Number of 
Genes 
Cardiovascular system development and function <0.05 6 
Hair and skin development and function <0.05 4 
Nervous system development and function <0.05 4 
Organismal function <0.05 1 
Renal and urological system development and function <0.05 1 
 
 
Table 34 Networks significantly associated with the genes identified to be 
differentially expressed as a result of the ApoE 4 allele 
Network Score No. of focus Molecules Top Functions 
1  26  13  Cardiovascular System Development and 
Function, Cell Death, Organismal Functions 
2  22  11  Infection Mechanism, Cellular 
Compromise, Lipid Metabolism 
3  22  11  Cell Signaling, Molecular Transport, 
Vitamin and Mineral Metabolism 
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3.1.5 Altered rapamycin-response elements in AD irrespective of severity of AD 
 
The rapamycin-regulated genes whose transcription were altered as a result of advanced AD 
(refer to section 3.1.3) were compared to the rapamycin-regulated genes whose transcription 
were altered as a result of mild stage AD (refer to section 3.1.2).  This analysis was carried 
out to identify rapamycin-regulated genes that were differentially expressed in the frontal 
lobe in both early and later phases of the disease. 
 
Of the 18 differentially expressed transcripts in early stage AD (limbic stage), 15 (83%) 
overlapped with the differentially expressed transcripts in advanced AD (neocortical stage) 
(104 genes) (Appendix 11, Table 79).  These genes are potential therapeutic and biomarker 
targets, irrespective of disease severity.  Of the 15 differentially expressed genes, 8 were 
identified as possible therapeutic targets, and 3 identified as possible biomarkers of disease 
(Appendix 11, Table 79).  No existing drugs target the genes identified as possible drug 
targets. 
 
Three of the genes were differentially transcribed in mild AD, but not advanced AD; 
whereas 89 of the genes were differentially transcribed in advanced AD, but not in mild AD.  
These genes could potentially be used as biomarkers of disease progression (Appendix 11, 
Table 80).  Fourteen of the genes met the requirements for a potential biomarker (Appendix 
11, Table 80).   
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3.1.6 Microarray validation 
 
The IPA Ingenuity knowledge database contains information about established gene 
associations with disease that have been manually derived from peer-reviewed journals and 
other high quality sources.  Only verified gene/disease associations are included in this 
database (associations based on genetics and expression).  
 
IPA Ingenuity identified 954 genes known to be involved in AD.  These genes were 
compared to the rapamycin-regulated genes that were shown to be altered in AD brain 
compared to control.  Two of the 18 (11%) altered mTOR genes in mild AD (limbic stage, 
ApoE 3/3), and 13 of the 104 (12.5%) altered mTOR genes in advanced AD (neocortical 
stage), were established to be associated with AD based on the IPA Ingenuity database.  To 
summarise, we have looked at approximately 2% (1172/ 40000) of the whole human genome 
(only genes downstream of the mTOR signalling pathway), and found that approximately 
12% of the identified AD associated mTOR genes, are already established to be associated 
with AD based on the IPA Ingenuity knowledge base.   
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3.1.7 Q-PCR validation of microarray 
 
Microarray analysis showed that eukaryotic translation initiation factor 4E (EIF4E), mitogen 
activated protein kinase 1 (MAPK1), gamma-aminobutyric acid B receptor 2 (GABBR2) and 
DAZ interacting protein 3 (DZIP3) were significantly down-regulated in advanced AD 
compared to control, whereas semaphorin 4C (SEMA4C) and serpin peptidase inhibitor, 
clade E, member 1 (SERPINE 1) were significantly up-regulated in advanced AD compared 
to control (Figure 9).  Q-PCR was used to measure the expression of the listed genes in the 
frontal lobe of the AD patients and controls that were examined with gene expression 
microarray (all ApoE 3/3).  The beta-actin content of the samples was also measured by Q-
PCR, to allow normalisation of the data.     
 
For all 6 genes, Q-PCR demonstrated differential expression in the same direction as the 
microarray, although results failed to reach statistical significance for all of the genes (Figure 
10).   
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Figure 9 Gene expression in control and advanced AD brain as determined by 
microarray (x-axis = gene-of-interest; y-axis = expression normalised to 
beta-actin, and expressed as a percentage of the control value (%); top of 
bar represents mean; error bars represent standard error of the mean; 
blue represents control subject; red represents advanced AD subject).   
 
 
Figure 10 Gene expression in control and advanced AD brain as determined by Q-
PCR (x-axis = Gene-of-interest; y-axis = expression normalised to beta-
actin, and expressed as a percentage of the control value (%); top of bar 
represents mean; error bars represent standard error of the mean; blue 
represents control subject; red represents advanced AD subject).  
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3.2. THE EFFECT OF THE P21CIP1 SNPS ON P21CIP1 EXPRESSION AND 
FUNCTION, AND ASSOCIATION WITH AD-RELATED 
PATHOLOGY 
 
The cell cycle theory of AD postulates that neurons degenerate as a consequence of aberrant 
cell cycle re-entry and progression beyond the G1/S checkpoint
30
.  P21
cip1
 is a member of the 
cip/kip family of CDKIs that inhibit the activity of the cyclin/CDK complexes that drive 
entry into the cell cycle and progression from one phase to the next.  P21
cip1
 specifically 
inhibits cyclin/CDK2 complexes, which are required for progression through the G1/S and 
S/G2 checkpoints.  It is possible that the inappropriate progression beyond the G1/S 
checkpoint, which is postulated to be a cause of neurodegeneration in AD, is a consequence 
of altered expression or activity of the p21
cip1
 protein in some individuals.   
 
Several genetic linkage studies suggest that genetic variants of p21
cip1 
may be associated 
with AD
80, 82, 83, 101
.  Furthermore, a previous study
74
 found that a genetic variant of p21
cip1
 
that is known to be cancer associated
77
 is also associated with AD.  The genetic variant 
contained a cytosine to adenine substitution on an exonic region (SNP A), and a cytosine to 
thymine substitution on the 3’- untranslated region (SNP B).  The literature suggests that the 
SNPs are only associated with cancer and AD when found together
74, 76, 77
.  An aim of the 
study was to determine the effect of the p21
cip1
 SNPs on the age of onset of AD, cognitive 
performance, and the accumulation of AD-related pathology in the brain.  We also 
investigated the effect of the p21
cip1
 SNPs on the stability of the p21
cip1
 mRNA, and on the 
expression and function of the p21
cip1 
protein.     
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Subjects that were heterozygous or homozygous for both SNP A and B were identified as 
having the variant version of p21
cipl
; whereas individuals that were wild type for SNP A and 
B (or had only one of the SNPs) were identified as having the wild type version of p21
cip1
.   
 
3.2.1 Frequency of the p21cip1 variant 
 
Post-mortem brain tissue sections, from 209 AD sufferers, were available for the study.  Of 
the 209 subjects, one was homozygous for SNP A and B, 24 were heterozygous for SNP A 
and B, and 184 were wild type for SNP A and B or heterozygous or homozygous for one of 
the SNPs only (Table 35).  Overall, 12% of the cohort was either heterozygous or 
homozygous for the p21
cip1 
SNPs (A and B).  The distribution of the p21
cip1
 variant in the 
population followed the Hardy-Weinberg equilibrium
102
.   
 
Table 35 Frequency of the p21
cip1
 variant in the cohort 
p21
cip1
 genotype Number of patients Relative frequency % 
Wild type 184 88.0 
Heterozygous 24 11.5 
Homozygous 1 0.5 
TOTAL 209  
 
 
The frequency of the p21
cip1
 variant in subjects in different stages of AD is summarised in 
Table 36 (note that only 193 of the 209 subjects had information regarding Braak staging).  
Of the pre-clinical (entorhinal stage), mild (limbic stage) and advanced (neocortical stage) 
AD sufferers: 9.3%, 10.7% and 15.7% respectively had at least one copy of the p21
cip1 
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variant.  There was a trend (not statistically significant) for patients with advanced AD to 
have a higher frequency of variant p21
cip1
 than patients earlier stages of AD (see odds ratios 
in Table 36, and Figure 11).  
 
Table 36 Frequency of the p21
cip1 
variant in subjects in different stages of AD 
DIAGNOSIS Number of patients 
that are wild type for 
p21
cip1 
 
Number of 
patients that have 
variant p21
cip1
  
Relative 
frequency 
(%) 
Odds ratio 
Pre-clinical 49 5 9.3  
Mild AD 50 6 10.7 1.18 
Advanced AD 70 13 15.7 1.82 
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Figure 11  Distribution of variant p21
cip1 
in subjects in different stages of AD (x-axis: 
E = entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = 
percentage of total; legend: purple = p21
cip1
 variant; blue = p21
cip1
 wild 
type).  
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3.2.2 Distribution of additional pathology by AD severity and p21cip1 genotype 
 
The AD cohort included subjects with Parkinson’s disease, vascular disease, Lewy bodies 
and tumours in addition to AD.  It was not possible to exclude subjects with additional 
pathology from the analysis, as removal of these subjects would have reduced the number of 
patients in the p21
cip1
 variant group to an extent where meaningful statistical analysis would 
not have been possible.  Patients with less common additional pathologies were excluded 
from the analysis.   
 
The analysis of the frequency of additional pathology by disease severity showed that a 
significantly greater proportion of subjects in the early stages of AD had additional 
pathology compared to subjects with advanced AD (p=0.009) (Figure 12).  There was no 
significant difference in the distribution of additional pathology by p21
cip1
 genotype (Figure 
13), irrespective of disease severity (data not shown).    
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Figure 12 Frequency of additional pathology in subjects in different stages of AD 
(x-axis: severity of AD as defined by Braak: E= entorhinal stage, L = 
limbic stage, N = neocortical stage; y-axis = percentage of total; key: VD= 
vascular dementia, TU= tumours, PD= Parkinson’s disease, LB= Lewy 
body dementia, none= no additional pathology).   
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Figure 13 Frequency of additional pathology in subjects with different p21 
genotype (x-axis: p21
cip1
 genotype, 0 = wild type, 1 = variant; y-axis = 
percentage of total; legend: VD= Vascular dementia, TU= tumours, PD= 
Parkinson’s disease, LB= Lewy body dementia, none= no additional 
pathology).   
  
3.2.3 Distribution of ApoE genotypes by AD severity and p21cip1 genotype 
 
The ApoE 4 allele is an established risk factor for late-onset AD22.  There is a significant 
difference in the distribution of ApoE genotypes in patients in different stages of AD: a 
significantly greater percentage of advanced AD patients had the ApoE 4/4 and ApoE 
4/3 genotypes compared to patients in earlier stages of AD (p<0.001) (Figure 14).  
However, there was no significant difference in the distribution of ApoE genotypes between 
the p21
cip1
 wild type and p21
cip1
 variant groups (Figure 15), irrespective of the severity of 
AD (data not shown).    
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Figure 14 The distribution of ApoE genotypes by severity of AD (x-axis = disease 
severity as defined by Braak: E = entorhinal stage, L = limbic stage, N = 
neocortical stage; y-axis = percentage of total; legend refers to ApoE 
genotype).   
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Figure 15 The distribution of ApoE genotypes in groups defined by the p21
cip1 
genotype (x-axis = p21 genotype, 0 = wild type, 1 = variant; y-axis = 
percentage of total; key: ApoE genotype).   
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3.2.4 Distribution of the ApoE 4 allele by AD severity and p21cip1 genotype 
 
A significantly greater percentage of subjects with advanced AD were ApoE 4 carriers than 
subjects with pre-clinical or mild AD (p<0.001) (Figure 16).  There was no difference in the 
frequency of the ApoE 4 allele in the p21cip1 wild type group compared to p21cip1 variant 
group (Figure 17), irrespective of disease severity (data not shown).   
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Figure 16 The distribution of the ApoE 4 allele by the severity of AD (x-axis = 
severity of AD as defined by Braak: E = entorhinal stage, L = limbic 
stage, N = neocortical stage; y-axis = percentage of total; key: purple = 
carrier of the ApoE 4 allele, light blue = non-carrier of the ApoE 4 
allele).    
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Figure 17 The distribution of the ApoE 4 allele in groups defined by p21cip1 
genotype (x-axis = p21 genotype: 0 = wild type, 1 = variant; y-axis = 
percentage of total; purple = carrier of the ApoE 4 allele, light blue = 
non-carrier of the ApoE 4 allele).   
  
3.2.5 The effect of the p21cip1 genotype on the age of onset, age at death, and the 
duration of AD 
 
The severity of AD at the time of death is dependent, at least partially, on the age of onset of 
AD and the age of the patient at death.  To elucidate the effect of the p21
cip1
 genotype on the 
age of onset of AD, age at death and disease duration, we first examined the association of 
these outcomes with disease severity.   
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3.2.5.1. The effect of the severity of AD on the age of onset of AD 
 
The mean age of onset of AD of subjects with mild (limbic stage) and advanced (neocortical 
stage) AD at the time of death are outlined in Table 37 and Figure 18.  Subjects with 
entorhinal stage AD had no age of AD onset, as these individuals were in a pre-clinical stage 
at the time of death.   
 
Advanced AD (neocortical stage) sufferers had a mean age of onset of 69 years.  This was 
significantly lower (p<0.001) than the mean age of onset of subjects with mild AD (limbic 
stage) (77 years) (Figure 18).     
 
Table 37 Mean age of onset of AD of subjects in different stages of AD 
Diagnosis  
(Braak staging of AD) 
Number of patients Mean age of AD onset (years) 
Entorhinal stage  N/A 
Limbic stage 40 77 
Neocortical stage 76 69 
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Figure 18 Mean age of onset of AD of subjects in different stages of AD (x-axis = 
severity of disease: L = limbic stage, N = neocortical stage; y-axis = age of 
onset of AD in years; top of bars represents mean; error bars represent 
standard error of the mean) (one-way ANOVA). 
 
3.2.5.2. The effect of the severity of AD on the age at death 
 
The mean age at death of subjects with pre-clinical (entorhinal stage), mild (limbic stage) 
and advanced (neocortical stage) AD at the time of death are outlined in Table 38 and Figure 
19. 
 
Table 38 Mean age of death of subjects in different stages of AD 
Diagnosis (Braak staging of AD) Number of patients Mean age at death (years) 
Entorhinal stage 49 80 
Limbic stage 50 84 
Neocortical stage 70 77 
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Figure 19 Mean age at death of subjects in different stages of AD (x-axis = severity 
of disease: E = entorhinal stage, L = limbic stage, N = neocortical stage; 
y-axis = age at death in years; top of bars represent mean; error bars 
represent standard error of the mean) (one-way ANOVA). 
 
Advanced AD sufferers (neocortical stage) had a mean age at death of 77, which was 
significantly lower (p<0.001) than the mean age at death of mild AD sufferers (limbic stage) 
at 84.  The mean age at death of subjects with preclinical AD (entorhinal stage) was between 
the mean age at death of mild and advanced AD suffers at 80.     
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3.2.5.3. The effect of the severity of AD on the disease duration 
 
The mean disease duration of subjects with mild AD (limbic stage) was significantly lower 
than the mean disease duration of subjects with advanced AD (neocortical stage) (Table 39 
and Figure 20) (p=0.012).   
 
Table 39 Disease duration of subjects in different stages of AD 
Diagnosis (Braak staging of AD) Mean Disease duration (years) 
Limbic stage 6 
Neocortical stage 7.7 
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Figure 20 Mean age of disease duration of subjects in different stages of AD (x-axis 
= severity of disease: L = limbic stage, N = neocortical stage; y-axis = 
duration of disease in years; top of bars represent mean; error bars 
represent standard error of the mean) (one-way ANOVA).   
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3.2.5.4. The effect of the p21cip1 genotype on the age of onset, age at 
death and the duration of AD 
 
The p21
cip1
 genotype had no effect on the age of AD onset of subjects with preclinical 
(entorhinal) or mild (limbic stage) AD at the time of death (data not shown).  In subjects 
with advanced AD, the age of onset of AD was significantly lower in subjects with the 
variant p21
cip1
 compared to subjects with wild type p21
cip1
 (p=0.016) (Figure 21).  
 
The p21
cip1
 genotype had no effect on the age at death, or the duration of AD, irrespective of 
AD severity (data not shown).  
  
 Advanced AD only
56
60
64
68
72
p21 genotype
A
g
e
 o
f 
o
n
s
e
t
0 1
 
Figure 21 The effect of the p21 genotype on the mean age of onset of AD in subjects 
with advanced AD only (x-axis = p21
cip1
 genotype: 0 = wild type, 1 = 
variant; y-axis = age of onset in years; top of bars represent mean; error 
bars represent standard error of the mean) (one-way ANOVA). 
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3.2.6 The effect of the p21cip1 genotype on the accumulation of AD-related 
pathology  
 
To elucidate the effect of the p21
cip1
 genotype on the accumulation of AD-related pathology 
in the brain, the 193 subjects in the entorhinal, limbic and neocortical stage of AD were 
genotyped for the p21
cip1
 SNPs; and temporal, frontal and occipital lobe protein extracted for 
quantification of AD-related pathology proteins (beta-amyloid, AT8, APP-C, DC11, GAP-
43, synaptophysin, NeuN and p21
cip1
: see Table 17 for description of markers).  As the 
accumulation of AD-related pathology is dependent on brain region, data from the temporal, 
frontal and occipital lobes were analysed separately.      
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3.2.6.1. The effect of the severity of AD on beta-amyloid expression  
 
Subjects in later stages of AD had significantly greater beta-amyloid accumulation in the 
temporal (Figure 22) and frontal lobe (Figure 23) than subjects in earlier stages of the 
disease (p=0.007 and 0.045 respectively).  This was not true of the occipital lobe, with 
subjects in different stages of AD showing no difference in beta-amyloid expression in this 
region (data not shown). 
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Figure 22 The effect of the severity of AD on beta-amyloid expression in the 
temporal lobe (x-axis =severity of AD based on Braak staging, E= 
entorhinal, L= limbic, N= neocortical; y-axis= amount of beta-amyloid in 
the temporal lobe as determined by ELISA; top of bars represent mean; 
error bars represent standard error of the mean) (one-way ANOVA).  
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Figure 23 The effect of the severity of AD on beta-amyloid expression in the frontal 
lobe (x-axis =severity of AD based on Braak staging, E= entorhinal, L= 
limbic, N= neocortical; y-axis= amount of beta-amyloid in the frontal 
lobe as determined by ELISA; top of bars represent mean; error bars 
represent standard error of the mean) (one-way ANOVA).  
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3.2.6.2. The effect of the p21cip1 genotype on beta-amyloid expression  
 
MANOVA was carried out to investigate the effect of the p21
cip1
 genotype on beta-amyloid 
expression in the temporal, frontal and occipital lobe.  The p21
cip1
 genotype had no effect on 
beta-amyloid expression, irrespective of severity of AD, or brain region examined (data not 
shown).  However, there was a trend (not statistically significant) for greater beta-amyloid 
accumulation in the occipital lobe in the earlier stages of AD (see Figure 24).  
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Figure 24 The effect of the p21
cip1
 genotype on beta-amyloid expression in the 
occipital lobe (x-axis = severity of AD as defined by Braak staging: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = amount 
of beta-amyloid in the occipital lobe as determined by ELISA; top of bars 
represent mean; error bars represent standard error of the mean) 
(MANOVA). 
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3.2.6.3. The effect of the p21cip1 genotype on APP-C expression 
 
MANOVA was carried out to investigate the effect of the p21
cip1
 genotype on APP-C 
expression in the temporal, frontal and occipital lobe, independent of AD severity.  APP-C 
expression was not altered by the severity of AD (data not shown).  However, the 21
cip1
 
genotype had a weak effect, with variant p21
cip1 
carriers in the early stages of AD (entorhinal 
and limbic stage) expressing a significantly greater amount of APP-C in the frontal lobe than 
non carriers (p=0.028) (see Figure 25).  The amount of APP-C expressed in the temporal and 
occipital lobe was independent of disease severity and p21
cip1
 genotype (data not shown).   
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Figure 25  The effect of the p21
cip1
 genotype on APP-C expression in the frontal lobe 
(x-axis = severity of AD as defined by Braak: E = entorhinal stage, L = 
limbic stage, N = neocortical stage; y-axis = amount of APP-C in the 
frontal lobe; top of bars represent mean; error bars represent standard 
error of the mean) (MANOVA). 
 
 
3.2.6.4. The effect of the p21cip1 genotype on beta-amyloid relative to 
APP-C expression  
 
The p21
cip1 
genotype had no effect on the relative expression of beta-amyloid to APP-C in 
the temporal, frontal or occipital lobe, irrespective of AD severity (data not shown).   
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3.2.6.5. The effect of the p21cip1 genotype on the accumulation of 
phospho-tau  
 
AT8 is a marker of a pathologically hyperphosphorylated version of tau that is found in 
NFT.  It detects hyperphosphorylated tau both prior to incorporation into tangles and within 
tangles
93
.   
 
There was a significant increase in the amount of phospho-tau (AT8) expressed in the 
temporal, frontal and occipital lobe as AD progressed from an early to more advanced stage 
(p>0.001) (Figure 26 to 28).  Furthermore, there was a trend for greater phospho-tau (AT8) 
expression in the frontal and occipital lobes of subjects with variant p21
cip1
 compared to wild 
type p21
cip1
, which reached significance in the occipital lobe of limbic and neocortical stage 
patients only (p = 0.0156 and p=0.0446 respectively) (Figure 27 and 28).  The p21
cip1 
genotype had no effect on phospho-tau (AT8) accumulation in the temporal lobe, 
irrespective of AD severity (Figure 26).    
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Figure 26 The effect of the p21
cip1
 genotype on phospho-tau (AT8) deposition in the 
temporal lobe (x-axis = severity of AD as defined by Braak staging: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = amount 
of AT8 in the temporal lobe; top of bars represent mean; error bars 
represent standard error of the mean) (Kruskal Wallis).    
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Figure 27 The effect of the p21
cip1
 genotype on phospho-tau (AT8) deposition in the 
frontal lobe (x-axis = severity of AD as defined by Braak staging: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = amount 
of AT8 in the frontal lobe; top of bars represent mean; error bars 
represent standard error of the mean) (Kruskal Wallis). 
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Figure 28 The effect of the p21
cip1
 genotype on phospho-tau (AT8) deposition in the 
occipital lobe (x-axis = severity of AD as defined by Braak staging, E= 
entorhinal, L= limbic, N= neocortical; y-axis= amount of AT8 in the 
occipital lobe; top of bars represent mean; error bars represent standard 
error of the means) (Kruskal Wallis). 
   
The need to take the severity of AD into account when analysing the effect of the p21
cip1
 
genotype lead to very low subject numbers in the p21
cip1
 variant sub-groups defined by the 
severity of AD.  This may have contributed to the lack of statistically significant results 
despite visible trends.  Phospho-tau (AT8) z-scores were calculated for each subject taking 
into account the Braak stage of the individual (a measure of AD severity) (refer to 2.10).   
     
The results showed that ~60% of individuals with variant p21
cip1
 had greater phospho-tau 
(AT8) deposition in the frontal lobe than the group mean; whereas only ~33% of individuals 
with wild type p21
cip1
 had greater phospho-tau (AT8) deposition in the frontal lobe than the 
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group mean (Figure 29).  This difference was statistically significant (p = 0.0419), indicating 
that a significantly greater percentage of individuals with variant p21
cip1
 had “high” frontal 
lobe phospho-tau deposition than individuals with wild type p21
cip1
, irrespective of severity 
of AD (“high” defined as above the group mean).  One-way ANOVA showed that 
individuals with variant p21
cip1
 expressed significantly more phospho-tau (AT8) in the 
frontal lobe than individuals with wild type p21
cip1
, irrespective of AD  severity (p=0.007) 
(Figure 30). 
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Figure 29 The effect of the p21
cip1
 genotype on phospho-tau (AT8) deposition in the 
frontal lobe: independent of disease severity (x-axis = p21
cip1
 genotype: 0 
= wild type, 1 = variant; y-axis: blue = percentage of subjects that 
expressed more AT8 in the frontal lobe than the group mean, purple = 
percentage of subjects that expressed less AT8 in the frontal lobe than 
the group mean; groups defined by Braak stage) (chi-square test). 
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Figure 30 The effect of the p21
cip1
 genotype on phospho-tau (AT8) deposition in the 
frontal lobe: independent of disease severity (x-axis = p21
cip1
 genotype: 
0= wild type, 1= variant; y-axis = z-scores: deviation of each frontal lobe 
AT8 score from the group mean; error bars represent standard error of 
the means) (ANOVA).   
 
Furthermore, ~55% of subjects with variant p21
cip1 
had greater phospho-tau (AT8) 
deposition in the occipital lobe than the group mean; whereas only ~26% of subjects with 
wild type p21
cip1
 had greater phospho-tau (AT8) deposition in the occipital lobe than the 
group mean (Figure 31).  This difference was statistically significant (p=0.0352), indicating 
that a significantly greater percentage of individuals with variant p21
cip1
 had “high” 
phospho-tau (AT8) expression in the occipital lobe than individuals with wild type p21
cip1
, 
irrespective of AD severity (high” is defined as above the group mean).   
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Figure 31 The effect of the p21
cip1
 genotype on phospho-tau (AT8) deposition in the 
occipital lobe: independent of disease severity (x-axis = p21
cip1
 genotype: 
0 = wild type, 1 = variant; y-axis: blue = percentage of subjects that 
express more AT8 in the occipital lobe than the group mean, purple = 
percentage of subjects that express less AT8 in the occipital lobe than the 
group mean; groups are defined by Braak stage) (chi-square test). 
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Additionally, one-way ANOVA showed that subjects with variant p21
cip1
 had a significantly 
greater amount of phospho-tau (AT8) in the occipital lobe than subjects with wild type 
p21
cip1
, irrespective of disease severity (p=0.025) (Figure 32). 
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Figure 32  The effect of the p21
cip1
 genotype on phospho-tau (AT8) deposition in the 
occipital lobe: independent of disease severity (x-axis = p21
cip1
 genotype: 
0= wild type, 1= variant; y-axis = z-scores: deviation of each occipital 
lobe AT8 score from the group mean; error bars represent standard 
error of the means) (ANOVA).   
 
 
The p21
cip1
 genotype had no effect on phospho-tau (AT8) deposition in the temporal lobe, 
irrespective of severity of AD (data not shown).   
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3.2.6.6. The effect of the p21cip1 genotype on neurofibrillary tangle 
deposition 
 
DC11 is a marker of neurofibrillary tangles (NFT), one of the hallmarks of AD
94
.  Kruskal 
Wallis analysis showed that tangle (DC11) deposition was strongly dependent on disease 
severity (p<0.001) in all brain regions examined (temporal, frontal and occipital lobe).  The 
p21
cip1
 genotype had no effect on tangle deposition in the temporal lobe (data not shown).  
However, there was a trend for increase in tangle deposition in the frontal and occipital lobes 
of individuals with variant p21
cip1
 compared to wild type p21
cip1 
(Figure 33 and 34).  The 
trend reached statistical significance in the occipital lobe of limbic stage patients only 
(p=0.0328). 
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Figure 33  The effect of the p21
cip1
 genotype on tangle (DC11) deposition in the 
frontal lobe (x-axis = AD severity as defined by Braak staging: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = amount 
of DC11 in the frontal lobe; top of bars represent mean; error bars 
represent standard error of the mean) (Kruskal Wallis). 
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Figure 34 The effect of the p21
cip1
 genotype on tangle deposition (DC11) in the 
occipital lobe (x-axis = AD severity as defined by Braak staging: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = amount 
of DC11 in the occipital lobe; top of bars represent mean; error bars 
represent standard error of the mean) (Kruskal Wallis). 
 
The need to take the severity of AD into account when analysing the effect of the p21
cip1
 
genotype on NFT (DC11) deposition lead to very low subject numbers in the p21
cip1
 variant 
groups defined by the severity of AD.  As this may have contributed to the lack of 
statistically significant results, DC11 z-scores were calculated for each subject taking into 
account disease severity (refer to 2.10).   
     
The p21
cip1
 genotype had no effect on tangle (DC11) deposition in the temporal lobe, 
irrespective of disease severity (data not shown).  However, the p21
cip1
 genotype had a 
significant effect on tangle (DC11) deposition in the frontal and occipital lobe.      
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Approximately 65% of individuals with variant p21
cip1
 had greater tangle deposition (DC11) 
in the frontal lobe than the group mean; whereas only ~37% of individuals with wild type 
p21
cip1
 had greater tangle deposition (DC11) in the frontal lobe than the group mean (Figure 
35).  This difference was statistically significant (p=0.0395), indicating that a significantly 
greater percentage of subjects with variant p21
cip1
 had “high” tangle deposition in the frontal 
lobe than subjects with wild type p21
cip1
, irrespective of AD severity (“high” defined as 
above the group mean).  
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Figure 35 The effect of the p21
cip1
 genotype on tangle deposition (DC11) in the 
frontal lobe: independent of AD severity (x-axis = p21
cip1
 genotype: 0 = 
wild type, 1 = variant; y-axis: blue = percentage of subjects that express 
more DC11 in the frontal lobe than the group mean, purple = percentage 
of subjects that express less DC11 in the frontal lobe than the group 
mean; groups are defined by Braak stage). 
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 Furthermore, one-way ANOVA showed that individuals with variant p21
cip1
 had 
significantly greater tangle deposition (DC11) in the frontal lobe than individuals with wild 
type p21
cip1
, irrespective of severity of AD (p=0.002) (Figure 36).  
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Figure 36 The effect of the p21
cip1
 genotype on tangle deposition (DC11) in the 
frontal lobe: independent of disease severity (x-axis = p21
cip1
 genotype: 
0= wild type, 1= variant; y-axis = z-scores: deviation of each frontal lobe 
DC11 value from the group mean; error bars represent standard error of 
the means) (ANOVA).    
 
There was no significant difference between the p21
cip1
 wild type group and p21
cip1 
variant 
group in terms of  percentage of subjects with occipital lobe tangle deposition (DC11) above 
the group mean, irrespective of AD severity (data not shown).  However, one-way ANOVA 
showed that individuals with variant p21
cip1
 had significantly greater tangle deposition 
(DC11) in the occipital lobe than wild type p21
cip1 
subjects (p=0.029) (Figure 37). 
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Figure 37 The effect of the p21
cip1
 genotype on tangle deposition (DC11) in the 
occipital lobe: independent of disease severity (x-axis = p21
cip1
 genotype: 
0= wild type, 1= variant; y-axis = z-scores: deviation of each frontal lobe 
DC11 value from the group mean; error bars represent standard error of 
the means) (ANOVA).   
. 
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3.2.6.7. The effect of the p21cip1 genotype on the spread of 
hyperphosphorylated tau from the temporal to the frontal lobe  
 
In AD, tau pathology characteristically accumulates in the temporal lobe, with some 
accumulation in the frontal lobe in later stages of the disease.  The occipital lobe is relatively 
spared even in advanced AD
15
.  The extent and rate of spread of phospho-tau (AT8) from the 
temporal to the frontal lobe was calculated by dividing the relative amount of phospho-tau 
(AT8) expressed in the frontal lobe by the relative amount of phospho-tau expressed in the 
temporal lobe.   
 
We demonstrate that there was significantly greater phospho-tau spread from the temporal to 
the frontal lobe in advanced AD patients (neocortical stage) compared to preclinical and 
mild AD sufferers (limbic and entorhinal stage) (p<0.001) (Figure 38).  There was a trend 
for greater phospho-tau (AT8) spread from the temporal to the frontal lobe in variant p21
cip1
 
carriers compared to non-carriers, which reached significance in subjects with mild AD only 
(limbic stage) (p=0.0455) (Figure 39).    
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Figure 38 The effect of the severity of AD on the rate of spread of tau pathology 
(AT8) from the temporal to the frontal lobe (x-axis= severity of AD, as 
defined by Braak staging, E= entorhinal, L= limbic, N= neocortical; y-
axis= spread of AT8 pathology from the temporal to the frontal lobe; top 
of bars represent mean; error bars represent standard error of the 
means) (Kruskal Wallis).  
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Figure 39 The effect of the p21
cip1
 genotype on the rate of phospho-tau (AT8) 
spread from the temporal to the frontal lobe (x-axis = severity of AD, as 
defined by Braak: E= entorhinal stage, L = limbic stage, N = neocortical 
stage; y-axis = spread of AT8 pathology from the temporal lobe to the 
frontal lobe; top of bars represent mean; error bars represent standard 
error of the mean) (Kruskal Wallis).   
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3.2.6.8. The effect of the p21cip1 genotype on the spread of 
hyperphosphorylated tau from the temporal to the occipital lobe  
 
The extent of phospho-tau (AT8) spread from the temporal to the occipital lobe was 
calculated by dividing the relative amount of phospho-tau expressed in the occipital lobe by 
the relative amount expressed in the temporal lobe.  We found significantly greater phospho-
tau spread from the temporal to the occipital lobe in advanced AD patients (neocortical 
stage) compared to preclinical and mild AD suffers (entorhinal and limbic stage) (p<0.001) 
(Figure 40).  The p21
cip1
 genotype had no effect on phospho-tau spread from the temporal to 
the occipital lobe, irrespective of disease severity.  However, there was a trend (not 
statistically significant) for greater phospho-tau spread in variant p21
cip1
 carriers compared to 
non-carriers (data not shown). 
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Figure 40 The effect of the severity of AD on the rate of spread of phospho-tau 
(AT8) from the temporal to the occipital lobe (x-axis= severity of AD, as 
defined by Braak staging, E= entorhinal, L= limbic, N= neocortical; y-
axis= spread of AT8 pathology from the temporal to the occipital lobe; 
top of bars represent mean; error bars represent standard error of the 
means). 
 
 
3.2.6.9. The effect of the p21cip1 genotype on the spread of NFT from 
the temporal to the frontal lobe 
 
As previously discussed, tangle pathology accumulates predominately in the temporal lobe 
in AD, with some accumulation in the frontal lobe in later stages.  The occipital lobe is 
relatively spared even in advanced AD
15
.  The extent and rate of spread of NFT from the 
temporal to the frontal lobe was calculated by dividing relative frontal lobe NFT (DC11) 
content by relative temporal lobe NFT (DC11) content.  We found that the rate of spread of 
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NFTs from the temporal to the frontal lobe was independent of disease severity (data not 
shown).  The p21
cip1
 genotype had no effect on the rate of spread from the temporal to the 
frontal lobe in preclinical or advanced AD sufferers.  However, in mild AD sufferers, the 
rate of spread of NFTs was significantly greater in variant p21
cip1
 carriers compared to non-
carriers (p=0.0431) (Figure 41).   
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Figure 41 The effect of the p21
cip1
 genotype on the rate of spread of NFT (DC11) 
from the temporal to the frontal lobe (x-axis = severity of AD, as defined 
by Braak: E= entorhinal stage, L = limbic stage, N = neocortical stage; y-
axis = rate of spread of DC11 pathology from the temporal lobe to the 
frontal lobe; top of bars represent mean; error bars represent standard 
error of the mean) (Kruskal Wallis).   
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3.2.6.10. The effect of p21cip1 genotype on the spread of NFT from the 
temporal to the occipital lobe 
 
The rate of spread of NFTs from the temporal to the occipital lobe was calculated by 
dividing occipital lobe NFT (DC11) content by temporal lobe NFT (DC11) content.  The 
rate of spread of NFTs was not altered by the severity of AD (data not shown).  Whilst the 
p21
cip1 
genotype had no effect on the rate of spread of NFTs from the temporal to the 
occipital lobe in subjects in a preclinical or advanced stage of AD: rate of spread of NFTs 
was significantly greater in mild AD patients (limbic stage) that were carriers of the variant 
p21
cip1
 than non-carriers (p=0.0335) (Figure 42).   
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Figure 42 The effect of the p21
cip1
 genotype on the rate of spread of NFTs (DC11) 
from the temporal to the occipital lobe in sufferers of mild AD only (x-
axis = p21
cip1
 genotype: 0 = wild type, 1 = variant; y-axis = rate of spread 
of DC11 from the temporal to the occipital lobe; top of bars represent 
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mean; error bars represent standard error of the means) (Kruskal 
Wallis).   
3.2.6.11. The effect of the p21cip1 genotype on synaptic density 
 
Synaptophysin is a glycoprotein located on neuronal synapses that can be used as a marker 
of synaptic density
95
.  We found a trend for a decrease in the synaptic density of the 
temporal, frontal and occipital lobe as AD progressed from an early to more advanced stage.  
The trend reached statistical significance in the occipital lobe only (p=0.0012) (Figure 43).  
The p21
cip1
 genotype had no effect on the synaptic density of any brain region, irrespective 
of severity of AD (data not shown).    
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Figure 43 The effect of the p21
cip1
 genotype on synaptic density in the occipital lobe 
(x-axis = AD severity as defined by Braak: E = entorhinal stage, L = 
limbic stage, N = neocortical stage; y-axis = synaptophysin expression in 
the occipital lobe; top of bars represent mean; error bars represent 
standard error of the mean) (Kruskal Wallis).   
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3.2.6.12. The effect of the p21cip1 genotype on neuronal density 
 
Neuronal nuclei (NeuN) is a neuron specific protein that can be used as a marker of neuronal 
density
97
.  We found a trend for decrease in the neuronal density of the temporal, frontal and 
occipital lobe as AD progressed from an early to advanced stage, which reached statistical 
significance in the frontal lobe only (p<0.001) (Figure 44).  The p21
cip1
 genotype had no 
effect on neuronal density, irrespective of brain region or severity of AD.     
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Figure 44 The effect of the severity of AD on the neuronal density in the frontal 
lobe (x-axis = AD severity as defined by Braak: E = entorhinal stage, L = 
limbic stage, N = neocortical stage; y-axis = NeuN expression in the 
frontal lobe; top of bars represent mean; error bars represent standard 
error of the mean) (Kruskal Wallis).   
 
Chapter 3  Results  
113 
 
3.2.6.13. The effect of the p21cip1 genotype on synaptic remodelling 
activity 
 
Growth associated protein-43 (GAP-43) is expressed on axonal growth cones during 
synaptic remodelling, and can be used as a marker of synaptic remodelling activity
96
.  The 
synaptic remodelling activity of neurons in the temporal and frontal lobe was independent of 
AD severity and p21
cip1
 genotype.  In the occipital lobe, the synaptic remodelling activity 
significantly decreased as AD progressed from an early to more advanced stage (p<0.001) 
(Figure 45).  The p21
cip1
 genotype had no effect on the synaptic remodelling activity in the 
occipital lobe, although there was a trend for advanced AD patients (neocortical stage) who 
were carriers of the variant p21
cip1
 to have lower remodelling activity than those who were 
wild type for p21
cip1 
(Figure 46).  
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Figure 45 The effect of the severity of AD on the synaptic remodelling activity of 
neurons in the occipital lobe (x-axis = severity of AD as defined by 
Braak: E = entorhinal stage, L = limbic stage, N = neocortical stage; y-
axis = synaptic remodelling activity of neurons (GAP-43) in the occipital 
lobe; top of bars represent mean; error bars represent standard error of 
the mean) (one-way ANOVA).   
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Figure 46 The effect of the p21
cip1
 genotype on the synaptic remodelling activity of 
neurons in the occipital lobe of sufferers of advanced AD only (x-axis = 
p21
cip1
 genotype: 0 = wild type, 1 = variant; y-axis = GAP-43 expression in 
the occipital lobe of sufferers of advanced AD only; top of bars represent 
mean; error bars represent standard error of the mean) (one-way 
ANOVA).   
 
3.2.7 The effect of the p21cip1 genotype on cognitive performance 
 
The available cognitive performance scores (CAMCOG) were the results of the last 
cognitive assessment carried out at most 6 months prior to death.  As expected, the 
CAMCOG scores were highly dependent on severity of AD, with advanced AD patients 
showing significantly lower CAMCOG scores than patients in earlier stages of AD 
(p<0.001) (Figure 47).  The cognitive performance was independent of the p21
cip1
 genotype, 
irrespective of disease severity.     
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Figure 47 The effect of the p21
cip1
 genotype on cognitive performance (x-axis = 
severity of AD as defined by Braak stage: E = entorhinal stage, L = limbic 
stage, N = neocortical stage; y-axis = cognitive performance, at most 6 
months prior to death; top of bars represent mean; error bars represent 
standard error of the mean) (Kruskal Wallis).   
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3.2.8 The effect of the p21cip1 genotype on the stability of p21cip1 mRNA and 
protein 
 
The frontal lobe p21
cip1
 mRNA content was measured by Q-PCR with normalisation to beta-
actin content.  We found that the p21
cip1
 mRNA content was independent of the severity of 
AD (data not shown).  The p21
cip1
 mRNA content of the frontal lobe was also independent of 
p21
cip1
 genotype in individuals with preclinical (entorhinal stage) and mild (limbic stage) 
AD.  However, advanced AD (neocortical stage) patients with variant p21
cip1
 had 
significantly lower p21
cip1
 mRNA content in the frontal lobe than wild type patients (p= 
0.0195) (Figure 48).    
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Figure 48 The effect of the p21
cip1
 genotype on the stability of p21
cip1
 mRNA in the 
frontal lobe of advanced AD patients only (x-axis = p21
cip1
 genotype: 0 = 
wild type; 1 = variant; top of bars represent mean; error bars represent 
standard error of the mean) (Kruskal Wallis).   
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The p21
cip1
 protein content of the temporal, frontal and occipital lobe of each subject was 
measured by ELISA, with normalisation to overall protein content.  We found that p21
cip1
 
protein content was significantly greater in the temporal and frontal lobe of advanced AD 
patients compared to control (p= 0.0087 and 0.046 respectively) (Figure 49 and Figure 50).  
The p21
cip1
 protein content of the occipital lobe was independent of disease severity (data not 
shown). There was a trend for patients with advanced AD to express more p21
cip1
 protein per 
mRNA in the frontal lobe than control, although results failed to reach statistical significance 
(Figure 51).   
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Figure 49 The effect of the severity of AD on p21
cip1
 protein expression in the 
temporal lobe (x-axis = severity of AD as defined by Braak stage: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = p21
cip1 
protein content of the temporal lobe; top of bars represent mean; error 
bars represent standard error of the mean) (Kruskal Wallis).   
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Figure 50 The effect of the severity of AD on p21
cip1
 protein expression in the 
frontal lobe (x-axis = severity of AD as defined by Braak stage: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = p21
cip1 
protein content of the frontal lobe; top of bars represent mean; error 
bars represent standard error of the mean) (Kruskal Wallis).   
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Figure 51 The effect of the severity of AD on p21
cip1
 protein expression per mRNA 
in the frontal lobe (x-axis = severity of AD as defined by Braak stage: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = p21
cip1 
protein expression per mRNA in the frontal lobe; top of bars represent 
mean; error bars represent standard error of the mean) (Kruskal Wallis).   
 
The p21
cip1
 genotype had no effect on p21
cip1
 protein expression in any brain region 
examined, or on amount of p21
cip1
 protein expressed per mRNA in the frontal lobe (data not 
available for the temporal or occipital lobe).  Furthermore, we found no correlation between 
p21
cip1
 mRNA content and p21
cip1
 protein content in the frontal lobe, irrespective of AD 
severity or p21
cip1
 genotype (data not shown).  Multiple regression analysis showed that 
frontal lobe p21
cip1
 protein content was dependent on frontal lobe NFT content (DC11) (R
2
= 
0.1, p = 0.003), and independent of p21
cip1
 mRNA content and disease severity. 
Chapter 3  Results  
121 
 
3.2.9 Relative expression at mRNA level of wild type to variant p21cip1 
heterozygous subjects  
 
SNP A and B on p21
cip1
 tend to be inherited together
77
.  In our cohort, a small number of 
subjects had SNP A, but not SNP B.  These subjects were excluded from this analysis.   
 
The 26 subjects that were heterozygous for both SNP A and B on p21
cip1
 were analysed by 
SNP dependent Q-PCR, to determine the relative expression of mRNA corresponding to 
wild type p21
cip1
 and variant p21
cip1
 in the brain of these subjects (Table 40).  We would 
expect heterozygous subjects to express equal amounts of wild type and variant p21
cip1 
mRNA, unless the rate of transcription, or stability of p21
cip1
 mRNA, was altered by the 
p21
cip1
 SNPs.  Note that the brain region examined varied from subject to subject. 
 
Table 40 Relative p21
cip1
 wild type to variant mRNA expression heterozygous 
subjects 
Effective genotype Number of cases Percentage of all cases 
(26) 
Equal amount of wild type and 
variant p21
cip1
 
13 50% 
More variant p21
cip1
  12 46% 
More wild type p21
cip1
  1 4% 
 
 
Of the 26 subjects that were heterozygous for both p21
cip1 
SNPs: half expressed equal 
amounts of mRNA corresponding to the wild type and variant p21
cip1
 (50%); 46% of 
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subjects expressed significantly more mRNA corresponding to variant p21
cip1 
than wild type 
p21
cip1
; whereas only 1 subject (4%) expressed significantly more mRNA corresponding to 
wild type p21
cip1
 than variant p21
cip1
.  The ratio of wild type to variant p21
cip1
 mRNA was 
not altered by AD, irrespective of disease severity (data not shown).   
 
3.2.10 The effect of the p21cip1 genotype on the function and expression of p21cip1  
 
In order to elucidate the effects of the p21
cip1
 SNPs on the function of the protein in vitro, 
human embryonic kidney cells (Flp-In-T-Rex-293, Invitrogen) were transiently transfected 
with a vector designed to express either wild type p21
cip1
, variant p21
cip1
 (with SNP A and 
B); or no p21
cip1
 (mock transfection: negative control).  The Flp-In-T-Rex-293 cells were 
rapidly dividing and intrinsically wild type for p21
cip1
.  
 
To investigate the success of transfection, the relative expression of p21
cip1
 mRNA and 
protein were determined by Q-PCR and Acumen Cytometry respectively in the transfected 
cells.  Both p21
cip1
 mRNA and protein content were normalised to beta-actin content (Table 
41 and 42).  The ratio of p21
cip1 
protein to mRNA for each transfected cell population is 
shown in Table 43.   
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Table 41  P21
cip1
 mRNA expression in the transfected cells (p21
cip1
 mRNA content 
determined by Q-PCR with normalisation to beta-actin content)   
Transfected population RNA 
(p21
cip1 
/ beta-actin) 
Value relative to mock 
(expressed as a multiple) 
Wild type p21
cip1
 1524 298  
Variant p21
cip1
 1405 275  
Control 5   
 
 
Table 42  P21
cip1
 protein expression in the transfected cells (p21
cip1
 protein content 
determined by Acumen Cytometry with normalisation to beta-actin 
content)   
Transfected population PROTEIN 
(p21
cip1
/ beta-actin) 
Value relative to mock 
(expressed as a multiple) 
Wild type p21
cip1
 2,609 7.2 
Variant p21
cip1
 2,932 8.1 
Control 362   
 
 
Table 43  Ratio of p21
cip1
 protein to mRNA content of the transfected cells (p21
cip1 
protein and mRNA normalised to beta-actin content).    
Transfected population p21
cip1 
PROTEIN/mRNA  Relative to wild type 
p21
cip1  
(expressed as percentage) 
Wild type p21
cip1
 1.71  
Variant p21
cip1
 2.09 122 
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The p21
cip1
 transfected cells had significantly greater p21
cip1
 mRNA and protein content than 
the control cells, irrespective of p21
cip1
 genotype (Table 41 and 42).  To elaborate, the cells 
transfected with wild type p21
cip1 
had 298 times more p21
cip1
 mRNA than the control; 
whereas the cells transfected with variant p21
cip1
 had 275 times more p21
cip1
 mRNA than the 
control.  Furthermore, the cells transfected with wild type p21
cip1
 expressed 7.2 times more 
p21
cip1
 protein than the control; whereas the cells transfected with variant p21
cip1
 expressed 
8.1 times more p21
cip1
 protein than the control.  This indicates that transfection was 
successful and that the mRNA was successfully translated to protein.     
 
We compared p21
cip1
 protein expression per mRNA in the wild type and variant transfected 
populations, and found that cells transfected with variant p21
cip1
 expressed 22% more p21
cip1
 
protein per mRNA than the cells transfected with wild type p21
cip1 
(Table 43).  This implies 
that the SNPs either increase the stability of the p21
cip1
 protein, or decrease the stability of 
the p21
cip1
 mRNA, hence altering protein to mRNA ratio. 
 
3.2.10.1. The effect of the p21cip1 genotype on the nuclear translocation 
efficiency of p21
cip1
 
 
The expression of p21
cip1
 protein, in the cells transfected with wild type or variant p21
cip1
, 
was investigated 2 days post-transfection with the Acumen Cytometer after immunostaining 
with a p21
cip1
 antibody.  Within each well, cells that were positive and negative for p21
cip1 
protein were analysed separately, to avoid misinterpretation of data as a result of unequal 
transfection efficiency or seeding density.  The p21
cip1
 expression per cell was calculated by 
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dividing the total amount of p21
cip1
 protein expressed in the transfected population by the 
total number of p21
cip1
 positive cells in the sample.  To allow comparison of the cells 
transfected with wild type or variant p21
cip1
, p21
cip1
 expression in each transfected 
population was normalised to that of the wild type transfected population.  All results 
concerning p21
cip1
 expression in the wild type population are therefore displayed as 100%.    
 
There was no significant difference in p21
cip1
 protein expression per cell in cells transfected 
with wild type or variant p21
cip1
 (Figure 52).  Furthermore, there was no significant 
difference in the p21
cip1
 protein density per nucleus (Figure 53), or in the percentage of 
p21
cip1
 nuclear positive cells (Figure 54), in cells transfected with wild type or variant 
p21
cip1
.  Taken together, the results indicate that the nuclear translocation efficiency of 
p21
cip1 
was not altered by the SNPs.     
   
 
Figure 52 Mean cellular p21
cip1
 protein content of cells that were positive for p21
cip1
 
(x-axis: dark blue = cells transfected with wild type p21
cip1
, light blue = 
cells transfected with variant p21
cip1
; y-axis: p21
cip1
 protein expression 
per cell expressed as a percentage of that in the wild type population).   
Chapter 3  Results  
126 
 
 
 
Figure 53 Mean p21
cip1
 density per nucleus of cells that were positive for p21
cip1 
 
(x-axis: dark blue = cells transfected with wild type p21
cip1
, light blue = 
cells transfected with variant p21
cip1
; y-axis: p21
cip1
 protein density per 
nucleus expressed as a percentage of that of the wild type population).   
 
 
Figure 54 Percentage of cells that were nuclear positive for p21
cip1
 (x-axis: dark 
blue = cells transfected with wild type p21
cip1
, light blue = cells 
transfected with variant p21
cip1
; y-axis: percentage of all p21
cip1
 positive 
cells that were nuclear positive for p21
cip1
, normalised to the wild type 
transfected population). 
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3.2.10.2. The effect of the p21cip1 genotype on cell cycle kinetics 
 
The cell cycle activity of the cells transfected with wild type or variant p21
cip1 
was 
determined 2 days post-transfection with the Acumen Cytometer after propidium iodide 
staining.  The percentage of cells in G1, S and G2/M phase of the cell cycle was calculated 
for each cell population.  The results are displayed as a percentage change relative to the 
non-transfected cells within the same well (cells that were identified as negative for p21
cip1 
within the cell population).  Therefore, 100% represents cell cycle kinetics identical to that 
of the non-transfected population.        
 
We show that the effect of p21
cip1
 on cell cycle kinetics is dependent on p21
cip1
 genotype, 
despite comparable expression and nuclear translocation efficiency of wild type and variant 
p21
cip1
.  Whilst wild type p21
cip1
 induced a 41% increase in cells in the G2 phase compared 
to non-transfected cells, variant p21
cip1
 only induced a 20% increase in G2 cells: both at the 
expense of cells in the G1 and S phase (Figure 55).  This indicates that p21
cip1
, expressed 
independently of p53, is a G2/M checkpoint inhibitor, and that wild type p21
cip1
 is more 
effectively so than variant p21
cip1
.          
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Figure 55 Percentage of p21
cip1
 positive cells in G1 (green) and G2 (purple) phase of 
the cell cycle (x-axis: wt p21 = cells transfected with wild type p21
cip1
, 
mut p21 = cells transfected with variant p21
cip1
; y-axis: percentage of 
p21
cip1
 positive cells in G1 (green) and G2 (purple) phase of the cell cycle, 
expressed as a percentage change relative to cells that were not 
transfected with p21
cip1
). 
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3.2.10.3. The effect of the p21cip1 genotype on apoptotic activity 
 
The effect of p21
cip1
 on the apoptotic activity of the transfected cells was determined with 
the Acumen Cytometer after propidium iodide staining.  The results are displayed as a 
percentage change relative to the non-transfected cells within the same well (100% 
represents apoptotic activity equal to that of the non-transfected population).  We show that 
the effect of p21
cip1
 on the rate of apoptosis is dependent on p21
cip1 
genotype.  Wild type 
p21
cip1
 reduced the rate of apoptosis to 42% of that of non-transfected cells, whereas variant 
p21
cip1
 only reduced the rate of apoptosis to 49% of that of non-transfected cells (Figure 56).  
This indicates that p21
cip1
 is an anti-apoptotic agent, and that wild type p21
cip1
 is more 
effectively so than variant p21
cip1
.   
 
 
Figure 56 Percentage of p21
cip1
 positive cells undergoing apoptosis (x-axis: wt p21 = 
cells transfected with wild type p21
cip1
, mut p21 = cells transfected with 
variant p21
cip1
; y-axis: percentage of p21
cip1
 positive cells undergoing 
apoptosis, expressed as a percentage change relative to the cells that were 
not transfected with p21
cip1
).   
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3.2.10.4. The effect of the p21cip1 genotype on cellular beta-actin 
expression 
 
The expression of beta-actin in the transfected cells was determined with the Acumen 
Cytometer by immunostaining with a beta-actin specific antibody.  The amount of beta-actin 
expressed per cell was calculated by dividing the total amount of beta-actin expressed in the 
population by the total number of cells in the sample.  We did not double stain with p21
cip1
 
antibody; and so were unable to differentiate the p21
cip1
 positive population (transfected 
cells) from the p21
cip1 
negative population (non-transfected cells).  Therefore, the results are 
normalised to the results of the cells that were transfected with an empty vector (the negative 
control) (Figure 57).   
 
 
Figure 57 Mean beta-actin expression per cell (x-axis: mock = negative control, wt 
p21 = cells transfected with wild type p21
cip1
, mut p21 = cells transfected 
with variant p21
cip1
; y-axis: beta-actin expression per cell, expressed as a 
percentage change relative to the cells that were transfected with an 
empty vector).   
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We show that the cells transfected with p21
cip1 
expressed a significantly greater amount of 
beta-actin per cell than the control, irrespective of p21
cip1
 genotype (Figure 57).  However, 
p21
cip1
 wild type transfected cells expressed a significantly greater amount of beta-actin per 
cell than the p21
cip1
 variant transfected cells (approximately 18% and 11% more than the 
control respectively).    
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3.3.  ELUCIDATING THE IMPRINTING STATUS OF P57KIP2 IN THE 
HUMAN BRAIN; AND THE EFFECTS OF A SNP OF P57
KIP2
 ON 
PROTEIN EXPRESSION, AND ITS ASSOCIATION WITH AD 
 
p57
kip2
 is involved in regulating cell cycle activity, cell survival and cytoskeleton dynamics; 
and has an important role in development
33
.  It is an established CDKI that directly inhibits 
the activity of several cyclin/CDK complexes: including complexes required for progression 
from G1 to S phase.  Aberrant neuronal progression from the G1 to S phase is hypothesised 
to be a cause of neurodegeneration in AD (reviewed in
29, 30
), suggesting that genetic variants 
of p57
kip2
 that are less effective G1/S checkpoint inhibitors, or have reduced expression, may 
contribute to pathogenesis.  Notably, Nagy
74
 found that a genetic variant of p57
kip2 
may be 
associated with an earlier age of onset of AD (although the result failed to reach statistical 
significance due to small sample size).  The genetic variant had a single nucleotide 
substitution at a polymorphic site that triggered an amino acid substitution (alanine to valine) 
within the central domain of the p57
kip2
 protein (residue 159).  Despite a strong association 
between reduced p57
kip2
 expression and cancer
31
, there are no known cancer associated SNPs 
of p57
kip2
.  The investigated SNP was located within a proline/ alanine rich domain (PAPA 
domain), whose function is not fully understood, although it may be involved in the 
interaction of p57
kip2
 with the proteins required for its role in regulating apoptosis and 
cytoskeleton dynamics
33
.   
 
The elucidation of the effect of the p57
kip2
 SNP on AD pathogenesis is complicated by the 
finding that p57
kip2
 is paternally imprinted to some extent: with the maternal allele 
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preferentially expressed
33
.  The expression and extent of imprinting of p57
kip2
 are tissue-
dependent in humans, although it has not been fully investigated in most tissues.  Whilst it is 
known to be expressed in the adult brain
33
; there is no literature on its imprinting status in 
this tissue: although Matsuoka and co-workers
85
 found that there was two-fold expression of 
the maternal allele over the paternal allele in foetal brain, in contrast to an approximately 
twenty-fold expression of the maternal allele over the paternal allele in the other foetal 
organs investigated.  Therefore, an aim of the project was to determine the imprinting status 
of p57
kip2
 in the aging brain.  A second aim was to investigate the relationship between 
severity of AD and p57
kip2 
imprinting status.  It is known that abnormal imprinting of p57
kip2
 
can lead to altered expression and ultimately disease (for example, Beckwith-Wiederman 
syndrome)
31
.  We will investigate the association between p57
kip2
 imprinting and AD.  We 
will also investigate the association of the p57
kip2
 SNP with AD and AD-related pathology. 
 
3.3.1 The p57kip2 imprinting status in the aging human brain    
 
DNA from the frontal lobe, and cDNA from the frontal and occipital lobes, of individuals in 
different stages of AD were genotyped for the p57
kip2
 SNP.  Individuals that were 
heterozygous for the SNP (as determined by genotyping from DNA) were informative in 
terms of imprinting status, as genotyping from cDNA allowed the analysis of proportion of 
expression of the wild type allele to the variant allele.  Of the 69 individuals that were 
heterozygous for the p57
kip2
 SNP: in the frontal lobe, 13% expressed only one of the alleles 
(complete imprinting); 54% showed preferential expression of one of the alleles (partial 
imprinting); whereas 33% had approximately equal expression of the two alleles (no 
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imprinting) (Table 44).  In the occipital lobe: 2.9% expressed only one of the alleles 
(complete imprinting); 55.1% showed preferential expression of one of the alleles (partial 
imprinting); whereas 42% had equal expression of the two alleles (no imprinting) (Table 45).  
The p57
kip2
 imprinting status in the frontal lobes was identical to that in the occipital lobe in 
45.7% of cases (Table 46).    
 
Table 44 p57
kip2
 imprinting status in the frontal lobe 
p57
kip2
 imprinting status Number of patients Percentage of total (%) 
Fully imprinted 9 13 
Partially imprinted 37 54 
Not imprinted 23 33 
TOTAL 69  
 
Table 45 p57
kip2
 imprinting status in the occipital lobe 
p57
kip2
 imprinting status Number of patients Percentage of total (%) 
Fully imprinted 2 2.9 
Partially imprinted 38 55.1 
Not imprinted 29 42.0 
TOTAL 69  
 
Table 46 Comparison of p57
kip2
 imprinting status in the frontal and occipital lobe 
Comparison of p57
kip2
 imprinting 
status in frontal and occipital lobe 
Number of patients Percentage of total (%) 
same 27 45.7 
different 32 54.2 
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3.3.2 The effect of AD on p57kip2 imprinting status  
 
There was no significant difference in the p57
kip2
 imprinting status of the occipital lobe of 
subjects with AD compared to control (Figure 58), or in subjects in different stages of AD 
(Figure 59).  In the majority of subjects, p57
kip2
 was either not imprinted (~42%), or partially 
imprinted (~58%) in this brain region, irrespective of disease severity.   
 
In the frontal lobe, there was a trend (not statistically significant) for loss of p57
kip2 
imprinting in AD subjects compared to control (Figure 60).  Whilst p57
kip2
 was fully 
imprinted (~15%), or not imprinted (15%), in the frontal lobe of some control subjects, in the 
majority of these cases (70%) p57
kip2 
was partially imprinted.  In contrast, 40% of AD 
sufferers had no p57
kip2
 imprinting in the frontal lobe, whereas full imprinting of p57
kip2
 in 
these subjects was reduced to only ~12% of cases.  The trend for loss of imprinting with AD 
was also visible when subjects were analysed by disease severity (not statistically 
significant) (Figure 61). 
 
The imprinting status of p57
kip2
 in the frontal lobe was compared to the imprinting status of 
p57
kip2
 in the occipital lobe in individuals in different stages of AD.  There was a trend (not 
statistically significant) for the imprinting status of p57
kip2
 to become more similar in the 
frontal and occipital lobe in later stages of AD (Figure 62).  Our results suggest that p57
kip2
 
is differentially imprinted in the frontal and occipital lobe of elderly brain: with greater 
imprinting in the frontal lobe compared to the occipital lobe.  There is a tendency for loss of 
imprinting in the frontal lobe as AD becomes increasingly severe.   
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Figure 58 Occipital lobe p57
kip2
 imprinting status (x-axis = diagnosis: AD = subjects 
with AD, not AD = subjects without AD; y-axis = percentage of total; 
dark blue = no imprinting, light blue = partial imprinting, green = full 
imprinting).   
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Figure 59 Occipital lobe p57
kip2
 imprinting status (x-axis = diagnosis: E = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = 
percentage of total; dark blue = no imprinting, light blue = partial 
imprinting, green = full imprinting).   
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Figure 60 Frontal lobe p57
kip2
 imprinting status (x-axis = diagnosis: AD = subjects 
with AD, not AD = subjects without AD; y-axis = percentage of total; 
dark blue = no imprinting, light blue = partial imprinting, green = full 
imprinting).   
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Figure 61 Frontal lobe p57
kip2
 imprinting status (x-axis = diagnosis: E = entorhinal 
stage, L = limbic stage, N = neocortical stage; y-axis = percentage of 
total; dark blue = no imprinting, light blue = partial imprinting, green = 
full imprinting).   
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Figure 62 Comparison of frontal and occipital lobe p57
kip2
 imprinting status (x-axis 
= severity of AD: E = entorhinal stage, L = limbic stage, N = neocortical 
stage, y-axis = percentage of total; purple = identical imprinting status in 
the frontal and occipital lobe; light blue = different imprinting status in 
the frontal and occipital lobe).   
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3.3.3  Frequency of the p57kip2 variant 
 
Of the 209 subjects available for the study, the Braak stage and p57
kip2
 genotype were 
available for 178.  Of these 178 subjects, 91 were wild type (51%), 71 heterozygous (40%), 
and 16 homozygous (9%) for the p57
kip2
 SNP of interest (Table 47).  This is consistent with 
the Hardy-Weinberg equilibrium.  The frequency of the p57
kip2
 variant allele was not 
significantly different in individuals in different stages of AD (Table 48).  However, there 
was a trend (not statistically significant) for a greater percentage of advanced AD sufferers to 
be homozygous for the p57
kip2
 variant compared to preclinical and mild AD sufferers (odds 
ratio = 1.7) (Table 49 and Figure 63).    
 
Table 47 Frequency of the p57
kip2
 SNP  
P57
kip2
 genotype Number of patients Relative frequency % 
Wild type 91 51 
Heterozygous 71 40 
Homozygous 16 9 
TOTAL 178  
 
Table 48 Frequency of the p57
kip2
 allele in subjects in different stages of AD 
DIAGNOSIS P57
kip2 
wild type 
allele 
P57
kip2
 variant 
allele 
Relative frequency of p57
kip2
 
variant allele (%) 
Control 72 28 28 
Limbic stage 75 29 28 
Neocortical 
stage 
106 46 30 
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Table 49 Frequency of subjects homozygous for the p57
kip2
 SNP  
DIAGNOSIS P57
kip2 
(total no. 
of cases) 
P57
kip2
 
(homozygous) 
Relative 
frequency of 
homozygotes (%) 
Odds ratio 
(homozygotes) 
Control 50 3 6.0  
Limbic stage 52 3 5.7 0 
Neocortical 
stage 
76 10 13 1.7 
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Figure 63 Distribution of p57
kip2
 SNP in subjects in different stages of AD (x-axis = 
entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = 
percentage of total; HOM = homozygous, HET = heterozygous, WT = 
wild type).   
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3.3.4 Frequency of additional pathology, the ApoE 4 allele and variant p21cip1 in 
subjects wild type, heterozygous and homozygous for the p57
kip2 
SNP 
 
The ApoE genotype, p21
cip1
 genotype and any additional pathology are potential 
confounding factors in the analysis of the effect of the p57
kip2
 genotype on the risk and age 
of onset of AD, and the accumulation of AD-related pathology.  The distribution of 
additional pathology and ApoE genotypes by severity of AD are described previously 
(Figure 12, 14 and 16).  The distribution of additional pathology (Figure 64), ApoE 
genotypes (Figure 65), the ApoE 4 allele (Figure 66), and variant p21cip1 (Figure 68) were 
investigated by p57
kip2
 genotype, irrespective of disease severity. 
 
There was a trend (not statistically significant) for individuals that were homozygous for the 
p57
kip2
 SNP to have less additional pathology than individuals that were wild type or 
heterozygous for the p57
kip2
 SNP, irrespective of AD severity (Figure 64).  There was no 
significant difference in the distribution of additional pathology in individuals that were wild 
type or heterozygous for the p57
kip2 
SNP, irrespective of disease severity.  
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Figure 64 Frequency of additional pathology in subjects grouped according to 
p57
kip2
 genotype (x-axis: p57
kip2
 genotype, 0 = wild type, 1 = 
heterozygous, 2 = homozygous; y-axis = percentage of subjects; key: VD= 
Vascular dementia, TU= tumours, PD= Parkinson’s disease, LB= Lewy 
bodies, None = no additional pathology).   
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There was a significant difference in the distribution of ApoE genotypes in subjects that 
were wild type, heterozygous and homozygous for the p57
kip2
 SNP (p = 0.028) (Figure 65).   
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Figure 65 Distribution of ApoE genotypes by p57
kip2
 genotype (x-axis = p57
kip2
 
genotype, 0 = wild type, 1 = heterozygous, 2 = homozygous; y-axis = 
percentage of subjects; key outlined ApoE genotypes).  
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However, this did not translate to a significant difference in the distribution of the ApoE 4 
allele in the different groups, irrespective of AD severity, although there was a trend for a 
smaller percentage of p57
kip2 
homozygous subjects to be ApoE 4 carriers than wild type or 
heterozygous subjects
 
(not statistically significant) (Figure 66).  .  This was particularly true 
of subjects with advanced AD at the time of death (Figure 67), with results close to statistical 
significance.   
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Figure 66 Distribution of the ApoE 4 allele by p57kip2 genotype (x-axis = p57kip2 
genotype, 0 = wild type, 1 = heterozygous, 2 = homozygous; y-axis = 
percentage of subjects; key: purple = carriers of the ApoE 4 allele, blue 
= non-carriers of the ApoE 4 allele). 
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Figure 67 Distribution of the ApoE 4 allele by p57kip2 genotype in subjects with 
advanced AD (x-axis = p57
kip2
 genotype, 0 = wild type, 1 = heterozygous, 
2 = homozygous; y-axis = percentage of subjects; key: purple = carriers 
of the ApoE 4 allele, blue = non-carriers of the ApoE 4 allele). 
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Similarly, there was a trend (not statistically significant) for a greater percentage of subjects 
that were homozygous for the p57
kip2
 SNP to be non-carriers of the p21
cip1
 variant compared 
to subjects that were wild type or heterozygous for p57
kip2
. 
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Figure 68 Distribution of variant p21
cip1
 by p57
kip2
 genotype (x-axis = p57
kip2
 
genotype, 0 = wild type, 1 = heterozygous, 2 = homozygous; y-axis = 
percentage of subjects; key: purple = carriers of variant p21
cip1
, blue = 
non-carriers of variant p21
cip1
). 
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3.3.5 The effect of the p57kip2 genotype on the age at onset, age at death, the 
duration of AD, and the cognitive performance 
 
In subjects with advanced AD, the age of onset of AD was independent of the p57
kip2
 
genotype (data not shown).  However, in subjects with mild AD, there was a trend (not 
statistically significant) for carriers of variant p57
kip2
 (heterozygous or homozygous for the 
p57kip2 SNP) to have an earlier age of onset than non-carriers
 
(Table 50 and Figure 69).   
 
Table 50 Mean age of onset of AD of mild AD sufferers that were carriers or non-
carriers of the p57
kip2
 SNP 
P57
kip2
 genotype Number of patients Mean age of onset of AD 
Wild type for p57
kip2
 19 79.7 
Heterozygous or homozygous for 
p57
kip2
 SNP 
16 74.5 
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Figure 69 Mean age of onset of AD of mild AD sufferers that were carriers or non-
carriers of the p57
kip2
 SNP (x-axis = p57
kip2
 genotype: 0 = wild type for 
p57
kip2
 SNP, 1 = heterozygous or homozygous for p57
kip2
 SNP; y-axis = 
age of onset of AD; top of bars represent mean; error bars represent 
standard error of the mean) (one-way ANOVA).   
 
The p57
kip2
 genotype had no effect on the mean age at death or the duration of AD, 
irrespective of disease severity (data not shown).  Furthermore, the p57
kip2
 genotype had no 
effect on the cognitive performance of the patients (camcog score recorded at most 6 months 
prior to death), irrespective of disease severity (data not shown).  
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3.3.6 The effect of the p57kip2 genotype on the accumulation of AD-related 
pathology 
 
To elucidate the effect of the p57
kip2
 genotype on the accumulation of AD-related pathology 
in the frontal and occipital lobe, we first determined the effective p57
kip2
 genotype in the 
frontal and occipital lobe, taking into account the imprinting status of p57
kip2
.  The effective 
genotype is a measure of the ratio of expression of the wild type p57
kip2
 mRNA to the variant 
p57
kip2
 mRNA, and was calculated as a value between zero and one: 0 representing 100% 
expression of the wild type p57
kip2
; 1 representing 100% expression of the variant p57
kip2
.  
Protein extracted from the frontal and occipital lobe was used to quantify various markers of 
AD-related pathology (beta-amyloid, AT8, APP-C, DC11, GAP-43, synaptophysin, and 
NeuN: see Table 17 for description of markers).     
 
Multiple regression analysis was used to identify the independent variables that most 
accurately predict the expression of the markers of AD-related pathology in the frontal and 
occipital lobe.  The independent variables included in the model were: effective p57
kip2
 
genotype; p21
cip1
 genotype; ApoE genotype; and disease severity.  The effective p57
kip2
 
genotype was not a significant predictor of the accumulation of any of the markers of AD-
related pathology in the frontal or occipital lobe (data not shown).   
 
The effect of the dose of the p57
kip2
 variant allele on AD-related pathology in the frontal and 
occipital lobe was determined by appropriate statistical analysis (MANOVA or Kruskal 
Wallis depending on the distribution of the data).  Note that individuals with some 
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expression of both the wild type and variant p57
kip2
 were marked as heterozygous for the 
purpose of this analysis.   
 
The p57
kip2
 variant allele had no effect on the accumulation of beta-amyloid, 
hyperphosphorylated tau (AT8), tangles (DC11), synaptic density (synaptophysin) or 
synaptic remodelling activity (GAP-43) in the frontal lobe, irrespective of disease severity 
(data not shown).  However, the p57
kip2
 variant allele was significantly associated with 
reduced synaptic density (synaptophysin) in the frontal lobe of individuals with advanced 
AD (p= 0.026) (Figure 70).  The p57
kip2
 variant allele had no effect on the accumulation of 
tau pathology (AT8 and DC11), synaptic density (synaptophysin), synaptic regeneration 
activity (GAP-43) or neuronal number in the occipital lobe, irrespective of disease severity 
(data not shown).  However, the p57
kip2
 variant allele was significantly associated with 
increased accumulation of beta-amyloid in the occipital lobe of advanced AD patients (p= 
0.031) (Figure 71).  Furthermore, mild AD patients with the variant p57
kip2
 had significantly 
fewer tangles relative to the amount of hyperphosphorylated tau in the frontal lobe (p= 
0.0105) (Figure 72).   
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Figure 70 The effect of the expressed version of p57
kip2 
on the synaptic density of 
the frontal lobe of advanced AD patients (x-axis = patients grouped 
according to expression of the variant p57
kip2
 allele: 0 = no p57
kip2
 variant 
allele expression, 1 = some p57
kip2 
variant allele expression; y-axis = 
synaptic density of the frontal lobe; top of bars represent mean; error 
bars represent standard error of the mean) (one-way ANOVA).  
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Figure 71 The effect of the expressed version of p57
kip2
 on beta-amyloid expression 
in the frontal lobe of advanced AD patients (x-axis = patients grouped 
according to expression of p57
kip2
 variant allele: 0 = no p57
kip2
 variant 
allele expression, 1 = some p57
kip2 
variant allele expression; y-axis = beta-
amyloid content of the frontal lobe; top of bars represent mean; error 
bars represent standard error of the mean) (one-way ANOVA). 
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Figure 72 The effect of the expressed version of p57
kip2
 on the ratio of tau tangles to 
hyperphosphorylated tau in the frontal lobe of mild AD patients (x-axis = 
patients grouped according to expression of p57
kip2
 variant allele: 0 = no 
p57
kip2
 variant allele expression, 1 = some p57
kip2 
variant allele expression; 
y-axis = ratio of tau tangle to hyperphosphorylated tau content of the 
frontal lobe; top of bars represent mean; error bars represent standard 
error of the mean) (one-way ANOVA). 
 
3.3.7 The effect of the p57kip2 genotype on the stability and expression of p57kip2 
mRNA and protein 
 
Q-PCR was used to measure the amount of p57
kip2
 mRNA expressed in the frontal lobe of 
the subjects in our cohort (results normalised to beta-actin); whereas ELISA was used to 
measure the amount of 57
kip2
 protein expressed in the frontal lobe (results normalised to 
beta-actin to allow comparison).     
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Regression analysis showed a weak but significant positive correlation between p57
kip2
 
mRNA expression and p57
kip2
 protein expression in the frontal lobe of subjects that 
expressed only wild type p57
kip2
 in this region (R
2
= 0.1338, p= 0.006).  There was no 
correlation between the expression of p57
kip2
 mRNA and p57
kip2
 protein in the frontal lobe of 
subjects that expressed variant p57
kip2
 to some extent (Figure 73).  The result suggests that 
the p57
kip2
 SNP alters p57
kip2 
expression at the mRNA or protein level.   
 
 
Figure 73 Correlation between p57
kip2
 mRNA and protein expression in the frontal 
lobe (x-axis = p57
kip2
 mRNA expression in the frontal lobe; y-axis = 
p57
kip2
 protein expression in the frontal lobe; blue represents subjects 
who did not express variant p57
kip2
; red represents subjects who 
expressed variant p57
kip2
). 
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Multiple regression analysis was carried out to identify the independent variables that most 
accurately predict the frontal lobe expression of p57
kip2
 at the protein level.  The independent 
variables included in the model were: p57
kip2
 mRNA content; frontal lobe effective p57
kip2
 
genotype; frontal lobe beta-amyloid content; frontal lobe NFT content (AT8 and DC11); and 
disease severity.  P57
kip2
 expression was most accurately predicted by the p57
kip2
 mRNA 
content, p57
kip2
 genotype and NFT content (R
2
 = 0.25, p < 0.001) (Table 51).  P57
kip2
 protein 
expression in the frontal lobe positively correlated with p57
kip2
 mRNA and NFT content, and 
negatively correlated with effective genotype.  Note that for the effective genotype: 0 = 
100% wild type p57
kip2 
expression and 1 = 100% variant p57
kip2
 expression, indicating that 
variant p57
kip2
 was associated with reduced expression at the protein level.    
 
Table 51 Multiple regression: Predictors of p57
kip2
 protein expression 
Independent variable Co-efficient p-value 
p57
kip2
 mRNA content 0.617 <0.001 
p57
kip2
 effective genotype -0.224 0.004 
NFT content 0.727 0.003 
 
The effect of the p57
kip2
 genotype on p57
kip2
 expression in the frontal lobe, at the mRNA and 
protein level, was investigated in subjects in different stages of AD (MANOVA).  There was 
a trend (not statistically significant) for an increase in the p57
kip2
 mRNA content of the 
frontal lobe of mild and advanced AD patients that expressed only variant p57
kip2
, compared 
to patients that expressed only wild type, or both wild type and variant, p57
kip2
 (data not 
shown).  There was also a trend (not statistically significant) for lower frontal lobe p57
kip2
 
protein content of subjects that expressed only variant p57
kip2
, or wild type and variant 
p57
kip2
, compared to subjects that expressed only wild type p57
kip2
, irrespective of severity of 
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AD (data not shown).  This translated to a significantly lower amount of p57
kip2
 protein 
expressed per mRNA in the frontal lobe of subjects that expressed only variant p57
kip2
 
compared to subjects that expressed only wild type, or both wild type and variant, p57
kip2 
(p= 
0.001) (Figure 74).  
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Figure 74 The effect of the severity of AD, and the expressed version of p57
kip2
, on the 
ratio of p57
kip2
 protein to mRNA in the frontal lobe (x-axis = AD severity, E 
= entorhinal stage, L = limbic stage, N = neocortical stage; y-axis = ratio of 
p57 protein to mRNA in the frontal lobe; top of bars represent mean; error 
bars represent standard error of the means; legend: green = subjects who 
expressed only wild type p57, light blue = subjects who expressed both wild 
type and variant p57, dark blue = subjects that expressed only variant p57).   
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4. DISCUSSION 
 
4.1. ALTERED RAPAMYCIN RESPONSE ELEMENTS IN THE BRAIN 
OF ALZHEIMER’S DISEASE PATIENTS 
 
Two previous studies
71, 72
 have shown that lymphocytes from AD patients have a reduced 
response to a cell cycle inhibitor compared to lymphocytes from controls.  In both studies, 
the cell cycle inhibitor was rapamycin: an upstream inhibitor of the cell cycle promoting 
mTOR pathway.  The results suggest that lymphocytes from AD patients have a deficiency 
downstream of mTOR that leads to loss of cell cycle control.  The cell cycle theory of AD 
postulates that neurons inappropriately re-enter and progress through the cell cycle, and that 
this activity is the cause of the neurodegeneration that defines AD
29, 30
.  We hypothesise that 
the mTOR pathway components that are defective in AD lymphocytes are also responsible 
for the loss of cell cycle control in neurons in AD.  An aim of the study was to identify the 
rapamycin-regulated genes that are differentially expressed in AD brain compared to control, 
as they may serve as novel therapeutic targets or biomarkers of AD.   
 
The custom-made gene expression microarray was designed to include rapamycin-regulated 
genes, as well as other genes-of-interest (see method 2.3.2).  However, only rapamycin-
regulated genes were included in the analysis, so all conclusions are based on differential 
expression of mTOR genes in AD brain compared to control.   
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SAM analysis identified mTOR genes that were differentially expressed in brain affected by 
mild AD (limbic stage) compared to control (18 genes), and in brain affected by advanced 
AD (neocortical stage) compared to control (104 genes).  For the purpose of the discussion, 
the mTOR genes altered as a result of advanced AD were taken as the overlap between the 
altered mTOR genes in brain affected by advanced AD from patients with the ApoE 3/3 
genotype and the altered mTOR genes in brain affected by advanced AD from patients with 
the ApoE 3/4 genotype (section 3.1.3).  This decision was based on the fact that the 
number of subjects in each group (advanced AD with ApoE 3/3 genotype; advanced AD 
with ApoE 3/4; and control with ApoE 3/3) was limited.  The overlap is likely to 
exclude false positives attributable to the low patient numbers, or to the 10% false discovery 
rate (FDR) that was accepted in our study (genes with less than 10% FDR were accepted as 
differentially expressed).   
 
4.1.1 Altered rapamycin response elements in mild and advanced AD 
 
Almost all of the differentially expressed mTOR genes identified early in the disease process 
(limbic stage) were also differentially expressed later in the disease (neocortical stage) (15 
out of 18: 83%).  At a simplistic level, this overlap could be expected, as genes involved 
early in the disease process could also be expected to be involved in advanced AD.  
However, the altered expression refers to a brain region (frontal lobe) that is largely 
unaffected by pathology in mild AD, but greatly affected in advanced AD
15
.  We 
hypothesised that inappropriate mTOR pathway activity may be responsible for the loss of 
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cell cycle control in neurons in AD, so we expected altered expression of mTOR genes to be 
mainly an early event in the pathogenic process.   
 
The fact that 18 of the 1172 rapamycin-regulated genes were altered in mild AD, and that 15 
of these 18 genes were also differentially expressed in advanced AD, suggests that parts of 
the mTOR pathway are altered from an early stage, and continue to be altered as the disease 
progresses.  mTOR pathway involvement in AD is reinforced by the large number of mTOR 
genes that are altered in advanced AD (104/1172: 12.5 %).     
 
4.1.1.1. Functional clusters 
 
The frontal lobe of both mild and advanced AD patients showed up-regulation of mTOR 
genes involved in transcriptional regulation, nucleic acid metabolism, post-translational 
modification of proteins, cell motility, tumour suppression, and inflammation.  In addition, 
advanced AD patients showed altered expression of mTOR genes coding for various 
receptors, channels, growth factors and cell signalling molecules.  As the number of 
differentially expressed genes in advanced AD was much greater than in mild AD, the 
number of genes in each functional category was greater for advanced AD (true for all 
functional categories).   
 
A number of published studies investigate differential expression of genes in AD brain 
compared to control brain: albeit with differences in choice of Braak staging of patients, 
brain region of choice, and microarray platform
90, 91, 103-105
.  In contrast to our study, the 
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papers discussed all used the whole human genome microarray, which identifies 
differentially expressed genes in the whole human genome.  Avramopolous and co-
workers
103
 investigated altered expression in the temporal lobe of advanced AD patients 
compared to control.  They showed up-regulation of genes involved in transcriptional 
regulation and nucleic acid metabolism; and down-regulation of genes involved in neuronal 
activities, such as synaptic transmission and ion channels.  They also showed enrichment of 
genes involved in the inflammatory response
103
.  It is long established that AD is associated 
with inflammation, gliosis and the loss of neurons and synapses
5
, so their finding was not 
surprising.   
 
Similarly, Blalock and co-workers
104
 investigated differential expression in the hippocampus 
of a mix of mild and advanced AD patients compared to control, whereas Xu and 
colleagues
90, 91
 investigated differential expression in the hippocampus of advanced AD 
patients only.  Both showed up-regulated of genes involved in transcription, cell motility, 
cell proliferation, tumour suppression, and inflammation.  Furthermore, they showed down-
regulation of genes involved in energy metabolism, neuronal activities and cell signalling.  
Whilst the exact genes reported as differentially expressed vary from study to study, the 
discussed papers summarise the functional clusters that are differentially regulated in AD 
brain.  As they all looked at brain regions that are severely affected in AD, at an advanced 
stage of the disease, the gene associations can be attributed to the pathological processes that 
define AD (for example: brain atrophy, inflammation and gliosis, and the accumulation of 
the hallmarks of AD)
5
.   
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A limitation of these studies is that they do not inform on the early events in AD.  One of the 
difficulties in interpretation of expression data lies in unravelling the causal changes from 
changes in response to pathology.  Our analysis of a brain region that is affected later in the 
disease process (frontal lobe) in an early stage of the disease (limbic stage) provides vital 
clues to the early pathological processes involved.  Our results show that the main early 
events that involve the mTOR pathway are up-regulation of transcriptional regulators, cell 
motility genes, tumour suppressors, and inflammatory genes.  Our findings concerning the 
late events in AD are in agreement with the published literature, with the enrichment of 
genes in similar functional clusters.  However, in contrast to the discussed studies, our 
expression data included only rapamycin-regulated genes.  This indicates that the mTOR 
pathway is involved in the regulation of many of the physiological and cellular processes 
that are altered in AD.   
 
The inclusion of only rapamycin-regulated genes in our analysis allowed a focused search of 
a pathway that is affected early in AD.  On the downside, it will have lead to a concentration 
of genes in certain functional categories, and exclusion of others.   
 
4.1.1.2. Pathways and networks 
 
The only pathways significantly altered in mild AD (limbic stage) were part of the 
inflammatory response; whereas several pathways were additionally affected in advanced 
AD (neocortical stage).  These included the corticotrophin releasing hormone (CRH) 
pathway, insulin-receptor pathway and transforming growth factor-beta (TGF-beta) pathway.  
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Reduced activity of the neuroprotective CRH signalling pathway
106, 107
, and alterations in the 
insulin receptor signalling pathway
108
, are known phenomena in AD.  The association of AD 
with neuro-inflammation is also long established
109, 110
, with our results indicating that 
inflammatory mediators are involved both early and late in the AD process.  The TGF-beta 
signalling pathway is involved in regulating cell cycle activity and apoptosis, and can both 
promote and inhibit cell cycle activity in the brain depending on context
111
.  Various studies 
have shown that TGF-beta signalling is reduced in neurons in AD
111-113
, although the 
downstream consequences are not fully understood.     
 
We have identified known genes of the mTOR signalling pathway that are differentially 
expressed in AD brain relative to control brain.  We can therefore conclude that parts of the 
mTOR signalling pathway are differentially regulated in AD brain.  This supports the 
hypothesis that defective components of the mTOR pathway may be responsible for the loss 
of cell cycle control in neurons in AD.  Our study has identified both established and 
unknown genes of the mTOR pathway for further investigation: with a large number of these 
genes identified as possible therapeutic targets or biomarkers of AD (see appendix 7 and 10).  
Furthermore, brain from both mild and advanced AD patients showed enrichment of genes 
involved in cellular development, cellular growth and proliferation, and cellular movement, 
suggesting that alterations in cell cycle control are involved early and throughout the disease 
process.   
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4.1.2 Altered rapamycin response elements in advanced AD as a result of the 
ApoE 4 allele 
 
64 rapamycin-regulated genes were differentially expressed in the brain of advanced AD 
patients with the ApoE 3/4 genotype but not differentially expressed in advanced AD 
patients with the ApoE 3/3 genotype.  They are presumably differentially expressed as a 
result of the ApoE 4 allele only.  As there were relatively few patients in each group, some 
of the altered genes may be false positives as a result of non-AD related patient-to-patient 
differences.  However, the number of false positives in the analysis should be minimal as the 
FDR cut-off point was set at 10%.    
 
4.1.2.1. Functional clusters 
 
The mTOR-related genes altered in response to the ApoE 4 allele included genes involved 
in apoptosis, energy metabolism (mitochondrial activity), fatty acid metabolism, synaptic 
activity, cell motility (e.g. adhesion, cytoskeleton structure, axonal guidance), transcriptional 
regulation, and cell signalling (receptors, channels and signalling molecules).  The genes 
were significantly enriched for involvement in cell death, cellular development, cellular 
growth and proliferation, drug metabolism and lipid metabolism.  The results should be 
interpreted in light of inclusion of only rapamycin-regulated genes.  The ApoE 4 allele may 
alter the expression of genes that were not included in the analysis, which may have 
prevented enrichment of genes in relevant functional clusters.   
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Xu and co-workers
90
 carried out a similar study, investigating genes that were differentially 
expressed in brain of AD patients with ApoE 4/4 genotype relative to control (ApoE3/3 
genotype) but not in brain of AD patients with ApoE3/3 genotype relative to control 
(ApoE 3/3 genotype)90, 91.  In contrast to our study, they analysed the expression of all 
genes in the human genome.   In agreement with our result, they demonstrate that the ApoE 
4/4 genotype is associated with cell cycle arrest and apoptosis; and alterations in cell 
signalling, mitochondrial activity, cell motility, and synaptic activity.  Additionally, they 
showed up-regulation of genes involved in cell protection and detoxification, and genes 
involved in myelinogenesis.  
 
 It is well established that the ApoE 4 allele is associated with increased risk of AD114 and 
an earlier age of onset
22, 115
; although the reasons for this remain unclear
22, 116
.  One of the 
functions of ApoE is involvement in lipid metabolism and transport in the body
116
, so it was  
not surprising that the ApoE 4 allele was associated with changes in lipid metabolism in 
AD.  ApoE has also been implicated in synaptic plasticity and dendritic spine formation
117, 
118
; with Tannenberg and colleagues
119
 demonstrating that the ApoE 4 allele is associated 
with faster rate of synaptic loss in AD.  Studies have also shown that the ApoE 4 allele is 
associated with defective mitochondrial metabolism
116, 120
.  Our findings indicate that the 
ApoE 4 allele alters mTOR pathways that affect lipid metabolism, mitochondrial activity, 
cell motility and synaptic plasticity.  Furthermore, it demonstrates that ApoE 4 affects 
numerous signalling pathways involved in regulating cell death, cell growth and cell 
proliferation.  The results suggest that ApoE 4 interacts with alterations in the mTOR 
Chapter 4  Discussion  
165 
 
pathway to contribute to a more severe outcome in terms of pathology.  This interaction 
could account for its association with greater risk and earlier age of onset of AD.       
 
4.1.3 Validation 
 
To validate our results, the mTOR-related genes that were differentially expressed in AD 
were compared to known AD associated genes, identified on the IPA Ingenuity database.  
The comparison showed that approximately 12% of the rapamycin-regulated genes that were 
differentially regulated in AD were already known to be associated with AD.  Our analysis 
included only rapamycin-regulated genes, whereas the 954 genes identified by IPA included 
all genes that are established to have an association with AD.  This difference in inclusion 
criteria accounts for the discordance in number of genes in each list.  As the IPA Ingenuity 
database includes only verified gene/disease associations, based on publications in high 
quality peer-reviewed journals, the list does not include all genes that have altered 
expression in AD brain.  Furthermore, our study was limited to mTOR-regulated genes, so 
did not include a large number of the genes that are known to be associated with AD.  Whilst 
12% overlap does not seem like a lot for validation, this must be interpreted in light of the 
different inclusion criteria of the two gene lists.     
 
Our microarray results were experimentally validated by comparing the direction of altered 
expression of 6 genes in advanced AD brain relative to control as determined by microarray 
to that as determined by real time PCR (Q-PCR).  Both the microarray and Q-PCR results 
showed down-regulation of EIF4E, MAPK1, GABBR2, and DZIP3, and up-regulation of 
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SEMA4C and SERPINE1 in advanced AD relative to control.  The altered expression was 
statistically significant for all the selected genes as determined by microarray.  However, 
despite the Q-PCR direction of expression matching that of the microarray for all genes 
tested, the results failed to reach statistical significance in Q-PCR.  This may have been due 
to platform differences.  The microarray results were normalised to a large number of 
housekeeping genes and internal controls as suggested by Agilent; whereas the Q-PCR 
results were only normalised to the beta-actin content of the samples. Poor choice of 
normalising gene for the Q-PCR may also have contributed.  The literature indicates that 
beta-actin is down-regulated in AD brain compared to control: so it not a reliable 
normalising gene for diseased brain
121
.  The literature indicates that the gene coding for 60S 
ribosomal protein L13 (RPL13) and ribosomal RNA (18S)
122
 are stability expressed in brain, 
irrespective of disease, and so would have been more appropriate choices for normalising 
gene.   
 
4.1.4 Conclusions and limitations 
 
This study identified genes that are differentially expressed in the frontal lobe of AD patients 
compared to control, and are involved in pathways that may play a causal role in the 
pathogenesis of AD.  A major drawback of microarray analysis is that it does not 
differentiate between the primary causal alterations and secondary alterations in response to 
pathology.  The use of a custom-made microarray allowed a more focused search, of a 
pathway-of-interest, which would not have been possible with a whole human genome 
microarray.  However, it may have excluded relevant genes.  It is also important to note that 
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the differential expression applies to the frontal lobe: a region that contains many different 
cell types (predominately neurons and glial cells).  Therefore, no conclusions can be drawn 
on expression changes in neurons alone, unless gene expression is neuron-specific.   
 
In order to investigate altered expression of mTOR genes in neurons only, laser capture 
microdissection could be used: a technique that allows isolation of cells-of-interest from 
other cell types
105
.  Another possible confounding factor was inclusion of mTOR-related 
genes that were polymorphic or had several splice variants on the custom-microarray.  The 
differential expression of some of the genes may be attributable to polymorphisms or 
alternative splice variants that are associated with AD.  It would be of interest to investigate 
whether published genome wide association studies have identified any of the differentially 
regulated mTOR genes as associated with AD.       
 
We would expect a small proportion of the differentially expressed genes in our study to be 
false positives.  Each group-of-interest had relatively few subjects (see 2.3.2.4), so a small 
proportion of the identified genes may have been differentially expressed based on non-AD 
related patient-to-patient differences.  Furthermore, the FDR cut-off point: the estimate of 
the percentage of genes that are incorrectly identified as differentially expressed in an 
analysis, was set at 10%.  However, the vast majority of the differentially expressed genes 
were assigned an FDR well below this value (many were around the 0% mark), keeping false 
positives to a minimum.  Overall, the inclusion of some false positives should not have 
impacted significantly on the conclusions as a large number of mTOR-regulated genes were 
shown to be involved both early and late in the AD process.    
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Another possible limitation was partial degradation of the human brain RNA (RIN value ~ 
2.5) secondary to unavoidable post-mortem time prior to freezing.  This may have lead to 
loss of true-positives or inclusion of false-positives.  However, RNA is thought to degrade at 
a steady rate, predominately in a 5’ to 3’ direction, with the Agilent microarrays designed to 
bind the 3’end where possible86; implying that the output is unlikely to be skewed by 
degradation.  Notably, Lee and colleagues demonstrate that good quality expression outputs 
can be obtained from highly degraded RNA, with minimum loss of true positives
123
. 
 
To conclude, this study demonstrates that components of the mTOR pathway are 
differentially regulated in AD brain compared to control.  Whilst this supports the hypothesis 
that defective components of the mTOR pathway may be responsible for loss of cell cycle 
control in AD neurons: expression data does not allow conclusions on causation.  However, 
the early involvement of the mTOR-regulated genes in a brain region that is not yet affected 
by AD pathology (frontal lobe in early AD) may suggest that the inappropriate regulation of 
this pathway precedes pathology, and may actually be a causal factor.  The identified 
rapamycin-regulated genes that are differentially expressed in AD brain may serve as novel 
therapeutic targets for AD or biomarkers of disease for further investigation.    
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4.2.  THE EFFECT OF THE P21CIP1 GENOTYPE ON P21CIP1 
EXPRESSION AND FUNCTION, AND ASSOCIATION WITH AD 
 
The CDK inhibitor: p21
cip1
 is capable of inducing cell cycle arrest at the G1/S and G2/M 
checkpoints
31
.  It is up-regulated on a transcriptional level in response to p53 (a DNA-
damage induced transcription factor), and inhibits CDK2/cyclin A and CDK2/ cyclin E, 
thereby acting as a G1/S checkpoint inhibitor.  In addition, a number of studies indicate that 
p21
cip1
,
 
expressed independently of p53, induces cell cycle arrest at the G2/M checkpoint
124-
127
.  Furthermore, p21
cip1
 has a number of additional cellular functions (reviewed in
31
).  It 
inhibits proliferating cell nuclear antigen (PCNA), a protein required for DNA replication
128
.  
It also has an anti-apoptotic role: inhibiting the activity of stress activated protein kinases 
(SAPKs), which are involved in stress signalling and the promotion of apoptosis
129
.  The 
location of p21
cip1
 within the cell may dictate its function: with a nuclear location required 
for its cell cycle regulatory role, and a cytoplasmic location required for its anti-apoptotic 
role
130, 131
.    
 
With its cell cycle regulatory role in mind, it is possible that polymorphisms that reduce the 
function or expression of p21
cip1
, may contribute to the loss of cell cycle control and 
inappropriate progression beyond G1 phase, which is postulated to be a cause of 
neurodegeneration in AD
29, 30
.  Notably, a previous study
74
 found that a genetic variant of 
p21
cip1
, that is known to be associated with cancer
76, 77
, is also associated with an increased 
risk and earlier age of onset of AD.  Furthermore, four genetic linkage studies have 
identified genetic variants of the locus on which the p21
cip1
 gene is located, as associated 
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with an increased risk of AD
80, 82, 83, 101
.  The p21
cip1
 variant has a cytosine to adenine change 
that induces an amino acid substitution on codon 31 of the protein that will be referred to as 
SNP A; and a cytosine to thymine change on the 3-prime untranslated region that will be 
referred to as SNP B. 
 
An aim of the study was to elucidate the effect of the p21
cip1
 SNPs on the expression and 
function of the p21
cip1 
protein; and the association of the SNPs with AD.  The literature 
suggests that SNPs A and B are only associated with cancer and AD when found together
74, 
76, 77
.  Therefore, for the purpose of this study, subjects that are heterozygous or homozygous 
for SNP A and B are referred to as having the variant p21
cipl
; whereas individuals that are 
wild type for SNP A and B, or have only one of the SNPs, are referred to as having wild type 
p21
cip1
.  The cohort discussed consists of 209 subjects with a range of severities of AD 
(preclinical, mild and severe AD at the time of death).      
   
4.2.1 Frequency of the p21cip1 variant 
 
Overall, we found that 12% of the cohort (patients with preclinical, mild and severe AD at 
the time of death) had the p21
cip1
 variant.  This is slightly above the 10% frequency found by 
Nagy
74
 in an AD cohort of similar size; and the 10.7% frequency found by Mousses and co-
workers
77
 in a healthy population.  The frequency of variant p21
cip1
 is highest in advanced 
AD (neocortical stage) patients at 15.7%, but is also greater in patients with mild AD 
(10.7%) compared to subjects with few symptoms of AD at the time of death (entorhinal 
stage) (9.3%).  Despite the trend suggesting that the p21
cip1
 variant occurs more frequently in 
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individuals with advanced AD compared to control (odds ratio = 1.82), results failed to reach 
statistical significance.  The p21
cip1
 variant is relatively rare in the population, which lead to 
a small number of subjects with the p21
cip1
 variant in the subgroups defined by severity of 
AD.  This may have contributed to the lack of statistically significant results.  The increased 
frequency of the p21
cip1
 variant in patients with advanced and mild AD relative to control, 
suggests that the p21
cip1
 variant is associated with increased AD risk.  Nagy
74
 found a similar 
association, despite reporting a lower frequency of variant p21
cip1
 in both the AD and control 
group (10% and 6% frequency of variant p21
cip1
 in the AD and control group respectively
74
).     
   
The distribution of the variant p21
cip1
 in the population followed the Hardy-Weinberg 
equilibrium.  The Hardy-Weinberg equilibrium models the distribution of alleles in a 
population based on the assumption that the alleles are passed on randomly from generation 
to generation undisturbed by evolutionary forces (for example, natural selection)
102
.  This 
implies that the p21
cip1
 SNPs are not subject to negative selection. 
 
4.2.2 Distribution of additional pathology and the ApoE 4 allele 
 
The cohort included some individuals with additional pathology: limited to Parkinson’s 
disease, vascular disease, Lewy bodies and tumours.  The removal of these cases from the 
analysis was not possible as doing so would have reduced the number of p21
cip1
 variant cases 
in each subgroup defined by disease severity, to an extent where meaningful statistical 
analysis would not be possible.  We found that a significantly greater percentage of the 
individuals in the preclinical stages of AD had additional pathology compared to individuals 
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in later stages of AD (p<0.001).  This may alter the effect of the severity of AD on the 
outcomes analysed in our study.  However, there was no significant difference in the 
distribution of additional pathologies in the p21
cip1
 variant group compared to p21
cip1
 wild 
type group, irrespective of disease severity.   
 
Similarly, and for the same reason, it was not possible to remove ApoE 4 carriers from the 
analysis, despite the association of the ApoE 4 allele with increased risk and earlier age of 
onset of AD
25
.  As expected, we found that the ApoE 4 allele was more common in patients 
with advanced AD compared to individuals in earlier stages of the disease (p<0.001).  
However, there was no significant difference in the distribution of ApoE genotypes, or in the 
frequency of ApoE 4 carriers, in the p21cip1 variant group compared to p21cip1 wild type 
group, irrespective of disease severity.  Overall, this implies that neither additional 
pathologies, nor the ApoE genotype, are likely to influence the outcome of our analysis 
concerning the effect of the p21
cip1
 genotype.     
 
4.2.3 The effect of the p21cip1 genotype on the age of onset and age at death 
 
We found that patients with mild AD (limbic stage) had a significantly greater age of onset 
(77 years) than patients with advanced AD (neocortical stage) (69 years) (p<0.001).  
Furthermore, patients with advanced AD on average had a disease duration that was 
significantly longer (7.7 years) than that of patients with mild AD (6 years) (p=0.012).  This 
was in agreement with the expectation: AD is a disease of long duration that occurs in the 
elderly, so patients that die early in the disease process (in the entorhinal or limbic stage) 
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would be expected to develop AD at a more advanced age, and die of conditions unrelated to 
AD.  Individuals with entorhinal stage AD were in a pre-clinical stage at the time of death, 
and so did not have an age of onset.    
 
The mean age of death of patients with advanced AD (age 77) was significantly lower 
(p<0.001) than the mean age of death of patients with mild AD (age 84).  Whilst AD 
sufferers can expect a relatively normal lifespan, advanced AD may increase the risk of 
certain life threatening conditions
132, 133
 that contribute to the earlier age of death of patients 
in this group.  Interestingly, the mean age of death of patients in a preclinical stage of AD 
(age 80) was significantly lower than the mean age of death of patients with mild AD (84) 
(p<0.001).  This may be explained by the higher prevalence of additional pathologies 
(discussed in section 4.2.2) in preclinical subjects compared to mild AD patients, which may 
have contributed to the earlier age at death of these patients.  We were unable to remove 
cases with common additional pathologies from the analysis, as doing so would have 
reduced the number of cases to an extent where meaningful statistical analysis would not be 
possible.    
 
In agreement with the results of a previous dataset
74
, we demonstrate that the p21
cip1 
variant 
is associated with an earlier age of onset of AD in patients with advanced AD at the time of 
death (p= 0.016).  This suggests that the p21
cip1 
variant may contribute to AD pathogenesis.  
The association was not apparent in patients with mild AD.  Furthermore, the p21
cip1
 
genotype had no effect on the age at death or disease duration, irrespective of disease 
severity.   
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4.2.4 The effect of the severity of AD on AD-related pathology 
 
ELISA was used to measure markers of neuronal number (NeuN), synaptic density 
(synaptophysin), synaptic regeneration potential (growth associated protein-43: GAP-43), 
beta-amyloid accumulation (beta-amyloid and APP-C) and NFT accumulation (AT8 and 
DC11) in the temporal, frontal and occipital lobes of 193 patients in different stages of AD 
(refer to Table 17 for more detailed description of markers).  The accumulation of AD-
related brain pathology is dependent on the severity of AD and brain region examined, and is 
well documented in the literature
5
.  To ensure that our cohort was representative of the AD 
population, the effect of severity of AD on the accumulation of the selected markers in the 
temporal, frontal and occipital lobe was analysed, and is described below. 
 
We found that subjects with advanced AD had significantly greater deposition of phospho-
tau and tangle pathology in the temporal, frontal and occipital lobes than subjects in earlier 
stages of AD (p<0.001 for all brain regions).  In addition, the rate of spread of phospho-tau 
from the temporal lobe to the frontal and occipital lobes was significantly greater in patients 
with advanced AD patients compared to control (p<0.001).  Tau pathology was measured 
with the AT8 antibody that specifically detects a pathologically hyperphosphorylated version 
of tau, both prior to incorporation into tangles and within tangles
93
; and with the DC11 
antibody that specifically detects AD tangles
94
.  The spread of NFT pathology in the brain is 
known to correlate well with disease severity, and is the basis of the Braak staging system 
that was used to define severity of AD
15
.  Subjects with NFT deposition in the entorhinal 
cortex are classed as pre-clinical (entorhinal stage); subjects with deposition in the entorhinal 
and limbic regions are classed as mild (limbic stage); whereas subjects with additional 
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widespread deposition throughout the neocortex are classed as advanced (neocortical stage).  
The association of severity of AD with NFT accumulation was consistent with the 
expectation for all three brain regions examined (p<0.001).  Notably, we also found that the 
severity of AD correlated well with cognitive decline (p< 0.001)
12, 13
.   
         
Secondly, and consistent with the literature
5
, we found that the accumulation of beta-amyloid 
in the temporal and frontal lobes significantly increased as AD progressed from an early to 
advanced stage, whereas beta-amyloid accumulation in the occipital lobe did not alter in 
different stages of AD.  The occipital lobe is relatively spared of pathology even in advanced 
stages
15, 134
, so this finding was expected.  Neither the expression of the precursor of beta-
amyloid (APP) nor the ratio of beta-amyloid to precursor APP was altered in the temporal, 
frontal or occipital lobes, irrespective of disease severity. 
 
Despite extensive brain atrophy in AD
135, 136
, and AD association with loss of neurons
137, 138
 
and synapses
139-142
, we only found a trend for decrease in the number of neurons (NeuN) and 
synapses (synaptophysin) in the temporal, frontal and occipital lobes as AD progressed from 
an early to advanced stage.  It is possible that the outcome was skewed by the uneven 
distribution of additional pathologies by severity of AD.  A significantly greater percentage 
of preclinical subjects had additional pathology than subjects with advanced AD (see section 
4.2.2).  It is possible that the additional pathologies negatively influenced neuronal number 
and synaptic density (for example, Parkinson’s disease), hence reducing the effect of disease 
severity on these outcomes.   
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The synaptic remodelling activity of neurons was investigated by measuring a neuron-
specific protein that is expressed on axonal growth cones during synaptic remodelling (GAP-
43).  We found that the synaptic remodelling activity of neurons is significantly reduced in 
the occipital lobe of advanced AD patients compared to patients in earlier stages of AD 
(p<0.001).  The synaptic remodelling activity of neurons in the frontal and temporal lobe did 
not alter in different stages of AD.  There is typically a strong correlation between synaptic 
density and cognitive decline
5, 143
, so we would have expected the synaptic remodelling 
activity of neurons to decrease in the brain regions primarily involved in cognition (for 
example, the temporal and frontal lobe).  However, overall, the effect of disease severity on 
the accumulation of the various markers of AD-related pathology was consistent with that of 
published datasets; indicating that our cohort is representative of the overall AD population. 
 
4.2.5 The effect of the p21cip1 genotype on AD-related pathology 
 
In order to elucidate the effect of the p21
cip1
 genotype on the accumulation of AD-related 
pathology, data from each brain region was analysed separately in subgroups defined by 
disease severity.  We found that AD patients with the p21
cip1
 variant had significantly greater 
accumulation of phospho-tau and tangle pathology in the frontal and occipital lobe compared 
to individuals that were wild type for p21
cip1
 (irrespective of disease severity) (p < 0.05 for 
all).  The p21
cip1
 genotype had no effect on the accumulation of tau pathology in the 
temporal lobe.  Furthermore, we found a trend for greater rate of spread of phospho-tau and 
tangle pathology from the temporal lobe to the frontal and occipital lobes in patients with the 
p21
cip1
 variant compared to patients that were wild type for p21
cip1
: with results reaching 
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statistical significance for phospho-tau spread from the temporal lobe to the frontal lobe in 
patient with mild AD only (p = 0.046), and statistical significance for tangle pathology 
spread from the temporal lobe to the frontal and occipital lobes in patients with mild AD 
only (p < 0.05). 
 
The association of the p21
cip1 
variant with tangle pathology was most apparent in the early 
stages of the disease (e.g. limbic stage), and in parts of the brain that are affected later in the 
disease process (e.g. frontal and occipital lobes).  When interpreted in light of the cell cycle 
theory of AD, this is compatible with our hypothesis.  p21
cip1
 is one of the G1/S checkpoint 
inhibitors that inhibits the cyclin/CDK complexes that are required for progression from G1 
to S phase.  We hypothesised that the p21
cip1
 SNPs may reduce the ability of the p21
cip1
 
protein to inhibit cyclin/CDK2, or may reduce its expression, based on the finding that the 
p21
cip1
 variant is associated with cancer
76, 77
.  In effect, we hypothesised that the G1/S 
checkpoint is less tightly regulated in individuals with the p21
cip1
 variant compared to 
individuals with wild type p21
cip1
.  We further hypothesised that the p21
cip1
 variant may 
contribute to the loss of cell cycle control that is postulated to be a cause of 
neurodegeneration in AD
30
.   
 
There is considerable evidence to indicate that neurons in AD re-enter the cell cycle and 
inappropriately progress beyond the G1/S checkpoint
44, 45, 47, 48, 50, 52, 53
.  However, the 
reasons for the loss of cell cycle control in neurons are not understood.  Studies indicate that 
the heritability of late-onset AD is in the range 60-80%
2, 3
, suggesting that there is a strong 
genetic component to the disease, despite few genes established to be associated.  This 
suggests that the reasons for the loss of cell cycle control are complex, and may differ 
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considerably from individual to individual.  Our results suggest that the p21
cip1
 variant may 
contribute to the loss of cell cycle control, which is postulated to be a cause of 
neurodegeneration in AD
30
, in some individuals who develop AD.          
 
The cell cycle theory
29, 30
 goes a long way to explain the accumulation of tau pathology in 
AD.  During a normal cell cycle, the microtubule structure of the cell is extensively re-
organised to allow DNA replication and ultimately cell division
10
.  Tau is a microtubule 
associated protein involved in the re-organisation of the microtubule structure, and is itself 
regulated by phosphorylation
10
.  Under normal circumstances, the cell cycle is driven by the 
activity of various kinases
31
.  The failure to prevent progression at the G1/S checkpoint, 
which is postulated to occur in neurons in AD, may result in inappropriate kinase activity: 
potentially resulting in the hyperphosphorylation of tau that drives formation of insoluble 
NFT
10
.   
 
The fact that the association of the p21
cip1
 variant with tau pathology was most apparent 
early in the disease process, and in brain regions that are relatively unaffected by AD, 
suggests that the p21
cip1
 gene is involved early in the disease process.  The p21
cip1
 genotype 
did not alter the accumulation of tau pathology in the severely affected temporal lobe.  It is 
plausible that other factors may mask the effect of the p21
cip1
 variant when a lot of pathology 
has already accumulated.  For example, the hallmarks of AD (tau and beta-amyloid) are 
themselves neurotoxic
21
, and accumulate primarily in the temporal lobe from an early stage, 
potentially masking the effect of the p21
cip1
 variant in this region. 
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The p21
cip1
 genotype had no significant effect on the accumulation of beta-amyloid, or ratio 
of beta-amyloid to APP-C, irrespective of brain region or severity of AD.  Furthermore, the 
p21
cip1
 genotype had no significant effect on the neuronal number, synaptic density or 
synaptic remodelling activity of neurons in the temporal, frontal or occipital lobe, 
irrespective of disease severity.  However, there was a trend (not statistically significant) for 
greater beta-amyloid accumulation in the occipital lobe of subjects with the p21
cip1
 variant in 
a preclinical or mild stage of AD.  APP levels were also significantly raised in the frontal 
lobe of mild AD patients with the p21
cip1 
variant (p= 0.028) compared to control.  
Furthermore, there was a trend (not statistically significant) for reduced remodelling activity 
of neurons in the occipital lobe of advanced AD patients with the p21
cip1
 variant compared to 
control.  The fact that the association of AD with reduced synaptic density and neuronal 
number was non-significant in our analysis, despite a strong established association
137-139
, 
suggests that the ELISA was not sensitive enough to pick up substantial changes in some 
cases.     
 
To summarise, the association of a genetic variant of p21
cip1
 (a G1/S checkpoint inhibitor) 
with increased accumulation of tau pathology is compatible with the cell cycle theory of AD, 
and suggests that the SNPs reduce the efficiency of the G1/S checkpoint.  Whilst the p21
cip1
 
SNPs did not appear to alter the expression of the other markers of AD-related pathology, all 
trends that failed to reach statistical significance were in a direction to suggest variant p21
cip1
 
association with more severe disease.     
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4.2.6 The effect of the p21cip1 genotype on p21cip1 expression 
 
We show that p21
cip1
 expression in the temporal and frontal lobe (regions affected by AD) 
significantly increases as AD progresses from an early to more advanced stage.  The 
occipital lobe, which is relatively unaffected by AD, did not show altered p21
cip1
 expression.  
Similarly, Engidawork and co-workers
131
 found a significant increase in p21
cip1
 expression in 
the frontal lobe of AD patients, but no alteration in its expression in the cerebellum (a region 
largely unaffected by AD).  They speculate that p21
cip1
 may be up-regulated for its anti-
apoptotic role in AD.  However, the multi-faceted role of p21
cip1
 within the cell, the lack of 
information regarding its cellular location, and the fact that protein was extracted from a 
brain region containing different cell types, prevents conclusions on the consequences or 
reasons for up-regulation.   
 
Whilst it is evident that p21
cip1
 levels are raised in brain regions affected by AD, it is 
possible that this is an artefact of inappropriate accumulation of p21
cip1
, and not an active up-
regulation.  This is supported by the finding that p21
cip1
 mRNA levels in the frontal lobe 
remain stable in different stages of AD.  Interestingly, multiple regression analysis showed 
that the accumulation of p21
cip1
 protein is most strongly dependent on the accumulation of 
tangle pathology in the brain, and not on the severity of AD itself.  It is possible that p21
cip1
 
non-specifically binds to tangles within the cells
10
, accumulating inappropriately; or that the 
mechanisms required for p21
cip1
 protein degradation are faulty in diseased neurons
84
. 
 
We demonstrate that the p21
cip1 
variant has no effect on p21
cip1
 expression at the protein 
level in the temporal, frontal or occipital lobe, irrespective of disease severity.  This may 
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suggest that the detrimental effects of variant p21
cip1
 are not attributable to altered 
expression.  However, we also demonstrate that advanced AD patients with the p21
cip1
 
variant have significantly less p21
cip1
 mRNA in the frontal lobe than patients with wild type 
p21
cip1
.  As discussed above, the raised levels of p21
cip1
 protein in AD may be a consequence 
of inappropriate accumulation as opposed to up-regulation.  If this is the case, a proportion 
of the p21
cip1
 protein in AD brain may be inappropriately located or non-functioning.  Our 
Q-PCR results may indicate that the p21
cip1
 SNPs reduce the stability of p21
cip1
 mRNA, 
potentially altering the expression of p21
cip1
 at the protein level.     
 
We have also shown that half of the individuals that are heterozygous for SNP A and B on 
p21
cip1
 express equal amounts of the wild type and variant p21
cip1 
mRNA; whereas 
approximately the other half express significantly more variant p21
cip1
 mRNA than wild type 
mRNA (although both are expressed to some extent).  As the p21
cip1
 gene is not imprinted, 
this was unexpected.  It suggests that the p21
cip1 
SNPs alter the stability of p21
cip1
 mRNA.  
The reason for the differential expression in only half of the subjects is unclear, and does not 
relate to AD, irrespective of disease severity.  Initially, we thought that the two SNPs may 
alter the stability of the p21
cip1
 mRNA only when they are located in cis (on the same 
strand).  However, the two p21
cip1
 SNPs tend to be inherited together
76, 77
, suggesting that the 
SNPs are located in cis in the majority of cases.  This could be investigated further by 
sequencing.     
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4.2.7 The effect of the p21cip1 genotype on the function and expression of the 
protein in vitro 
 
The fact that the p21
cip1
 variant is associated with cancer
76, 77
, suggests that the p21
cip1
 variant 
is either a less effective G1/S checkpoint inhibitor than the wild type version, or that the 
SNPs alter p21
cip1
 expression.  We have also found that the p21
cip1
 variant is associated with 
increased risk of AD, earlier age of onset, and increased accumulation of tau pathology
74
. 
 
The literature indicates that SNP A and B on p21
cip1
 are only associated with cancer and AD 
when found together
74, 76, 77
: the reasons for this are unclear.  SNP A triggers an amino acid 
change in the CDK2 binding region of p21
cip174
, potentially altering the ability of p21
cip1
 to 
inhibit cyclin/CDK2.  It is also possible that SNP A alters the stability or rate of degradation 
of the p21
cip1
 protein, as the amino acid substitution alters the tertiary structure of the 
protein: potentially altering its interaction with the proteins that regulate its stability and 
degradation
84
.  The functional consequences of SNP B are less clear, although we 
hypothesise that it alters the stability of the p21
cip1
 mRNA.  SNP B is located on the 3’-
untranslated region (UTR) of p21
cip1
, which is involved in regulating the stability of the 
p21
cip1
 mRNA by its interaction with various non-coding RNAs and proteins
84
.   
 
In order to elucidate the effect of the p21
cip1
 SNPs on the function and expression of the 
protein in vitro, the rapidly dividing Flp-In-T-Rex-293 cell line (Invitrogen) was transiently 
transfected with a vector designed to express either: wild type p21
cip1
; variant p21
cip1
 (with 
SNP A and B); or no p21
cip1
 (negative control).  The Flp-In-T-Rex-293 cells were found to 
be intrinsically wild type for SNP A and B on p21
cip1
.   
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We found that the cells transfected with p21
cip1
 contained a significantly greater amount of 
p21
cip1
 mRNA (as determined by Q-PCR) and p21
cip1
 protein (as determined by Acumen 
cytometry) than the control, irrespective of p21
cip1
 genotype.  Acumen cytometry also 
demonstrated that a significantly greater proportion of the p21
cip1
 wild type and variant 
transfected cells were positive and nuclear positive for p21
cip1
 protein than the control.  This 
indicates that the p21
cip1
 vector was successfully transfected into the cells, and that p21
cip1
 
was successfully translated.  The cells transfected with wild type p21
cip1
 contained 298 times 
more p21
cip1
 mRNA than the control; whereas the cells transfected with variant p21
cip1
 
contained 275 times more p21
cip1
 mRNA than the control.  This could suggest that 
transfection was more efficient for wild type p21
cip1
 than variant p21
cip1
.  However, we have 
also shown that the expression of beta-actin per cell differed significantly between the 
control, wild type and variant transfected cell populations.  The p21
cip1
 mRNA content was 
determined by Q-PCR, and normalised to beta-actin content: on the assumption that beta-
actin expression is constant.  The differential expression of beta-actin in the three cell 
populations implies that the results regarding transfection efficiency are skewed.   
 
4.2.8 The effect of the p21cip1 genotype on the stability of p21cip1 mRNA and 
protein 
 
p21
cip1
 expression is tightly controlled by the regulation of various steps in its production and 
degradation (reviewed in
84
), namely: rate of transcription; mRNA stability; rate of 
translation; protein stability; and rate of protein degradation.  The rate of transcription is 
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dependent on the binding of various transcription factors to a response element in the gene: 
the main transcription factor being the p53 protein that binds in response to DNA damage.  
The stability of the p21
cip1
 mRNA is extensively regulated by the binding of various non-
coding RNAs
144
 and proteins
84
 to its 5’ and 3’ -UTRs.  Similarly, the rate of translation can 
be altered by binding of various proteins to its 5’ -UTR (for example, CUG-binding protein 
1 and calreticulin
84
).  The stability and rate of degradation of p21
cip1
 protein is dependent on 
its interaction with various kinases and phosphotases, and the machinery that targets it for 
degradation
84
.  It appears that the p21
cip1
 protein can be degraded in an ubiquitin-dependent 
and independent manner
145
.   
 
In order to elucidate the effect of the SNPs on the stability of the p21
cip1
 mRNA and/or 
protein, we calculated the p21
cip1
 protein to mRNA ratio in the wild type and variant 
transfected cell populations.  To eliminate the problem of beta-actin normalisation, we 
normalised both the p21
cip1
 mRNA and protein results to beta-actin, to allow relative 
comparison of ratios in the wild type and variant transfected cells.  We found that the cells 
transfected with p21
cip1
 variant expressed 50.7% more p21
cip1 
protein per mRNA than the 
cells transfected with wild type p21
cip1
.  This could indicate that the SNPs increase the 
stability of the p21
cip1
 protein and/or that they decrease the stability of the p21
cip1
 mRNA.   
 
SNP A induces a serine to arginine substitution on codon 31: the CDK2 binding region of 
p21
cip1
.  Serine is a polar uncharged amino acid; whereas arginine is positively charged
146
: 
which may alter the tertiary structure of the protein and its interaction with other proteins 
(for example: the kinases and phosphatases that regulate its stability; or the ubiquitin ligases 
that target it for degradation).  Therefore, it is possible that SNP A alters the stability of the 
Chapter 4  Discussion  
185 
 
p21
cip1
 protein, or its rate of degradation.  SNP B is located within the 3’-UTR of p21cip1, so 
it is plausible that it alters the binding of the non-coding RNAs and proteins to the p21
cip1
 
mRNA that regulate its stability.  Two stabilising proteins that bind to the 3’-UTR are HuD 
and RNA-binding motif protein 38 (RBM38)
147, 148
.  Whilst we cannot conclude on the 
individual effects of SNP A and B from these results, they suggest that SNP A alters the 
stability or rate of degradation of the p21
cip1
 protein, and/or SNP B decreases the stability of 
p21
cip1
 mRNA.  The individual effects of the p21
cip1
 SNPs could be determined by a similar 
transfection method, albeit replacing the variant p21
cip1
 mRNA with a version contains only 
one of the SNPs.   
 
4.2.9 The effect of the p21cip1 genotype on the inhibitory function of p21cip1 
 
Cells transfected with wild type or variant p21
cip1
 expressed a significantly greater amount of 
p21
cip1
 protein per cell than the mock transfected cells (negative control).  Furthermore, there 
was no significant difference in the amount of p21
cip1
 protein expressed per cell, in the 
p21
cip1 
nuclear density, or in the percentage of cells that were positive for p21
cip1
 protein, in 
cells transfected with wild type or variant p21
cip1
.  This indicates that the nuclear 
translocation efficiency of p21
cip1
 protein was not altered by the p21
cip1
 SNPs.     
 
We found that a significantly greater percentage of p21
cip1
 transfected cells were in G2 phase 
compared to non-transfected cells, mainly at the expense of G1 cells, irrespective of p21
cip1 
genotype.  Whilst p21
cip1
 may inhibit cell cycle progression at the G1/S and G2/M 
checkpoints
31
, the literature indicates that p21
cip1
 protein, expressed independently of p53, 
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induces a G2 cell cycle arrest in human embryonic kidney cells
124-127
.  Therefore, the 
accumulation of cells in the G2 phase was expected.  Interestingly, we found that the cell 
cycle arrest was more effective for wild type p21
cip1
 than variant p21
cip1
: with wild type 
p21
cip1
 inducing a 41% increase in cells in the G2 phase, compared to only a 20% increase 
for variant p21
cip1
.  This suggests that wild type p21
cip1
 is a more effective G2/M checkpoint 
inhibitor than variant p21
cip1
.  Furthermore, we show that wild type p21
cip1
 is a more 
effective anti-apoptotic agent than variant p21
cip1
.  Wild type p21
cip1
 reducing the rate of 
apoptosis to 49% of that of non-transfected cells, whereas variant p21
cip1
 only reduced the 
rate of apoptosis by 42%.  
 
Additionally, we have shown that cells transfected with wild type p21
cip1
 expressed a 
significantly greater amount of beta-actin per cell than cells transfected with variant p21
cip1
, 
although both expressed more than the control.  Beta-actin is a cytoskeleton protein that is 
part of the internal structure of the cell, and a mediator of internal movement
149
.  The 
cytoskeleton is extensively re-organised during the cell cycle
150
.  The up-regulation of beta-
actin in the p21
cip1
 transfected cells suggests that both wild type and variant transfected cells 
are tending towards differentiation compared to control, with the effect strongest for wild 
type p21
cip1
.   
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4.2.10 Conclusion and limitations 
 
Our results indicate that variant p21
cip1
 is associated with an increased risk of AD, an earlier 
age of onset, and an increase in the accumulation and spread of tau pathology in AD.  
Despite a relatively large cohort (193 subjects) the low prevalence of the p21
cip1
 variant in 
the population (approximately 12%) lead to very few patients in the p21
cip1
 variant 
subgroups defined by disease severity.  This may have contributed to the lack of statistically 
significant results despite visible trends in some cases.  Furthermore, there may be unknown 
confounding factors that were not accounted for in our analysis.  The two identified potential 
confounding factors (ApoE genotype and additional pathology) were found to be balanced 
across the p21
cip1
 wild type and variant groups, irrespective of disease severity, implying that 
they are unlikely to have altered the outcome of the effect of the p21
cip1
 genotype on AD.   
 
Our cell culture results indicate that variant p21
cip1
 is a less effective G2/M checkpoint 
inhibitor, and anti-apoptotic agent, than wild type p21
cip1
.  We also demonstrate that the 
SNPs either decrease the stability of the p21
cip1
 mRNA and/or increase the stability of the 
p21
cip1
 protein; potentially altering p21
cip1
 expression at the protein level.   
 
We cannot conclude on the individual effects of the p21
cip1
 SNPs, as the variant version of 
p21
cip1
 contained both SNPs.  However, as SNP A induces an amino acid change in the 
CDK2 binding region of p21
cip1
, it is plausible that this SNP alters the ability of p21
cip1
 to 
bind and inhibit CDK2.  This could be investigated further by separating complexes of 
cyclin/CDK2/p21
cip1
 from cells transfected with wild type or variant p21
cip1
 (for example by 
immunoprecipitation), and capturing the complexes on G protein beads.  The strength of the 
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binding of p21
cip1
 to cyclin/CDK2 could be investigated by the use of a salt gradient.  It is 
also possible that SNP A increases p21
cip1
 protein levels within the cell, by altering the 
tertiary structure of the p21
cip1
 protein and its interaction with the proteins that targets it for 
degradation
84
.  Similarly, SNP B may alter the interaction of the p21
cip1
 mRNA with the non-
coding RNAs and proteins that regulate its stability
84
.  The fact that the p21
cip1
 SNPs are 
only associated with cancer and AD when found together, suggests that the individual effects 
of the p21
cip1
 SNPs are required for a significant loss of G1/S checkpoint control. 
   
As discussed, our findings are compatible with the cell cycle theory of AD.  They suggest 
that variant p21
cip1
 may contribute to the loss of cell cycle control that is postulated to be the 
cause of neurodegeneration in AD, in some individuals that develop AD.  Previous studies 
have shown that lymphocytes from AD patients have a reduced response to rapamycin 
induced inhibition of the mTOR signalling pathway compared to lymphocytes from 
controls
71, 72
.  We hypothesised that the downstream inhibitory components of the mTOR 
pathway that are defective in AD lymphocytes are also responsible for the loss of cell cycle 
control in neurons in AD.  The p21
cip1
 protein is one of the inhibitory proteins that functions 
downstream of mTOR
31
, so it is plausible that variant p21
cip1
 may contribute to the loss of 
cell cycle control that has been detected in lymphocytes from AD patients.  
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4.3. ELUCIDATING THE IMPRINTING STATUS OF P57KIP2 IN THE 
HUMAN BRAIN, AND THE EFFECT OF A SNP OF P57
KIP2
 ON 
PROTEIN EXPRESSION, AND ITS ASSOCIATION WITH AD 
 
p57
kip2
 is a member of the cip/kip family of CDKIs that regulate cell cycle progression.  In 
addition, it is involved in regulating cell survival, apoptosis and cytoskeleton dynamics.  The 
p57
kip2
 protein is essential for development: with p57
kip2 
knockout mice suffering severe 
developmental abnormalities and early death
33
.  The loss of p57
kip2
 expression has also been 
implicated in Beckwith-Wiedermann syndrome: an overgrowth syndrome associated with 
cancer (for review, see
33
).   
 
Unlike the other cip/kip family members, the p57
kip2
 gene is paternally imprinted to some 
extent in humans: with the maternal allele preferentially expressed
85
.  Genomic imprinting 
refers to the highly complex epigenetic mechanisms that lead to preferential expression of an 
allele of one parent-of-origin over the other
151
.  The epigenetic mechanisms can include 
parent-of-origin specific methylation, chromatin organisation and histone modification; and 
are heritable.  Imprinting is made more complex by the finding that imprinted genes are 
often imprinted in clusters via  an imprinting control region (ICR) located at a distance from 
the genes; and that imprinted genes can help regulate the imprinting of other genes.  Whilst it 
is established that p57
kip2
 is expressed in the human brain
33
, its imprinting status in this 
region is not known.  The literature indicates that p57
kip2
 expression and extent of imprinting 
are tissue dependent, with imprinting established to be partial in some human tissues
85
.  
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The regulation of p57
kip2
 imprinting in human tissues is highly complex.  The p57
kip2
 gene is 
located within a cluster of imprinted genes on chromosome 11p15.5 that share involvement 
in the regulation of development and cell survival
151
.  p57
kip2
 imprinting is controlled by an 
ICR located within KvDMR1: another gene member of the 11p15.5 cluster.  It appears that 
the ICR controls imprinting by two mechanisms
152, 153
: namely, by regulating chromatin 
structure in a methylation-dependent manner; and by coding for an RNA transcript that 
inhibits p57
kip2
 expression in cis.  The transcriptional repressor: CTCF binds the ICR in a 
methylation-dependent manner: altering the chromatin structure to suppress gene expression.  
The methylation status of the ICR is heritable and established in the germline: with the 
maternal ICR methylated, preventing CTCF binding and promoting expression of the 
maternal p57
kip2 
allele; and the paternal ICR unmethylated, promoting CTCF binding and 
preventing expression of the paternal p57
kip2
 allele
154
.  Secondly, the KvDMR1 ICR is itself 
paternally expressed; and codes for the promoter of a non-coding RNA (termed LIT1) that 
prevents expression of p57
kip2
 in cis.  As only the paternal LIT1 is expressed, only the 
paternal p57
kip2
 allele is suppressed
33, 153
.  
 
Shin and co-workers
153
 found that the involvement of the two mechanisms is tissue 
dependent, although it has not been investigated in the human brain.  In addition, an 
imprinted gene (ZAC) located on chromosome 6q24 can bind the ICR of interest in a 
methylation-dependent manner, altering expression of the non-coding LIT1 transcript
155
 and 
hence altering p57
kip2
 imprinting.  This highlights the complexity of p57
kip2
 imprinting, and 
suggests that other unknown mechanisms may yet be discovered.  It is established that 
abnormal p57
kip2
 imprinting can be associated with disease
33
.  However, the lack of 
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information about the correct imprinting of p57
kip2
 in the human brain prevents research 
concerning disease and p57
kip2
 imprinting in this region from being possible.  
 
4.3.1 The imprinting status of p57kip2 in the aging brain 
 
We found that p57
kip2
 imprinting status ranged from full to none in the frontal and occipital 
lobe of aging control brain and brain affected by AD.  The imprinting status in the frontal 
lobe differing from that in the occipital lobe in just above half of the cases examined.  
Despite this, partial imprinting was the most common status in both the frontal and occipital 
lobe of control subjects: with p57
kip2
 partially imprinted in approximately half of informative 
cases.  Of the remaining half, imprinting status was split equally between full and none in the 
frontal lobe, whereas imprinting was largely absent in the occipital lobe.  This suggests that 
p57
kip2
 imprinting is brain-region specific, and that p57
kip2
 is more tightly imprinted in the 
frontal than occipital lobe.   
 
It could also suggest that different cell types in the brain imprint p57
kip2
 to a different extent.  
The cDNA used for determination of p57
kip2
 imprinting status was extracted from a tissue 
block that contained different cell types (neurons and glial cells etc).  Assuming p57
kip2
 
imprinting status is cell-specific, the results are an average of the p57
kip2
 imprinting status of 
the individual cells in the sample.  The large variation in extent of imprinting in the elderly 
brain (ranging from full to none) could be a result of different proportion of cell types in the 
brain samples obtained from different patients and brain regions.  This could be investigated 
further by measuring cell type-specific markers by ELISA to allow calculation of the 
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proportion of different cell types in a sample (for example: NeuN for neuronal density and 
glial fibrillary acidic protein for astrocyte density).  It is also possible that p57
kip2
 imprinting 
status is altered by aging or disease.  All the brains in our cohort were from elderly 
individuals with or without AD, so we cannot conclude on p57
kip2
 imprinting status in the 
brain of subjects at an earlier stage of life. 
 
As of yet, the imprinting status of p57
kip2
 in the human brain has not been investigated.  
Matsuoka and co-workers
85
 found that there was approximately two fold preferential 
expression of the maternal allele in the foetal brain, in contrast to approximately twenty fold 
preferential expression of the maternal allele in the other foetal organs tested.  Furthermore, 
they found approximately nine fold preferential expression of the maternal allele in the 
healthy human kidney.  This forms the background to all literature regarding p57
kip2
 
imprinting: with p57
kip2 
imprinting generally accepted as partial in human tissues.  
Interestingly, Muller and colleagues
156
 found that TSSC3, another paternally imprinted 
member of the 11p15.5 imprinted cluster, was not imprinted in the human brain
156
.  TSSC3 
imprinting is under the control of the same ICR as p57
kip2
, implying that it should have 
similar imprinting to p57
kip2
, unless other unknown mechanisms, independent of the ICR, are 
involved in regulation.  We have shown that p57
kip2
 imprinting status may range from full to 
none in the human brain, and that imprinting status is brain region and/or cell type-specific, 
suggesting that the control of p57
kip2
 imprinting may be more complex than generally 
thought.   
 
It is known that abnormal imprinting of p57
kip2
 and other imprinted genes may lead to 
disease.  For example, Beckwith-Wiederman syndrome is associated with loss of p57
kip2
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imprinting
33
; whereas some brain tumours are associated with gain-of-imprinting of 
TSSC3
156
.  In light of this, we investigated the association of AD with p57
kip2
 imprinting 
status in the frontal and occipital lobe.  We found that p57
kip2
 imprinting was not altered in 
the occipital lobe of AD patients compared to controls, irrespective of disease severity.  
However, there was a trend (not statistically significant) for loss of p57
kip2
 imprinting in the 
frontal lobe of AD patients compared to control.  Approximately 85% of control subjects had 
57
kip2
 imprinting (full or partial) in the frontal lobe, whereas only ~ 60% of AD patients had 
p57
kip2
 imprinting (full or partial) in this region.  There was also a trend (not statistically 
significant) for the extent of imprinting to become more similar in the frontal and occipital 
lobe as AD progressed from a preclinical to advanced stage.  It is well established that the 
frontal lobe is affected by AD-related pathology in AD, whereas the occipital lobe is 
relatively spared, even at an advanced stage
5
.  The loss of p57
kip2
 imprinting in the frontal 
lobe, but not in the occipital lobe, may be indicative of an association between AD and loss 
of p57
kip2
 imprinting.  It would be of interest to investigate the p57
kip2 
imprinting status in the 
temporal lobe of controls and AD subjects, as this region is most severely affected in AD. 
 
The cell cycle theory of AD states that neurodegeneration is secondary to inappropriate 
neuronal cell cycle activity and progression beyond the G1/S checkpoint.  Nagy
74
 proposed 
that the inappropriate progression may be a consequence of inefficient G1/S checkpoint 
control by the members of the cip/kip family of CDKIs, namely: p21
cip1
, p27
kip1
 and p57
kip2
.  
The regulation of the imprinting of p57
kip2 
contributes to the regulation of its expression
33
, so 
it is plausible that inappropriate imprinting may lead to inappropriate expression, and 
inefficient G1/S checkpoint control in some cases.  Alternatively, the p57
kip2
 imprinting 
status may be altered as a consequence of disease.  It is important to note that we cannot 
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conclude on whether imprinting is maternal or paternal, as we did not have access to parental 
DNA.  
4.3.2 The association of a SNP of p57kip2 with AD  
 
As mentioned above, it has been hypothesised that inefficient G1/S checkpoint control by the 
cip/kip family members of CDKIs may contribute to loss of cell cycle control in neurons in 
AD.  We have demonstrated that a genetic variant of p21
cip1
 is associated with an increased 
risk of AD, an earlier age of onset, and an increase in the accumulation of AD-related 
pathology in AD.  Nagy
74
 identified a genetic variant of p57
kip2
 that may be associated with 
AD.  The genetic variant contained a SNP in an exonic region that induced an amino acid 
substitution within the central PAPA domain of p57
kip2 
(residue 159).  The effect of the SNP 
on the function and expression of p57
kip2
 is unknown.  The SNP has not been reported to be 
associated with cancer.   
 
The p57
kip2
 gene has three domains: the N-terminal domain responsible for its CDKI role; 
the central PAPA (proline/ alanine rich) domain of unknown function; and a C-terminal 
domain containing its nuclear localisation signal, which is involved in its anti-apoptotic 
role
33
.  The central domain is postulated to be involved in the interaction of p57
kip2
 with the 
proteins required for its additional functions.  It is possible that the p57
kip2
 SNP alters the 
expression of p57
kip2
 by altering its stability or interaction with the protein degradation 
machinery.  We investigate the effect of the p57
kip2
 SNP on p57
kip2
 expression and 
association with AD. 
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In our cohort, 51% of subjects were wild type, 40% heterozygous, and 9% homozygous for 
the p57
kip2
 SNP.  This is consistent with the Hardy-Weinberg equilibrium
102
, indicating that 
the frequency of the p57
kip2
 variant remains constant in the population from one generation 
to the next.  There was no significant difference in the distribution of the p57
kip2
 variant 
allele in individuals in different stages of AD.  However, there was a trend (not statistically 
significant) for a greater percentage of patients with advanced AD to be homozygous for the 
p57
kip2
 SNP compared to individuals in earlier stages of AD, suggesting that the SNP’s 
association with AD follows a recessive model, and is independent of dose.    
 
In agreement with the Nagy study
74
, our results suggest that the p57
kip2
 SNP may be 
associated with an increased risk of AD.  It may also be associated with a reduced age of 
onset of AD, although results failed to reach statistical significance.  Variant p57
kip2
 was 
associated with more severe pathology for some aspects of pathology investigated.  Namely, 
synaptic density in the frontal lobe (p = 0.026), and beta-amyloid accumulation in the 
occipital lobe (p = 0.011) of advanced AD patients only (the p57
kip2
 imprinting status was 
taken into account when analysing the data).  Variant p57
kip2 
was also associated with greater 
accumulation of phospho-tau relative to tangles in the frontal lobe of mild AD patients (p = 
0.011), although overall accumulation of phospho-tau and tangles was independent of p57
kip2
 
genotype, irrespective of AD severity.  This suggests that the p57
kip2
 SNP alters tau 
processing; and may interact with its role in regulating cytoskeleton dynamics
33
.  Variant 
p57
kip2
 was not associated with the other aspects of AD-related pathology (neuronal density 
or synaptic regeneration potential), irrespective of severity of AD.   
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We investigated the distribution of various confounding factors by p57
kip2
 genotype to 
ensure that the association of variant p57
kip2
 with AD was not altered by these factors.  There 
was a trend for a smaller percentage of p57
kip2
 homozygous subjects to have additional 
pathology, and to be ApoE 4 and variant p21cip1 carriers, than subjects wild type or 
heterozygous for the p57
kip2
 SNP (irrespective of severity of AD).  However, none of the 
trends reached statistical significance.  The confounding factors were balanced across the 
wild type and heterozygous groups.  This implies that the mentioned factors do not confound 
the association of the p57
kip2
 variant with AD, although it is possible that there are other 
unknown factors.  A larger cohort would be required to further disentangle the association.   
 
4.3.3 The effect of the p57kip2 SNP on p57kip2 expression  
 
The reason for the association of the p57
kip2
 SNP with AD is unclear.  Presumably the SNP 
reduces the expression or function of the p57
kip2
 protein; contributing to the loss of G1/S 
checkpoint control that is postulated to be a cause of neurodegeneration in AD
30
.  The SNP 
is located, not within the CDKI domain of the p57
kip2
 protein, but within the central PAPA 
domain of unknown function.  Therefore, it is unlikely that the p57
kip2
 SNP reduces the 
CDKI function of the p57
kip2
 protein; although it may interfere with the proteins’ other 
functions (for example, role in regulating apoptosis or cytoskeleton dynamics).  It is possible 
that the loss of the other functions may contribute to the development of AD. Alternatively, 
the SNP may reduce p57
kip2
 expression by altering the stability or rate of degradation of the 
p57
kip2
 protein.  Our results suggest that this is the case.     
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We found a weak but significant positive correlation between the amount of p57
kip2
 mRNA 
and protein in the frontal lobe of subjects that were wild type for the p57
kip2
 SNP (R
2
 = 0.13, 
p = 0.006).  The association was not present in subjects that expressed only the p57
kip2
 
variant, or expressed the variant to some extent, suggesting that the SNP alters p57
kip2
 
expression at the mRNA and/or protein level.  Furthermore, multiple regression analysis 
showed that p57
kip2
 protein content was most accurately predicted by the p57
kip2
 mRNA 
content, p57
kip2
 genotype, and NFT content in the frontal lobe (R
2
 = 0.25, p < 0.001).  The 
p57
kip2
 protein content negatively correlated with the expression of variant p57
kip2
 (p = 
0.004), indicating that the SNP is associated with reduced expression.  The positive 
association between p57
kip2
 protein content and NFT content may suggest that p57
kip2
 protein 
non-specifically binds to tau tangles, as was hypothesised to be the case for p21
cip1
 (see 
4.2.6).  Interestingly, we found that p57
kip2
 homozygous subjects had a trend for increased 
p57
kip2
 mRNA expression and reduced p57
kip2
 protein expression in the frontal lobe 
compared to wild type and heterozygous subjects.  The trends translated to a significantly 
reduced amount of p57
kip2
 protein per mRNA in subjects that were homozygous for the 
p57
kip2
 SNP compared to wild type and homozygous subjects.   
 
Overall, our results indicate that the p57
kip2
 SNP may decrease the half-life of the protein.  
The expression of p57
kip2
 is subject to extensive regulation; and can be rapidly altered as a 
consequence of  rapid turn-over (for review, see
33
).  It is degraded by the proteosome in an 
ubiquitin-dependent manner: its rate of ubiquitination dependent on its phosphorylation 
status.  Therefore, its stability is dependent on its interaction with various kinases and 
phosphotases, ubiquitin ligases, and the proteosome.  It is plausible that the alanine to valine 
amino acid substitution induced by the p57
kip2
 SNP may trigger a structural change, or alter a 
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phosphorylation site, that leads to more rapid degradation of the protein.  However, as of yet, 
the altered amino acid residue (codon 159) has not been identified as involved in its 
degradation.     
4.3.4 Conclusions and limitations  
 
We found that p57
kip2
 imprinting status ranged from full to none in the elderly brain: with 
p57
kip2
 more tightly imprinted in the frontal lobe than occipital lobe.  This could suggest that 
p57
kip2
 imprinting status is brain-region or cell-type specific, as the distribution of different 
cell types in the samples was not investigated.  We found a weak (not statistically 
significant) association between loss of p57
kip2
 imprinting in the frontal lobe (affected by 
AD), but not in the occipital lobe (not affected by AD), which may be indicative of an 
association between AD and loss of imprinting of p57
kip2
.   
 
Our results may suggest that the p57
kip2
 SNP is associated with an increased risk of AD, an 
earlier age of onset, and an increased accumulation of some aspects of AD-related 
pathology, although few of the results reached statistical significance.  We found that the 
p57
kip2
 SNP may reduce the half-life of the p57
kip2
 protein, suggesting a mechanism for the 
G1/S checkpoint failure in patients with the p57
kip2
 SNP.  It is compatible with the cell cycle 
theory of AD, and suggests that the p57
kip2
 SNP may contribute to the loss of cell cycle 
control in neurons in some individuals that develop the disease.  AD may also be associated 
with loss of imprinting of p57
kip2
 in some patients, potentially leading to reduced p57
kip2 
expression and reduced G1/S checkpoint control.  A larger cohort would be required to 
further disentangle these associations. 
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Table 52 Manufacturers of chemicals required for DNA, RNA and protein 
extraction (TRI-reagent method) 
Product Manufacturer 
1-bromo-3 chloropropane Sigma 
acetone Sigma 
aprotinin Sigma 
EDTA Sigma 
Ethanol Sigma 
glycerol Sigma 
guanidine hydrochloride Sigma 
high-Capacity cDNA Reverse Transcription kit  Applied bioscience 
isopropanol Sigma 
nuclease free water Qiagen 
phenylmethanesulfonylfluoride  Roche 
sodium chloride Sigma 
sodium citrate Sigma 
sodium dodecyl sulphate Sigma 
TRI-reagent Sigma 
tris-hydrochloride Sigma 
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Table 53 Manufacturers of chemicals required for gene expression microarray 
analysis (Agilent) 
Chemical Manufacturer 
acetonitrile  
DNase Promega 
ethanol Sigma 
GEx Hybridisation buffer HI-RPM  Agilent Technologies 
low-input quick amplification labelling kit  Agilent Technologies 
RLT-mix: Rneasy mini column kit Qiagen 
RNeasy mini column  Qiagen 
RPE buffer: Rneasy mini column kit Qiagen 
stabilisation and drying solution  Agilent Technologies 
wash buffer 1  Agilent Technologies 
wash buffer 2 Agilent Technologies 
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DNase treatment of RNA  
1 unit of RNase free DNase (Qiagen) was sufficient to treat 1 µg of RNA.  The quantity of 
RNA was determined by nanodrop spectrophotometry; and the DNase treatment mixture set 
up as outlined in Table 3.   The mixture was incubated at 37ºC for 30 minutes; and RNA re-
extracted  by standardTRI-reagent protocol (adjusted for volume of TRI-reagent used) to 
inactive DNase (see method 2.2).   
   
Table 54  DNase treatment of RNA 
Reagent Volume 
RNA in water 1-8 µl 
RQ1 RNase free DNase buffer (Qiagen) 1 µl 
RQ1 RNase free DNase (Qiagen) 1unit/µg RNA (1 µl contains 1 unit) 
Water to final volume (Qiagen) 10µl 
 
Purification of RNA with Qiagen RNeasy mini column  
84µl of nuclease free water (Qiagen), 350µl buffer RLT (Qiagen) and 250µl of 100% 
ethanol (Sigma) were added per cRNA sample.  The cRNA mix was transferred to an 
RNeasy mini column (Qiagen) and centrifuged at 4ºC for 30 seconds at 13,000 rotations per 
minute (rpm).  The RNeasy mini column filter was subsequently washed twice with 500µl 
buffer RPE (Qiagen) (with ethanol added as stated in the kit protocol), with centrifugation at 
13,000rpm for 60 seconds at 4
o
C between washes.  The cRNA was eluted from the filter by 
the addition of 30µl nuclease free water, incubation at room temperature for 1 minute, and 
centrifugation at 4º for 30 sec at 13,000rpm.  
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Determination of p57
kip2
 imprinting status 
 
The subjects that were heterozygous for the p57
kip2
 SNP were informative in terms of 
imprinting status.  For heterozygous DNA, the ratio of intensity of the wild type band to 
variant band represented equal quantity of wild type and variant allele.  The ratio of the wild 
type band to variant band for heterozygous DNA was dependent on the overall intensity of 
the bands, and ranged from 1.0 to 1.22.  Figure 1 shows the statistically significant positive 
correlation between the intensity of the wild type band and the wild type to variant band ratio 
for heterozygous DNA (R
2 = 0.68, p <0.001).  The DNA values deviated from the “expected 
values” by a maximum of 7% .  Note that the expected value denotes the value that would be 
expected if there was equal expression of wild type and variant p57
kip2
 as calculated from the 
regression equation (represented by the black line in Figure 75).   cDNA ratios that deviated 
from the expected value by more than 7% were interpreted as having unequal expression of 
wild type and variant p57
kip2 
(above the line = more wild type p57
kip2
 expression than variant 
p57
kip2
 expression; below the line = more variant p57
kip2
 expression than wild type 
expression).   
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Figure 75 Statistically significant positive correlation between the intensity of the 
wild type band and the ratio of the wild type to variant band intensity of 
heterozygous DNA (P>0.001, R
2
 = 0.6826) (x axis = wild type band 
intensity of heterozygous DNA samples, y-axis = wild type to variant 
band intensity ratios for heterozygous DNA samples; regression equation 
shown on graph). 
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Lymphocyte cell culture and rapamycin treatment in preparation for microarray 
based gene expression analysis 
 
Lymphocyte separation from blood 
 
To identify rapamycin-regulated genes in lymphocytes, viable lymphocytes from 4 healthy 
subjects with maximal rapamycin response, as determined by Flow Cytometry and cell 
counting, were selected for microarray analysis.  Buffy coat residues were provided by the 
NHS blood and transfusion centre.  The buffy coats were enriched with 360ml of RPMI-
1640 (Sigma), and diluted (15:35) with phosphate buffered saline (PBS) (Sigma).   30ml of 
the cell suspension was layered onto 15 ml lymphoprep (Axis Shield UK), centrifuged at 800 
RCF for 30 minutes, and upper layer discarded.  The middle layer was separated to a clean 
centrifuge tube, centrifuged at 400 RCF for 10 minutes, and supernatant discarded.  The cell 
pellets were resuspended in 90% foetal calf serum (FCS) gold (Sigma) and 10% DMSO 
(Sigma), and stored at -80ºC.    
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Lymphocyte culture and rapamycin treatment 
 
Frozen lymphocytes were washed in 12 times RPMI-1640 (Sigma), centrifuged at 400 RCF 
for 10 minutes at RT, and re-suspended in RPMI-1640 (Sigma), to give a final cell 
suspension of 2 million cells per ml.  75µl of cell suspension was added per well of a 96 well 
plate and supplemented with 75µl of lymphocyte culture medium (composed of RPMI-1640 
with L-glutamine (2% final), penicillin/streptomycine (1% final), foetal calf serum heat 
inactivated (15% final) and PHA (PAA) (2.5% final)).  After 48 hours at 37ºC, the 
lymphocyte cultures were treated with 150µl per well of 100ng/ml rapamycin in culture 
medium (composition as above).  The control lymphocytes were treated with culture 
medium only.  Cells were incubated at 37ºC for 24 hours prior to collection. 
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Transient transfection of p21
cip1
 into human embryonic kidney cells 
 
Two vectors (pCMV6-XL5) were ordered from Origene: plasmids containing wild type 
p21
cip1
 DNA; and plasmids containing variant p21
cip1
 DNA (with SNP A and B).  The 
plasmids were transiently transfected into Flp-In-T-Rex-293 cells (human embryonic kidney 
cell line HEK-293) (Invitrogen) by standard Lipofectamine-2000 (Invitrogen) protocol.  The 
Flp-In-T-Rex-293 cell line was chosen as it is suitable for transfection, whilst being low 
maintenance and fast growing.  Vector pcDNA5/FRT/TO/CAT (Invitrogen) was chosen as 
the negative control for the mock transfection as it does not express p21
cip1
.   
 
The Flp-In-T-Rex-293 cells were plated in 75cm
2 
flasks at a density of 40,000 cells/ml in 
18.75ml of culture medium (composition: Dulbecco’s modified eagle’s medium (DMEM) 
containing 4500mg glucose/litre (Sigma); 10% fetal calf serum (FCS) gold (PAA); and 2mM 
L-glutamine (Gibco).  The cells were grown at 37ºC until 90-95% confluence 
(approximately 2 days).  In preparation for transfection, 30µg of plasmid DNA was diluted 
in 1.875ml of Opti-MEM reduced serum medium (Gibco); and 75µl of Lipofectamine 2000 
(Invitrogen) diluted in 1.875ml Opti-MEM.  After 5 minute incubation, the two mixtures 
were combined and incubated at RT for 20 minutes.  The 3.75ml mixture was added to a 
flask of cultured cells and mixed by gentle rocking.  Four flasks of Flp-In-T-Rex-293 cells 
were transiently transfected for each p21
cip1
 vector, plus two flasks transfected with 
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pcDNA5/FRT/TO/CAT as the negative control.  After 36 hours at 37
o
C, the cells were 
dislodged by incubation with 5ml of 1mM EDTA in DMEM (Sigma) for 3 minutes.    
 
For the majority of the flasks, the cell suspensions were transferred to 50ml falcon tubes, 
topped up to 50ml with DMEM (Sigma) and centrifuged at 400g for 10 minutes at RT.  
After supernatant removal, the cell pellets were stored at -80
o
C in preparation for RNA and 
protein extraction (see section 2.2).    
 
One flask each of wild type p21
cip1
, variant p21
cip1
 and control transfected cells were plated 
into 96 well plates.  A small amount of cell suspension was transferred to a 15ml tube, 
topped up to 3ml with culture medium (DMEM (Sigma), 10% FCS gold (PAA), and 2mM 
L-glutamine (Gibco)), and mixed to produce a single cell suspension.  The solution was 
topped up with culture medium to a density of 5,000 cells/ 100µl, and incubated overnight at 
37
o
C.  Following supernatant removal, cells were incubated with 100µl of Glyo-Fixx 
(ThermoScientific) per well for 2 hours; and 100µl of 85% ice cold ethanol (Sigma) added in 
preparation for p21
cip1
 and beta-actin staining for Acumen analysis.   
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Immunostaining and propidium iodide labelling  
 
The transfected cells were immunolabelled for p21
cip1
 and beta-actin.   
Briefly, the cells were incubated with blocking solution for 30 minutes at RT (5% BSA, 
0.1% Triton X in PBS), with primary antibody overnight at 4ºC, and with secondary 
antibody overnight at 4ºC.  The primary and secondary antibodies were diluted in PBS with 
0.1% Triton X, and are outlined in Table 55.  Cells were subsequently stained with 
propidium iodide by incubation with 10µg/ml propidium iodide supplemented with 
100µg/ml RNaseA and 0.1% Triton-X in PBS for 20 minutes at 37ºC.  The results were read 
with the Acumen Explorer Cytometer. 
 
Table 55 Antibodies selected for immunostaining   
Protein Primary antibody Secondary antibody 
P21
cip1
 Rabbit polyclonal to p21
cip
1 (1:500, 
ABcam) 
Anti-rabbit IgG FITC (1:200, 
ABcam) 
Beta-actin Mouse monoclonal to beta-actin 
(1:500, ABcam) 
Anti-mouse IgG FITC (1:200, 
ABcam) 
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APPENDIX 6 
 
MICROARRAY RESULTS 
 
Table 56 Genes that were upregulated by rapamycin in lymphocytes (upregulated 
in rapamycin-treated lymphocytes compared to untreated lymphocytes, 
FDR cut-off point of 10%) (1138 genes)  
Gene Gene description 
38777 membrane-associated ring finger (C3HC4) 6 
39692 septin 8 
A2M alpha-2-macroglobulin 
AADACL2 arylacetamide deacetylase-like 2 
AASDH aminoadipate-semialdehyde dehydrogenase 
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8" 
ABCB5 ATP-binding cassette, sub-family B (MDR/TAP), member 5 
ABCD2 ATP-binding cassette, sub-family D (ALD), member 2" 
ABHD2 abhydrolase domain containing 2 
ABI3BP ABI family, member 3 (NESH) binding protein" 
ABLIM2 actin binding LIM protein family, member 2" 
ABRA actin-binding Rho activating protein 
ABTB1 ankyrin repeat and BTB (POZ) domain containing 1 
ACOX2 acyl-Coenzyme A oxidase 2, branched chain" 
ACPP acid phosphatase, prostate" 
ACSS1 acyl-CoA synthetase short-chain family member 1 
ACTRT1 actin-related protein T1 
ACVR2B activin A receptor, type IIB" 
ADAMTS13 ADAM metallopeptidase with thrombospondin type 1 motif, 13" 
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ADAMTS15 ADAM metallopeptidase with thrombospondin type 1 motif, 15" 
ADAMTS2 ADAM metallopeptidase with thrombospondin type 1 motif, 2" 
ADAMTS20 ADAM metallopeptidase with thrombospondin type 1 motif, 20" 
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3" 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9" 
ADAMTSL3 ADAMTS-like 3 
ADAMTSL4 ADAMTS-like 4 
ADAMTSL5 ADAMTS-like 5 
ADH6 alcohol dehydrogenase 6 (class V) 
ADIPOQ adiponectin, C1Q and collagen domain containing" 
ADSSL1 adenylosuccinate synthase like 1 
AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8)" 
AGTR1 angiotensin II receptor, type 1" 
AHNAK AHNAK nucleoprotein 
AKR1D1 
aldo-keto reductase family 1, member D1 (delta 4-3-ketosteroid-5-
beta-reductase)" 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3" 
AMY1C amylase, alpha 1C (salivary) 
ANGPT2 angiopoietin 2 
ANGPTL2 angiopoietin-like 2 
ANGPTL5 angiopoietin-like 5 
ANK1 ankyrin 1, erythrocytic" 
ANKRD12 ankyrin repeat domain 12 
ANKRD36B ankyrin repeat domain 36B 
ANKRD36B ankyrin repeat domain 36B 
ANKRD45 ankyrin repeat domain 45 
ANKRD50 ankyrin repeat domain 50 
ANKRD6 ankyrin repeat domain 6 
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B 
ANO3 anoctamin 3 
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ANXA10 annexin A10 
APBB1IP 
amyloid beta (A4) precursor protein-binding, family B, member 1 
interacting protein 
APOB apolipoprotein B (including Ag(x) antigen) 
APOBEC3G 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
3G" 
APOLD1 apolipoprotein L domain containing 1 
AQP12A aquaporin 12A 
AQP4 aquaporin 4 
AQP7P2 aquaporin 7 pseudogene 2 
ARHGEF4 Rho guanine nucleotide exchange factor (GEF) 4 
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
ARL14 ADP-ribosylation factor-like 14 
ARL17 ADP-ribosylation factor-like 17 
ARMC2 armadillo repeat containing 2 
ARPP-21 cyclic AMP-regulated phosphoprotein, 21 kD 
ARSE arylsulfatase E (chondrodysplasia punctata 1) 
ASAM adipocyte-specific adhesion molecule 
ASB11 ankyrin repeat and SOCS box-containing 11 
ASPM 
asp (abnormal spindle) homolog, microcephaly associated 
(Drosophila)" 
ASXL3 additional sex combs like 3 (Drosophila) 
ATF7IP activating transcription factor 7 interacting protein 
ATP13A4 ATPase type 13A4 
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2" 
ATP8B3 ATPase, class I, type 8B, member 3" 
ATRNL1 attractin-like 1 
AUTS2 autism susceptibility candidate 2 
B2M beta-2-microglobulin 
B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4" 
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B4GALT6 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 6" 
BAIAP2 BAI1-associated protein 2 
BAIAP2L2 BAI1-associated protein 2-like 2 
BARX2 BARX homeobox 2 
BCL2 B-cell CLL/lymphoma 2 
BEND2 BEN domain containing 2 
BEND6 BEN domain containing 6 
BEST3 bestrophin 3 
BMP7 bone morphogenetic protein 7 
BMX BMX non-receptor tyrosine kinase 
BNC1 basonuclin 1 
BPESC1 blepharophimosis, epicanthus inversus and ptosis, candidate 1 
BPI bactericidal/permeability-increasing protein 
BRIP1 BRCA1 interacting protein C-terminal helicase 1 
BRUNOL4 bruno-like 4, RNA binding protein (Drosophila)" 
BRUNOL6 bruno-like 6, RNA binding protein (Drosophila)" 
BSN bassoon (presynaptic cytomatrix protein) 
BSPRY B-box and SPRY domain containing 
BTNL9 butyrophilin-like 9 
BVES blood vessel epicardial substance 
C10orf10 chromosome 10 open reading frame 10 
C10orf107 chromosome 10 open reading frame 107 
C10orf111 chromosome 10 open reading frame 111 
C10orf72 chromosome 10 open reading frame 72 
C10orf79 chromosome 10 open reading frame 79 
C11orf67 chromosome 11 open reading frame 67 
C11orf87 chromosome 11 open reading frame 87 
C11orf88 chromosome 11 open reading frame 88 
C12orf42 chromosome 12 open reading frame 42 
C12orf67 chromosome 12 open reading frame 67 
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C14orf106 chromosome 14 open reading frame 106 
C15orf43 chromosome 15 open reading frame 43 
C15orf48 chromosome 15 open reading frame 48 
C16orf65 chromosome 16 open reading frame 65 
C16orf75 chromosome 16 open reading frame 75 
C17orf76 chromosome 17 open reading frame 76 
C17orf78 chromosome 17 open reading frame 78 
C18orf26 chromosome 18 open reading frame 26 
C19orf30 chromosome 19 open reading frame 30 
C1orf110 chromosome 1 open reading frame 110 
C1orf118 chromosome 1 open reading frame 118 
C1orf127 chromosome 1 open reading frame 127 
C1orf173 chromosome 1 open reading frame 173 
C1orf226 chromosome 1 open reading frame 226 
C1orf87 chromosome 1 open reading frame 87 
C1orf92 chromosome 1 open reading frame 92 
C1QTNF6 C1q and tumor necrosis factor related protein 6 
C20orf114 chromosome 20 open reading frame 114 
C20orf132 chromosome 20 open reading frame 132 
C20orf85 chromosome 20 open reading frame 85 
C21orf117 chromosome 21 open reading frame 117 
C2orf16 chromosome 2 open reading frame 16 
C2orf21 chromosome 2 open reading frame 21 
C3orf36 chromosome 3 open reading frame 36 
C3orf46 chromosome 3 open reading frame 46 
C3orf70 chromosome 3 open reading frame 70 
C4orf12 chromosome 4 open reading frame 12 
C4orf19 chromosome 4 open reading frame 19 
C4orf22 chromosome 4 open reading frame 22 
C4orf36 chromosome 4 open reading frame 36 
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C5orf39 chromosome 5 open reading frame 39 
C5orf41 chromosome 5 open reading frame 41 
C6orf223 chromosome 6 open reading frame 223 
C6orf91 chromosome 6 open reading frame 91 
C7orf41 chromosome 7 open reading frame 41 
C7orf51 chromosome 7 open reading frame 51 
C8orf42 chromosome 8 open reading frame 42 
C9orf144B hypothetical protein LOC259308 
CA12 carbonic anhydrase XII 
CA6 carbonic anhydrase VI 
CADPS Ca++-dependent secretion activator 
CALD1 caldesmon 1 
CARD14 caspase recruitment domain family, member 14 
CATSPER2 cation channel, sperm associated 2" 
CAV2 caveolin 2 
CBX7 chromobox homolog 7 
CBX7 chromobox homolog 7 
CC2D2A coiled-coil and C2 domain containing 2A 
CCDC141 coiled-coil domain containing 141 
CCDC28A coiled-coil domain containing 28A 
CCDC34 coiled-coil domain containing 34 
CCDC40 coiled-coil domain containing 40 
CCDC85A coiled-coil domain containing 85A 
CCL1 chemokine (C-C motif) ligand 1 
CCL11 chemokine (C-C motif) ligand 11 
CCL26 chemokine (C-C motif) ligand 26 
CCNB2 cyclin B2 
CCNG2 cyclin G2 
CCR1 chemokine (C-C motif) receptor 1 
CCR2 chemokine (C-C motif) receptor 2 
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CD177 CD177 molecule 
CD1A CD1a molecule 
CD1B CD1b molecule 
CD1E CD1e molecule 
CD44 CD44 molecule (Indian blood group) 
CD69 CD69 molecule 
CD96 CD96 molecule 
CDC14B CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
CDCP1 CUB domain containing protein 1 
CDH1 cadherin 1, type 1, E-cadherin (epithelial)" 
CDH13 cadherin 13, H-cadherin (heart)" 
CDH26 cadherin-like 26 
CDH7 cadherin 7, type 2 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1)" 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2)" 
CDKN2C cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)" 
CDKN2D cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
CDON Cdon homolog (mouse) 
CEACAM6 
carcinoembryonic antigen-related cell adhesion molecule 6 (non-
specific cross reacting antigen) 
CEP68 centrosomal protein 68kDa 
CFHR5 complement factor H-related 5 
CFTR 
cystic fibrosis transmembrane conductance regulator (ATP-binding 
cassette sub-family C, member 7)" 
CGA glycoprotein hormones, alpha polypeptide" 
CGNL1 cingulin-like 1 
CHD2 chromodomain helicase DNA binding protein 2 
CHP2 calcineurin B homologous protein 2 
CHRDL2 chordin-like 2 
CHRNA9 cholinergic receptor, nicotinic, alpha 9" 
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CKM creatine kinase, muscle" 
CLC Charcot-Leyden crystal protein 
CLCA2 chloride channel regulator 2 
CLEC7A C-type lectin domain family 7, member A" 
CLTB clathrin, light chain (Lcb)" 
CNRIP1 cannabinoid receptor interacting protein 1 
CNTN3 contactin 3 (plasmacytoma associated) 
COBL cordon-bleu homolog (mouse) 
COL11A1 collagen, type XI, alpha 1" 
COL13A1 collagen, type XIII, alpha 1" 
COL1A2 collagen, type I, alpha 2" 
COL6A3 collagen, type VI, alpha 3" 
COL6A6 collagen type VI alpha 6 
COMMD6 COMM domain containing 6 
CORIN corin, serine peptidase 
CORO2A coronin, actin binding protein, 2A" 
CPB2 carboxypeptidase B2 (plasma) 
CPE carboxypeptidase E 
CPLX2 complexin 2 
CPXM2 carboxypeptidase X (M14 family), member 2" 
CRB1 crumbs homolog 1 (Drosophila) 
CREB3L4 cAMP responsive element binding protein 3-like 4 
CRIM1 cysteine rich transmembrane BMP regulator 1 (chordin-like) 
CRIM2 cysteine rich BMP regulator 2 (chordin-like) 
CRP C-reactive protein, pentraxin-related" 
CRTAC1 cartilage acidic protein 1 
CRYBG3 beta-gamma crystallin domain containing 3 
CRYGB crystallin, gamma B" 
CRYGD crystallin, gamma D" 
CSDC2 cold shock domain containing C2, RNA binding" 
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CSF1R colony stimulating factor 1 receptor 
CSN2 casein beta 
CTAG1A cancer/testis antigen 1A 
CTDSP1 
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) 
small phosphatase 1" 
CTNNA3 catenin (cadherin-associated protein), alpha 3" 
CTSF cathepsin F 
CXorf51 chromosome X open reading frame 51 
CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9" 
CYP3A5 cytochrome P450, family 3, subfamily A, polypeptide 5" 
CYP4F11 cytochrome P450, family 4, subfamily F, polypeptide 11" 
CYP4F2 cytochrome P450, family 4, subfamily F, polypeptide 2" 
CYP4F3 cytochrome P450, family 4, subfamily F, polypeptide 3" 
CYP4V2 cytochrome P450, family 4, subfamily V, polypeptide 2" 
CYP4X1 cytochrome P450, family 4, subfamily X, polypeptide 1" 
CYP4Z1 cytochrome P450, family 4, subfamily Z, polypeptide 1" 
CYR61 cysteine-rich, angiogenic inducer, 61" 
CYSLTR2 cysteinyl leukotriene receptor 2 
DAOA D-amino acid oxidase activator 
DAPL1 death associated protein-like 1 
DCC deleted in colorectal carcinoma 
DCD dermcidin 
DCLK1 doublecortin-like kinase 1 
DCN decorin 
DDI1 DDI1, DNA-damage inducible 1, homolog 1 (S. cerevisiae)" 
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
DEFA4 defensin, alpha 4, corticostatin" 
DEFB119 defensin, beta 119 
DHRS12 dehydrogenase/reductase (SDR family) member 12 
DHRS3 dehydrogenase/reductase (SDR family) member 3 
  APPENDIX 6 
218 
 
Gene Gene description 
DKFZP586K1520 DKFZP586K1520 protein 
DLEU7 deleted in lymphocytic leukemia, 7 
DLG2 discs, large homolog 2 (Drosophila)" 
DLGAP4 discs, large (Drosophila) homolog-associated protein 4" 
DLX2 distal-less homeobox 2 
DMRTB1 DMRT-like family B with proline-rich C-terminal, 1" 
DMRTC1 DMRT-like family C1 
DMRTC2 DMRT-like family C2 
DNAH1 dynein, axonemal, heavy chain 1" 
DNAH6 dynein, axonemal, heavy chain 6" 
DNAJB7 DnaJ (Hsp40) homolog, subfamily B, member 7" 
DPY19L1P1 dpy-19-like 1 pseudogene 1 (C. elegans) 
DRP2 dystrophin related protein 2 
DSEL dermatan sulfate epimerase-like 
DST dystonin 
DTD1 D-tyrosyl-tRNA deacylase 1 homolog (S. cerevisiae) 
DUSP13 dual specificity phosphatase 13 
DUSP21 dual specificity phosphatase 21 
DUSP27 dual specificity phosphatase 27 (putative) 
DYNLRB1 dynein, light chain, roadblock-type 1 
DZIP1L DAZ interacting protein 1-like 
DZIP3 DAZ interacting protein 3, zinc finger" 
EBF2 early B-cell factor 2 
EBF3 early B-cell factor 3 
ECHDC2 enoyl Coenzyme A hydratase domain containing 2 
ECM2 extracellular matrix protein 2, female organ and adipocyte specific 
EEPD1 endonuclease/exonuclease/phosphatase family domain containing 1 
EFCAB3 EF-hand calcium binding domain 3 
EGF epidermal growth factor (beta-urogastrone) 
EGR1 early growth response 1 
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ELAVL3 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu 
antigen C)" 
ELAVL4 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu 
antigen D) 
ELOVL7 
ELOVL family member 7, elongation of long chain fatty acids 
(yeast)" 
EMCN endomucin 
EMX2OS EMX2 opposite strand (non-protein coding) 
ENPEP glutamyl aminopeptidase (aminopeptidase A) 
ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6 
EPB41L4B erythrocyte membrane protein band 4.1 like 4B 
EPHA5 EPH receptor A5 
EPO erythropoietin 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 
ESR1 estrogen receptor 1 
EVI1 ecotropic viral integration site 1 
EYA1 eyes absent homolog 1 (Drosophila) 
F11 coagulation factor XI 
F2 coagulation factor II (thrombin) 
F2RL2 coagulation factor II (thrombin) receptor-like 2 
F9 coagulation factor IX 
FAM100B family with sequence similarity 100, member B" 
FAM119A family with sequence similarity 119, member A" 
FAM12A family with sequence similarity 12, member A 
FAM12B family with sequence similarity 12, member B (epididymal)" 
FAM135B family with sequence similarity 135, member B 
FAM13C1 family with sequence similarity 13, member C1 
FAM149B1 family with sequence similarity 149, member B1" 
FAM153A family with sequence similarity 153, member A" 
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FAM155A family with sequence similarity 155, member A" 
FAM162B family with sequence similarity 162, member B" 
FAM171B family with sequence similarity 171, member B" 
FAM172A family with sequence similarity 172, member A" 
FAM181B family with sequence similarity 181, member B" 
FAM19A1 
family with sequence similarity 19 (chemokine (C-C motif)-like), 
member A1" 
FAM24A family with sequence similarity 24, member A" 
FAM26D family with sequence similarity 26, member D 
FAM43B family with sequence similarity 43, member B" 
FAM5C family with sequence similarity 5, member C 
FAM62C 
family with sequence similarity 62 (C2 domain containing), member 
C" 
FAM64A family with sequence similarity 64, member A" 
FAM71D family with sequence similarity 71, member D" 
FAM74A3 family with sequence similarity 74, member A3" 
FAM84A family with sequence similarity 84, member A" 
FAM92B family with sequence similarity 92, member B 
FAT3 FAT tumor suppressor homolog 3 (Drosophila) 
FBLN1 fibulin 1 
FBN2 fibrillin 2 
FBP2 fructose-1,6-bisphosphatase 2" 
FBXL16 F-box and leucine-rich repeat protein 16 
FCGBP Fc fragment of IgG binding protein 
FGB fibrinogen beta chain 
FGF11 fibroblast growth factor 11 
FGF23 fibroblast growth factor 23 
FGF7 fibroblast growth factor 7 (keratinocyte growth factor) 
FGFR1 fibroblast growth factor receptor 1 
FGG fibrinogen gamma chain 
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FGGY FGGY carbohydrate kinase domain containing 
FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog 
FIGN fidgetin 
FILIP1 filamin A interacting protein 1 
FKSG2 apoptosis inhibitor 
FLJ10357 hypothetical protein FLJ10357 
FLJ12993 hypothetical LOC441027 
FLJ13310 hypothetical protein FLJ13310 
FLJ13769 hypothetical protein FLJ13769 
FLJ21272 hypothetical protein FLJ21272 
FLJ23834 hypothetical protein FLJ23834 
FLJ30719 hypothetical protein FLJ30719 
FLJ32679 golgin-like hypothetical protein LOC440321 
FLJ32742 hypothetical locus FLJ32742 
FLJ36000 hypothetical protein FLJ36000 
FLJ37035 FLJ37035 protein 
FLJ37060 similar to FUN14 domain containing 2 
FLJ37644 hypothetical gene supported by AK094963 
FLJ39609 hypothetical protein FLJ39609 
FLJ40330 hypothetical LOC645784 
FLJ42875 hypothetical LOC440556 
FLJ45244 hypothetical locus FLJ45244 
FMO3 flavin containing monooxygenase 3 
FN1 fibronectin 1 
FN3K fructosamine 3 kinase 
FNBP1 formin binding protein 1 
FNDC5 fibronectin type III domain containing 5 
FRAT2 frequently rearranged in advanced T-cell lymphomas 2 
FREM3 FRAS1 related extracellular matrix 3 
FRMD4A FERM domain containing 4A 
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FRMD6 FERM domain containing 6 
FRMD7 FERM domain containing 7 
FSTL5 follistatin-like 5 
FUT9 fucosyltransferase 9 (alpha (1,3) fucosyltransferase) 
GAB1 GRB2-associated binding protein 1 
GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5" 
GABRG1 gamma-aminobutyric acid (GABA) A receptor, gamma 1 
GABRR2 gamma-aminobutyric acid (GABA) receptor, rho 2" 
GAGE1 G antigen 1 
GALNT10 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10) 
GALNT5 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 5 (GalNAc-T5) 
GBP3 guanylate binding protein 3 
GCM2 glial cells missing homolog 2 (Drosophila) 
GDA guanine deaminase 
GFAP glial fibrillary acidic protein 
GFRA1 GDNF family receptor alpha 1 
GFRA2 GDNF family receptor alpha 2 
GHRLOS ghrelin opposite strand (non-protein coding) 
GIGYF1 GRB10 interacting GYF protein 1 
GIPR gastric inhibitory polypeptide receptor 
GLI2 GLI-Kruppel family member GLI2 
GLP1R glucagon-like peptide 1 receptor 
GLRA1 glycine receptor, alpha 1" 
GNAL 
guanine nucleotide binding protein (G protein), alpha activating 
activity polypeptide, olfactory type" 
GNG8 guanine nucleotide binding protein (G protein), gamma 8" 
GPC3 glypican 3 
GPR109B G protein-coupled receptor 109B 
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GPR110 G protein-coupled receptor 110 
GPR116 G protein-coupled receptor 116 
GPR176 G protein-coupled receptor 176 
GPR177 G protein-coupled receptor 177 
GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 
GPR4 G protein-coupled receptor 4 
GPX6 glutathione peroxidase 6 (olfactory) 
GPX8 glutathione peroxidase 8 (putative) 
GRIA2 glutamate receptor, ionotropic, AMPA 2" 
GRIA3 glutamate receptor, ionotrophic, AMPA 3" 
GRIK2 glutamate receptor, ionotropic, kainate 2" 
GRIK3 glutamate receptor, ionotropic, kainate 3" 
GRINL1A glutamate receptor, ionotropic, N-methyl D-aspartate-like 1A 
GRM1 glutamate receptor, metabotropic 1" 
GRPR gastrin-releasing peptide receptor 
GSG1L GSG1-like 
GSN gelsolin (amyloidosis, Finnish type)" 
GSTA1 glutathione S-transferase alpha 1 
GSTA5 glutathione S-transferase alpha 5 
GUCY1A3 guanylate cyclase 1, soluble, alpha 3" 
GUCY2F guanylate cyclase 2F, retinal 
GVIN1 GTPase, very large interferon inducible 1" 
HAND1 heart and neural crest derivatives expressed 1 
HAND2 heart and neural crest derivatives expressed 2 
HAPLN1 hyaluronan and proteoglycan link protein 1 
hCG_1655019 hCG1655019 
hCG_1814486 hCG1814486 
hCG_1820661 hypothetical LOC400752 
HDAC5 histone deacetylase 5 
HDAC9 histone deacetylase 9 
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HESX1 HESX homeobox 1 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 
HHIP hedgehog interacting protein 
HHIPL1 HHIP-like 1 
HIST1H2BN histone cluster 1, H2bn 
HIST1H4E histone cluster 1, H4e" 
HIVEP2 human immunodeficiency virus type I enhancer binding protein 2 
HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) 
HNF4G hepatocyte nuclear factor 4, gamma" 
HOXA2 homeobox A2 
HOXA9 homeobox A9 
HOXC8 homeobox C8 
HOXD10 homeobox D10 
HRASLS5 HRAS-like suppressor family, member 5 
HSD17B13 hydroxysteroid (17-beta) dehydrogenase 13 
HTN3 histatin 3 
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C 
HTR3C 5-hydroxytryptamine (serotonin) receptor 3, family member C 
HYDIN hydrocephalus inducing homolog (mouse) 
IFFO1 intermediate filament family orphan 1 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 
IFNA16 interferon, alpha 16" 
IGBP1 immunoglobulin (CD79A) binding protein 1 
IGF2 insulin-like growth factor 2 (somatomedin A) 
IKZF4 IKAROS family zinc finger 4 (Eos) 
IL17B interleukin 17B 
IL18 interleukin 18 (interferon-gamma-inducing factor) 
IL1B interleukin 1, beta" 
IL1RAPL1 interleukin 1 receptor accessory protein-like 1 
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IL1RN interleukin 1 receptor antagonist 
IMPG1 interphotoreceptor matrix proteoglycan 1 
INSL5 insulin-like 5 
IQCF1 IQ motif containing F1 
IRS2 insulin receptor substrate 2 
IRX4 iroquois homeobox 4 
ISX intestine-specific homeobox 
ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)" 
ITGBL1 integrin, beta-like 1 (with EGF-like repeat domains)" 
JAK1 Janus kinase 1 (a protein tyrosine kinase) 
JAKMIP3 janus kinase and microtubule interacting protein 3 
JARID2 jumonji, AT rich interactive domain 2" 
JUN jun oncogene 
KANK2 KN motif and ankyrin repeat domains 2 
KCNA4 
potassium voltage-gated channel, shaker-related subfamily, member 
4" 
KCNA7 
potassium voltage-gated channel, shaker-related subfamily, member 
7 
KCNAB1 
potassium voltage-gated channel, shaker-related subfamily, beta 
member 1" 
KCNB2 potassium voltage-gated channel, Shab-related subfamily, member 2 
KCNC1 
potassium voltage-gated channel, Shaw-related subfamily, member 
1" 
KCNC2 
potassium voltage-gated channel, Shaw-related subfamily, member 
2" 
KCND3 potassium voltage-gated channel, Shal-related subfamily, member 3" 
KCNG4 potassium voltage-gated channel, subfamily G, member 4 
KCNH7 
potassium voltage-gated channel, subfamily H (eag-related), member 
7" 
KCNIP2 Kv channel interacting protein 2 
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KCNJ5 potassium inwardly-rectifying channel, subfamily J, member 5" 
KCNK10 potassium channel, subfamily K, member 10" 
KCNK17 potassium channel, subfamily K, member 17" 
KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1" 
KCNQ1DN KCNQ1 downstream neighbor 
KCTD19 potassium channel tetramerisation domain containing 19 
KCTD4 potassium channel tetramerisation domain containing 4 
KIAA0355 KIAA0355 
KIAA0894 KIAA0894 protein 
KIAA1045 KIAA1045 
KIAA1109 KIAA1109 
KIAA1239 KIAA1239 
KIAA1407 KIAA1407 
KIAA1462 KIAA1462 
KIAA1522 KIAA1522 
KIAA1545 HBV X-transactivated gene 9 protein 
KIAA1652 KIAA1652 protein 
KIAA1683 KIAA1683 
KIF6 kinesin family member 6 
KIRREL3 kin of IRRE like 3 (Drosophila) 
KLF12 Kruppel-like factor 12 
KLF2 Kruppel-like factor 2 (lung) 
KLHDC9 kelch domain containing 9 
KLHL24 kelch-like 24 (Drosophila) 
KLHL4 kelch-like 4 (Drosophila) 
KLRB1 killer cell lectin-like receptor subfamily B, member 1 
KRT2 keratin 2 
KRT72 keratin 72 
KRT75 keratin 75 
KRT82 keratin 82 
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KRTAP1-1 keratin associated protein 1-1 
KRTAP1-3 keratin associated protein 1-3 
KRTAP15-1 keratin associated protein 15-1 
KRTAP4-7 keratin associated protein 4-7 
KRTAP9-2 keratin associated protein 9-2 
LAIR2 leukocyte-associated immunoglobulin-like receptor 2 
LAMA1 laminin, alpha 1" 
LAYN layilin 
LCE1E late cornified envelope 1E 
LECT1 leukocyte cell derived chemotaxin 1 
LEF1 lymphoid enhancer-binding factor 1 
LEFTY1 left-right determination factor 1 
LEMD1 LEM domain containing 1 
LEP leptin 
LGALS13 lectin, galactoside-binding, soluble, 13" 
LGALS2 lectin, galactoside-binding, soluble, 2" 
LGR5 leucine-rich repeat-containing G protein-coupled receptor 5 
LIFR leukemia inhibitory factor receptor alpha 
LILRB2 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and 
ITIM domains), member 2" 
LIPF lipase, gastric" 
LL22NC03-
75B3.6 KIAA1644 protein 
LOC100127998 hypothetical protein LOC100127998 
LOC100128098 hypothetical protein LOC100128098 
LOC100128108 hypothetical protein LOC100128108 
LOC100128175 similar to PRO2591 
LOC100128178 similar to hCG2041313 
LOC100129198 PRO2866 
LOC100129406 hypothetical protein LOC100129406 
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LOC100129476 hypothetical protein LOC100129476 
LOC100129754 hypothetical protein LOC100129754 
LOC100129775 hypothetical protein LOC100129775 
LOC100130278 hypothetical protein LOC100130278 
LOC100130360 hypothetical protein LOC100130360 
LOC100130776 similar to hCG2014417 
LOC100130797 PRO0566 
LOC100130815 hypothetical LOC100130815 
LOC100131176 similar to hCG1991662 
LOC100131707 hypothetical LOC100131707 
LOC100131720 hypothetical protein LOC100131720 
LOC100131938 hypothetical LOC100131938 
LOC100132116 hypothetical LOC100132116 
LOC100132363 hypothetical protein LOC100132363 
LOC100132853 hypothetical LOC100132853 
LOC100133746 hypothetical protein LOC100133746 
LOC100170939 glucuronidase, beta pseudogene" 
LOC100190938 hypothetical LOC100190938 
LOC100190986 hypothetical LOC100190986 
LOC114227 hypothetical protein LOC114227 
LOC120376 Uncharacterized protein LOC120376 
LOC124220 similar to common salivary protein 1 
LOC150759 hypothetical protein LOC150759 
LOC200383 similar to Dynein heavy chain at 16F 
LOC201229 hypothetical protein LOC201229 
LOC255177 hypothetical protein LOC255177 
LOC282992 hypothetical protein LOC282992 
LOC283174 hypothetical LOC283174 
LOC283663 hypothetical LOC283663 
LOC283665 hypothetical protein LOC283665 
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LOC283861 hypothetical locus LOC283861 
LOC284033 hypothetical LOC284033 
LOC284260 
hypothetical gene supported by BC011527; BC021928; BC011527; 
BC021928 
LOC284861 hypothetical gene supported by BC039313 
LOC286071 hypothetical protein LOC286071 
LOC286382 hypothetical protein LOC286382 
LOC339260 hypothetical protein LOC339260 
LOC339483 hypothetical LOC339483 
LOC389023 hypothetical gene supported by BC032913; BC048425 
LOC389043 hypothetical gene supported by AK125982; BC042817 
LOC390595 similar to ubiquitin-associated protein 1 (predicted) 
LOC390705 
similar to protein phosphatase 2A 48 kDa regulatory subunit isoform 
1; serine/threonine protein phosphatase 2A, 48kDa regulatory 
subunit; PP2A, subunit B, PR48 isoform; PP2A B subunit PR48; 
NY-REN-8 antigen 
LOC400620 hypothetical LOC400620 
LOC400655 hypothetical gene supported by BC013370; BC034583 
LOC401097 Similar to LOC166075 
LOC401317 hypothetical LOC401317 
LOC440311 similar to P60 
LOC441601 septin 7 pseudogene 
LOC474358 hypothetical BC042079 locus 
LOC54492 neuralized-2 
LOC644192 hypothetical LOC644192 
LOC644246 hypothetical protein LOC644246 
LOC646471 hypothetical LOC646471 
LOC646548 hypothetical LOC646548 
LOC646627 phospholipase inhibitor 
LOC646891 similar to serologically defined colon cancer antigen 3 
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LOC647107 hypothetical protein LOC647107 
LOC648795 hypothetical protein LOC648795 
LOC653773 similar to mCG49427 
LOC728323 hypothetical LOC728323 
LOC728344 similar to hCG1978918 
LOC728460 similar to FLJ32921 protein 
LOC728516 hypothetical LOC728516 
LOC728543 hypothetical protein LOC728543 
LOC729082 hypothetical protein LOC729082 
LOC729121 hypothetical protein LOC729121 
LOC729915 hypothetical LOC729915 
LOC729970 hypothetical LOC729970 
LOC730834 similar to hCG1821160 
LOC780529 hypothetical LOC780529 
LOX lysyl oxidase 
LOXL4 lysyl oxidase-like 4 
LPIN2 lipin 2 
LRCH2 
leucine-rich repeats and calponin homology (CH) domain containing 
2 
LRP1 
low density lipoprotein-related protein 1 (alpha-2-macroglobulin 
receptor) 
LRP1B low density lipoprotein-related protein 1B (deleted in tumors) 
LRRC27 leucine rich repeat containing 27 
LRRC37A4 leucine rich repeat containing 37, member A4 (pseudogene) 
LRRC48 leucine rich repeat containing 48 
LRRCC1 leucine rich repeat and coiled-coil domain containing 1 
LTBP1 latent transforming growth factor beta binding protein 1 
LUM lumican 
LYPD2 LY6/PLAUR domain containing 2 
LYPD6 LY6/PLAUR domain containing 6 
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MACF1 microtubule-actin crosslinking factor 1 
MAEL maelstrom homolog (Drosophila) 
MAL mal, T-cell differentiation protein" 
MAPK4 mitogen-activated protein kinase 4 
MAPT microtubule-associated protein tau 
MARK1 MAP/microtubule affinity-regulating kinase 1 
MARVELD3 MARVEL domain containing 3 
MAS1 MAS1 oncogene 
MBD3L2 methyl-CpG binding domain protein 3-like 2 
MBP myelin basic protein 
MCHR2 melanin-concentrating hormone receptor 2 
MCTP1 multiple C2 domains, transmembrane 1" 
MDS1 myelodysplasia syndrome 1 
MEG3 maternally expressed 3 (non-protein coding) 
METTL7A methyltransferase like 7A 
MFAP5 microfibrillar associated protein 5 
MGC16075 hypothetical protein MGC16075 
MGC24103 hypothetical protein MGC24103 
MGC39545 hypothetical protein LOC403312 
MGC70870 C-terminal binding protein 2 pseudogene 
MGEA5 meningioma expressed antigen 5 (hyaluronidase) 
MIA2 melanoma inhibitory activity 2 
MIER1 mesoderm induction early response 1 homolog (Xenopus laevis) 
MLL 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila)" 
MLLT4 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 4" 
MME membrane metallo-endopeptidase 
MMP12 matrix metallopeptidase 12 (macrophage elastase) 
MMP16 matrix metallopeptidase 16 (membrane-inserted) 
  APPENDIX 6 
232 
 
Gene Gene description 
MMP2 
matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa 
type IV collagenase)" 
MMP8 matrix metallopeptidase 8 (neutrophil collagenase) 
MMP9 
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa 
type IV collagenase)" 
MNT MAX binding protein 
MORN5 MORN repeat containing 5 
MPP4 
membrane protein, palmitoylated 4 (MAGUK p55 subfamily 
member 4)" 
MPPED2 metallophosphoesterase domain containing 2 
MRO maestro 
MSMB microseminoprotein, beta- 
MTHFR 5,10-methylenetetrahydrofolate reductase (NADPH)" 
MTL5 metallothionein-like 5, testis-specific (tesmin)" 
MTMR7 myotubularin related protein 7 
MUC17 mucin 17, cell surface associated" 
MXI1 MAX interactor 1 
MYF6 myogenic factor 6 (herculin) 
MYO16 myosin XVI 
MYO3B myosin IIIB 
MYOM1 myomesin 1, 185kDa" 
MYPN myopalladin 
N4BP2L1 NEDD4 binding protein 2-like 1 
NAG20 NAG20 
NAV2 neuron navigator 2 
NBR1 neighbor of BRCA1 gene 1 
NDRG2 NDRG family member 2 
NECAB2 N-terminal EF-hand calcium binding protein 2 
NEGR1 neuronal growth regulator 1 
NEUROD4 neurogenic differentiation 4 
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NFIB nuclear factor I/B 
NHEDC1 Na+/H+ exchanger domain containing 1 
NIPBL Nipped-B homolog (Drosophila) 
NKX3-2 NK3 homeobox 2 
NLRP13 NLR family, pyrin domain containing 13 
NMNAT2 nicotinamide nucleotide adenylyltransferase 2 
NMU neuromedin U 
NOTCH2NL Notch homolog 2 (Drosophila) N-terminal like 
NOX1 NADPH oxidase 1 
NPTX1 neuronal pentraxin I 
NR2F2 nuclear receptor subfamily 2, group F, member 2" 
NR4A1 nuclear receptor subfamily 4, group A, member 1" 
NR4A2 nuclear receptor subfamily 4, group A, member 2" 
NRG2 neuregulin 2 
NRIP2 nuclear receptor interacting protein 2 
NRXN3 neurexin 3 
NSUN7 NOL1/NOP2/Sun domain family, member 7" 
NTN4 netrin 4 
NTSR1 neurotensin receptor 1 (high affinity) 
NUDT9P1 
nudix (nucleoside diphosphate linked moiety X)-type motif 9 
pseudogene 1 
OCA2 oculocutaneous albinism II 
OGN osteoglycin 
OIT3 oncoprotein induced transcript 3 
OLFML2A olfactomedin-like 2A 
OLIG2 oligodendrocyte lineage transcription factor 2 
OPRM1 opioid receptor, mu 1" 
OR10T2 olfactory receptor, family 10, subfamily T, member 2 
OR1E1 olfactory receptor, family 1, subfamily E, member 1 
OR2C3 olfactory receptor, family 2, subfamily C, member 3" 
  APPENDIX 6 
234 
 
Gene Gene description 
OR2L13 olfactory receptor, family 2, subfamily L, member 13 
OR2S2 olfactory receptor, family 2, subfamily S, member 2" 
OR2V2 olfactory receptor, family 2, subfamily V, member 2 
OR4N4 olfactory receptor, family 4, subfamily N, member 4" 
OR51E1 olfactory receptor, family 51, subfamily E, member 1" 
OR51E2 olfactory receptor, family 51, subfamily E, member 2" 
OR51Q1 olfactory receptor, family 51, subfamily Q, member 1" 
OR52B2 olfactory receptor, family 52, subfamily B, member 2" 
OR52K3P olfactory receptor, family 52, subfamily K, member 3 pseudogene 
OR5AK2 olfactory receptor, family 5, subfamily AK, member 2" 
OSBPL2 oxysterol binding protein-like 2 
OSTalpha organic solute transporter alpha 
OTX1 orthodenticle homeobox 1 
OVOL1 ovo-like 1(Drosophila) 
P2RY13 purinergic receptor P2Y, G-protein coupled, 13" 
P2RY14 purinergic receptor P2Y, G-protein coupled, 14" 
PABPC5 poly(A) binding protein, cytoplasmic 5" 
PAOX polyamine oxidase (exo-N4-amino) 
PARVA parvin, alpha" 
PASD1 PAS domain containing 1 
PAX3 paired box 3 
PCDH11Y protocadherin 11 Y-linked 
PCDH18 protocadherin 18 
PCDH21 protocadherin 21 
PCDH7 protocadherin 7 
PCDHB10 protocadherin beta 10 
PCDHB5 protocadherin beta 5 
PCDHGA9 protocadherin gamma subfamily A, 9 
PCDHGB8P protocadherin gamma subfamily B, 8 pseudogene" 
PCMTD2 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain 
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containing 2 
PCNXL2 pecanex-like 2 (Drosophila) 
PCSK2 proprotein convertase subtilisin/kexin type 2 
PDC phosducin 
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) 
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) 
PDE1A phosphodiesterase 1A, calmodulin-dependent 
PDE4C 
phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce 
homolog, Drosophila)" 
PDE4DIP phosphodiesterase 4D interacting protein 
PDE6A phosphodiesterase 6A, cGMP-specific, rod, alpha 
PDK4 pyruvate dehydrogenase kinase, isozyme 4" 
PDLIM3 PDZ and LIM domain 3 
PDZRN4 PDZ domain containing ring finger 4 
PEX5L peroxisomal biogenesis factor 5-like 
PHACTR1 phosphatase and actin regulator 1 
PHF12 PHD finger protein 12 
PHLDB2 pleckstrin homology-like domain, family B, member 2" 
PHYHD1 phytanoyl-CoA dioxygenase domain containing 1 
PIM1 pim-1 oncogene 
PIP prolactin-induced protein 
PITPNM2 phosphatidylinositol transfer protein, membrane-associated 2" 
PKD1L1 polycystic kidney disease 1 like 1 
PKHD1 polycystic kidney and hepatic disease 1 (autosomal recessive) 
PKP1 plakophilin 1 (ectodermal dysplasia/skin fragility syndrome) 
PLA2R1 phospholipase A2 receptor 1, 180kDa" 
PLAT plasminogen activator, tissue" 
PLB1 phospholipase B1 
PLCD4 phospholipase C, delta 4" 
PLCH1 phospholipase C, eta 1" 
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PLCZ1 phospholipase C, zeta 1" 
PLD1 phospholipase D1, phosphatidylcholine-specific" 
PLD3 phospholipase D family, member 3 
PLEKHA6 pleckstrin homology domain containing, family A member 6 
PLEKHH2 
pleckstrin homology domain containing, family H (with MyTH4 
domain) member 2" 
PLGLB1 plasminogen-like B1 
PLN phospholamban 
PLSCR2 phospholipid scramblase 2 
PLSCR4 phospholipid scramblase 4 
PM20D1 peptidase M20 domain containing 1 
PMCH pro-melanin-concentrating hormone 
PMCHL1 pro-melanin-concentrating hormone-like 1 
PNLIP pancreatic lipase 
PNPLA1 patatin-like phospholipase domain containing 1 
PNRC1 proline-rich nuclear receptor coactivator 1 
POLK polymerase (DNA directed) kappa 
PON3 paraoxonase 3 
POTED POTE ankyrin domain family, member D" 
POTEE POTE ankyrin domain family, member E" 
POU4F2 POU class 4 homeobox 2 
PP12708 hypothetical LOC100130609 
PPAPDC1A phosphatidic acid phosphatase type 2 domain containing 1A 
PPIC peptidylprolyl isomerase C (cyclophilin C) 
PRICKLE2 prickle homolog 2 (Drosophila) 
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit" 
PRO1596 hypothetical LOC29013 
PRO2012 hypothetical protein PRO2012 
PRODH2 proline dehydrogenase (oxidase) 2 
PRR16 proline rich 16 
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PRSS23 protease, serine, 23 
PSORS1C1 psoriasis susceptibility 1 candidate 1 
PTCH1 patched homolog 1 (Drosophila) 
PTGER3 prostaglandin E receptor 3 (subtype EP3) 
PTPRC protein tyrosine phosphatase, receptor type, C" 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1" 
PZP pregnancy-zone protein 
RAB37 RAB37, member RAS oncogene family" 
RAB39 RAB39, member RAS oncogene family 
RAB3C RAB3C, member RAS oncogene family" 
RAET1E retinoic acid early transcript 1E 
RAG1 recombination activating gene 1 
RAMP1 receptor (G protein-coupled) activity modifying protein 1 
RAVER2 ribonucleoprotein, PTB-binding 2" 
RBMY1B RNA binding motif protein, Y-linked, family 1, member B" 
RBPMS2 RNA binding protein with multiple splicing 2 
RERGL RERG/RAS-like 
REST RE1-silencing transcription factor 
RET ret proto-oncogene 
REXO1L1 REX1, RNA exonuclease 1 homolog (S. cerevisiae)-like 1" 
RGNEF Rho-guanine nucleotide exchange factor 
RHO rhodopsin 
RHOT1 ras homolog gene family, member T1" 
RIG regulated in glioma 
RIMBP3 RIMS binding protein 3 
RIMS2 regulating synaptic membrane exocytosis 2 
RIN2 Ras and Rab interactor 2 
RIT2 Ras-like without CAAX 2 
RLBP1L1 retinaldehyde binding protein 1-like 1 
RND3 Rho family GTPase 3 
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RNF125 ring finger protein 125 
RNF128 ring finger protein 128 
RNF133 ring finger protein 133 
RNF175 ring finger protein 175 
RNF8 ring finger protein 8 
RORB RAR-related orphan receptor B 
RP11-218C14.6 cystatin pseudogene 
RP11-327P2.4 hypothetical protein FLJ37307 
RP1-21O18.1 kazrin 
RP4-691N24.1 ninein-like 
RP5-1022P6.2 hypothetical protein KIAA1434 
RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1" 
RUFY2 RUN and FYVE domain containing 2 
RUNX1T1 
runt-related transcription factor 1; translocated to, 1 (cyclin D-
related)" 
RUNX2 runt-related transcription factor 2 
SALL3 sal-like 3 (Drosophila) 
SCARNA17 small Cajal body-specific RNA 17 
SCGN secretagogin, EF-hand calcium binding protein" 
SCN3B sodium channel, voltage-gated, type III, beta 
SCN8A sodium channel, voltage gated, type VIII, alpha subunit 
SEMA4C 
sema domain, immunoglobulin domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, (semaphorin) 4C" 
SEMA5A 
sema domain, seven thrombospondin repeats (type 1 and type 1-
like), transmembrane domain (TM) and short cytoplasmic domain, 
(semaphorin) 5A" 
SEMA6A 
sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6A" 
SEMG2 semenogelin II 
SERPINA10 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
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antitrypsin), member 10 
SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3" 
SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 
SERPIND1 serpin peptidase inhibitor, clade D (heparin cofactor), member 1 
SERPINE1 
serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1" 
SERTAD4 SERTA domain containing 4 
SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein)" 
SGCZ sarcoglycan zeta 
SH3PXD2A SH3 and PX domains 2A 
SHANK3 SH3 and multiple ankyrin repeat domains 3 
SHROOM2 shroom family member 2 
SHROOM4 shroom family member 4 
SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin 
SIM2 single-minded homolog 2 (Drosophila) 
SLC13A1 solute carrier family 13 (sodium/sulfate symporters), member 1" 
SLC15A1 solute carrier family 15 (oligopeptide transporter), member 1" 
SLC16A5 
solute carrier family 16, member 5 (monocarboxylic acid transporter 
6) 
SLC18A1 solute carrier family 18 (vesicular monoamine), member 1" 
SLC18A3 solute carrier family 18 (vesicular acetylcholine), member 3 
SLC19A3 solute carrier family 19, member 3" 
SLC22A18 solute carrier family 22, member 18" 
SLC22A9 solute carrier family 22 (organic anion transporter), member 9 
SLC25A27 solute carrier family 25, member 27" 
SLC25A36 solute carrier family 25, member 36" 
SLC35F3 solute carrier family 35, member F3 
SLC38A3 solute carrier family 38, member 3" 
SLC46A2 solute carrier family 46, member 2 
SLC6A1 solute carrier family 6 (neurotransmitter transporter, GABA), 
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member 1" 
SLC6A11 
solute carrier family 6 (neurotransmitter transporter, GABA), 
member 11 
SLC6A15 solute carrier family 6 (neutral amino acid transporter), member 15" 
SLC6A19 solute carrier family 6 (neutral amino acid transporter), member 19" 
SLCO1A2 solute carrier organic anion transporter family, member 1A2" 
SLFN5 schlafen family member 5 
SLITRK1 SLIT and NTRK-like family, member 1 
SLITRK5 SLIT and NTRK-like family, member 5 
SMA4 glucuronidase, beta pseudogene" 
SMAD3 SMAD family member 3 
SMG1 
SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. 
elegans)" 
SMOC1 SPARC related modular calcium binding 1 
SNIP SNAP25-interacting protein 
SNTB1 
syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic 
component 1)" 
SOCS2 suppressor of cytokine signaling 2 
SORBS2 sorbin and SH3 domain containing 2 
SOX11 SRY (sex determining region Y)-box 11 
SOX21 SRY (sex determining region Y)-box 21 
SOX7 SRY (sex determining region Y)-box 7 
SOX7 SRY (sex determining region Y)-box 7 
SP100 SP100 nuclear antigen 
SPATA17 spermatogenesis associated 17 
SPDYA speedy homolog A (Xenopus laevis) 
SPDYA speedy homolog A (Xenopus laevis) 
SPINLW1 
serine peptidase inhibitor-like, with Kunitz and WAP domains 1 
(eppin)" 
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
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(testican) 1" 
SPP1 secreted phosphoprotein 1 
SPRED2 sprouty-related, EVH1 domain containing 2" 
SPRYD5 SPRY domain containing 5 
SPSB3 splA/ryanodine receptor domain and SOCS box containing 3 
SPTB spectrin, beta, erythrocytic" 
SSBP1 single-stranded DNA binding protein 1 
SSPO SCO-spondin homolog (Bos taurus) 
SSTR1 somatostatin receptor 1 
SSX4B synovial sarcoma, X breakpoint 4B 
SSX8 synovial sarcoma, X breakpoint 8" 
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 
ST6GAL2 ST6 beta-galactosamide alpha-2,6-sialyltranferase 2" 
STAG3L1 stromal antigen 3-like 1 
STARD13 StAR-related lipid transfer (START) domain containing 13 
STK31 serine/threonine kinase 31 
STK32B serine/threonine kinase 32B 
STMN1 stathmin 1/oncoprotein 18 
STMN3 stathmin-like 3 
STON1-
GTF2A1L STON1-GTF2A1L readthrough transcript 
STRA8 stimulated by retinoic acid gene 8 homolog (mouse) 
STS steroid sulfatase (microsomal), isozyme S" 
STX1B syntaxin 1B 
SYCE2 synaptonemal complex central element protein 2 
SYCP3 synaptonemal complex protein 3 
SYNE2 spectrin repeat containing, nuclear envelope 2" 
SYNPO2 synaptopodin 2 
SYT14 synaptotagmin XIV 
TACSTD2 tumor-associated calcium signal transducer 2 
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tAKR aldo-keto reductase, truncated" 
TAOK1 TAO kinase 1 
TAS2R42 taste receptor, type 2, member 42 
TBX4 T-box 4 
tcag7.977 hypothetical protein LOC730130 
TCEA3 transcription elongation factor A (SII), 3 
TCF12 transcription factor 12 
TCL1B T-cell leukemia/lymphoma 1B 
TCTEX1D1 Tctex1 domain containing 1 
TDH L-threonine dehydrogenase 
TEDDM1 transmembrane epididymal protein 1 
TFAP2D 
transcription factor AP-2 delta (activating enhancer binding protein 2 
delta) 
TGFB3 transforming growth factor, beta 3" 
TGM4 transglutaminase 4 (prostate) 
THPO thrombopoietin 
THRA 
thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-
erb-a) oncogene homolog, avian)" 
THSD7B thrombospondin, type I, domain containing 7B" 
TINAG tubulointerstitial nephritis antigen 
TLL1 tolloid-like 1 
TLR4 toll-like receptor 4 
TLR4 toll-like receptor 4 
TLX1 T-cell leukemia homeobox 1 
TM4SF18 transmembrane 4 L six family member 18 
TM4SF4 transmembrane 4 L six family member 4 
TMC3 transmembrane channel-like 3 
TMEM146 transmembrane protein 146 
TMEM37 transmembrane protein 37 
TMEM45B transmembrane protein 45B 
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TMEM47 transmembrane protein 47 
TMEM56 transmembrane protein 56 
TMPRSS11A transmembrane protease, serine 11A" 
TNFAIP6 tumor necrosis factor, alpha-induced protein 6" 
TNFRSF10C 
tumor necrosis factor receptor superfamily, member 10c, decoy 
without an intracellular domain 
TNFRSF19 tumor necrosis factor receptor superfamily, member 19" 
TNRC4 trinucleotide repeat containing 4 
TP73 tumor protein p73 
TPSD1 tryptase delta 1 
TRAM2 translocation associated membrane protein 2 
TRIB1 tribbles homolog 1 (Drosophila) 
TRIM22 tripartite motif-containing 22 
TRIM34 tripartite motif-containing 34 
TRIM49 tripartite motif-containing 49 
TRIM6 tripartite motif-containing 6 
TRIM72 tripartite motif-containing 72 
TRIML1 tripartite motif family-like 1 
TRIML2 tripartite motif family-like 2 
TRPM1 transient receptor potential cation channel, subfamily M, member 1" 
TRPV1 transient receptor potential cation channel, subfamily V, member 1" 
TSPAN11 tetraspanin 11 
TSPAN12 tetraspanin 12 
TSPAN8 tetraspanin 8 
TTC18 tetratricopeptide repeat domain 18 
TTC23L tetratricopeptide repeat domain 23-like 
TTLL10 tubulin tyrosine ligase-like family, member 10" 
TTN titin 
TTPA tocopherol (alpha) transfer protein 
TTTY2 testis-specific transcript, Y-linked 2 (non-protein coding)" 
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TTTY8 testis-specific transcript, Y-linked 8" 
TUSC5 tumor suppressor candidate 5 
UACA uveal autoantigen with coiled-coil domains and ankyrin repeats 
UBE2R2 ubiquitin-conjugating enzyme E2R 2 
UBN2 ubinuclein 2 
UCA1 urothelial cancer associated 1 
UGT3A1 UDP glycosyltransferase 3 family, polypeptide A1 
ULK2 unc-51-like kinase 2 (C. elegans) 
UNQ3028 TSSP3028 
UNQ6484 ISPF6484 
USP11 ubiquitin specific peptidase 11 
UTS2 urotensin 2 
UTS2D urotensin 2 domain containing 
VEZF1 vascular endothelial zinc finger 1 
VISA virus-induced signaling adapter 
VN1R3 vomeronasal 1 receptor 3 
VN1R4 vomeronasal 1 receptor 4 
VSNL1 visinin-like 1 
VWA1 von Willebrand factor A domain containing 1 
VWA3B von Willebrand factor A domain containing 3B 
WASF2 WAS protein family, member 2" 
WDR17 WD repeat domain 17 
WDR40B WD repeat domain 40B 
WDR45 WD repeat domain 45 
WDR49 WD repeat domain 49 
WDR65 WD repeat domain 65 
WDR72 WD repeat domain 72 
WFDC11 WAP four-disulfide core domain 11 
WFDC5 WAP four-disulfide core domain 5 
WFDC6 WAP four-disulfide core domain 6 
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Gene Gene description 
WFDC9 WAP four-disulfide core domain 9 
WNT8B wingless-type MMTV integration site family, member 8B 
WWP2 WW domain containing E3 ubiquitin protein ligase 2 
XIRP2 xin actin-binding repeat containing 2 
XRN1 5'-3' exoribonuclease 1 
XYLB xylulokinase homolog (H. influenzae) 
YPEL1 yippee-like 1 (Drosophila) 
YPEL2 yippee-like 2 (Drosophila) 
YPEL5 yippee-like 5 (Drosophila) 
ZADH2 zinc binding alcohol dehydrogenase domain containing 2 
ZBTB10 zinc finger and BTB domain containing 10 
ZBTB20 zinc finger and BTB domain containing 20 
ZC3H6 zinc finger CCCH-type containing 6 
ZC3H6 zinc finger CCCH-type containing 6 
ZDHHC15 zinc finger, DHHC-type containing 15" 
ZFYVE16 zinc finger, FYVE domain containing 16" 
ZIC4 Zic family member 4 
ZMAT1 zinc finger, matrin type 1" 
ZNF292 zinc finger protein 292 
ZNF385B zinc finger protein 385B 
ZNF445 zinc finger protein 445 
ZNF45 zinc finger protein 45 
ZNF471 zinc finger protein 471 
ZNF572 zinc finger protein 572 
ZNF695 zinc finger protein 695 
ZNF704 zinc finger protein 704 
ZNF711 zinc finger protein 711 
ZNF804A zinc finger protein 804A 
ZNF81 zinc finger protein 81 
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Table 57 Genes that were downregulated by rapamycin in lymphocytes 
(downregulated in rapamycin-treated lymphocytes compared to 
untreated lymphocytes, FDR cut-off point of 10%) (95 genes) 
Gene symbol Gene description 
40238 membrane-associated ring finger (C3HC4) 10 
ACSL6 acyl-CoA synthetase long-chain family member 6 
ADAMTS16 ADAM metallopeptidase with thrombospondin type 1 motif, 16" 
AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8)" 
AHNAK2 AHNAK nucleoprotein 2 
ANKRD42 ankyrin repeat domain 42 
AP1S1 adaptor-related protein complex 1, sigma 1 subunit" 
AQP9 aquaporin 9 
AR androgen receptor 
ARHGAP28 Rho GTPase activating protein 28 
AS3MT arsenic (+3 oxidation state) methyltransferase 
ATAD3B ATPase family, AAA domain containing 3B" 
BCCIP BRCA2 and CDKN1A interacting protein 
BSND Bartter syndrome, infantile, with sensorineural deafness (Barttin)" 
C17orf99 chromosome 17 open reading frame 99 
C4orf26 chromosome 4 open reading frame 26 
C5orf36 chromosome 5 open reading frame 36 
C6orf168 chromosome 6 open reading frame 168 
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit" 
CCL2 chemokine (C-C motif) ligand 2 
CCL8 chemokine (C-C motif) ligand 8 
CDCP2 CUB domain containing protein 2 
COL1A2 collagen, type I, alpha 2" 
COL8A2 collagen, type VIII, alpha 2" 
CROT carnitine O-octanoyltransferase 
DYNC2LI1 dynein, cytoplasmic 2, light intermediate chain 1" 
DYNC2LI1 dynein, cytoplasmic 2, light intermediate chain 1" 
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Gene symbol Gene description 
EGLN3 egl nine homolog 3 (C. elegans) 
ENTPD8 ectonucleoside triphosphate diphosphohydrolase 8 
FAM177A1 family with sequence similarity 177, member A1" 
FAM27E3 family with sequence similarity 27, member E3" 
FGF18 fibroblast growth factor 18 
FGF2 fibroblast growth factor 2 (basic) 
FJX1 four jointed box 1 (Drosophila) 
FLJ32575 hypothetical protein FLJ32575 
FLJ35946 hypothetical protein FLJ35946 
FMN2 formin 2 
FUT9 fucosyltransferase 9 (alpha (1,3) fucosyltransferase)" 
G0S2 G0/G1switch 2 
GABBR2 gamma-aminobutyric acid (GABA) B receptor, 2" 
GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1" 
GPAM glycerol-3-phosphate acyltransferase, mitochondrial" 
GPR34 G protein-coupled receptor 34 
GRIA1 glutamate receptor, ionotropic, AMPA 1" 
GSTM3 glutathione S-transferase mu 3 (brain) 
HABP2 hyaluronan binding protein 2 
HCK hemopoietic cell kinase 
IL10 interleukin 10 
IL2 interleukin 2 
IL3 interleukin 3 (colony-stimulating factor, multiple)" 
IL31 interleukin 31 
IL6 interleukin 6 (interferon, beta 2)" 
INGX inhibitor of growth family, X-linked, pseudogene" 
INPP5E inositol polyphosphate-5-phosphatase, 72 kDa" 
KCNA3 potassium voltage-gated channel, shaker-related subfamily, member 3" 
KL klotho 
KRT6B keratin 6B 
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Gene symbol Gene description 
LOC100129522 similar to hCG1817212 
LOC643014 similar to MDS025 
LOC647946 hypothetical protein LOC647946 
LOC647954 similar to keratin 8 
LOXL3 lysyl oxidase-like 3 
MGC29506 hypothetical protein MGC29506 
MLF1 myeloid leukemia factor 1 
MOXD1 monooxygenase, DBH-like 1" 
MYCL1 
v-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma 
derived (avian) 
MYOZ1 myozenin 1 
NAV1 neuron navigator 1 
ODF1 outer dense fiber of sperm tails 1 
OR10J1 olfactory receptor, family 10, subfamily J, member 1 
PDE8B phosphodiesterase 8B 
PES1 pescadillo homolog 1, containing BRCT domain (zebrafish)" 
PHLDA3 pleckstrin homology-like domain, family A, member 3 
PHYHIPL phytanoyl-CoA 2-hydroxylase interacting protein-like 
PRKG1 protein kinase, cGMP-dependent, type I" 
PTGS2 
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase 
and cyclooxygenase) 
PYCR1 pyrroline-5-carboxylate reductase 1 
RPL32P3 ribosomal protein L32 pseudogene 3 
RRAD Ras-related associated with diabetes 
SGTA small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha" 
SLC4A2 
solute carrier family 4, anion exchanger, member 2 (erythrocyte 
membrane protein band 3-like 1)" 
ST6GALNAC2 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 2" 
TAC1 tachykinin, precursor 1 
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Gene symbol Gene description 
TFAP2A 
transcription factor AP-2 alpha (activating enhancer binding protein 2 
alpha) 
THBS1 thrombospondin 1 
TIMM17B translocase of inner mitochondrial membrane 17 homolog B (yeast) 
TIMP2 TIMP metallopeptidase inhibitor 2 
TMEM192 transmembrane protein 192 
TRPM6 transient receptor potential cation channel, subfamily M, member 6" 
TXNRD2 thioredoxin reductase 2 
UBE2M ubiquitin-conjugating enzyme E2M (UBC12 homolog, yeast)" 
UCP1 uncoupling protein 1 (mitochondrial, proton carrier)" 
USP38 ubiquitin specific peptidase 38 
VPS54 vacuolar protein sorting 54 homolog (S. cerevisiae) 
ZCCHC12 zinc finger, CCHC domain containing 12" 
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Table 58  Established rapamycin-regulated genes (based on IPA Ingenuity) that 
were not differentially regulated in rapamycin-treated lymphocytes 
compared to control (38 genes) 
Gene Gene description 
CLU clusterin 
DDIT4 DNA-damage-inducible transcript 4 
EIF4A1 eukaryotic translation initiation factor 4A1 
EIF4B eukaryotic translation initiation factor 4B 
EIF4E eukaryotic translation initiation factor 4E 
EIF4G1 eukaryotic translation initiation factor 4 gamma, 1 
FKBP1A FK506 binding protein 1A, 12kDa 
HIF1A 
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor) 
INS insulin 
INSR insulin receptor 
IRS1 insulin receptor substrate 1 
KIAA1303 raptor 
MAPK1 mitogen-activated protein kinase 1 
MAPK3 mitogen-activated protein kinase 3 
PDK1 pyruvate dehydrogenase kinase, isozyme 1 
PLD1 phospholipase D1, phosphatidylcholine-specific 
PLD2 phospholipase D2 
PLD3 phospholipase D family, member 3 
PLD4 phospholipase D family, member 4 
PRKAA1 protein kinase, AMP-activated, alpha 1 catalytic subunit 
PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit 
PRKCA protein kinase C, alpha 
PRKCD protein kinase C, delta 
PRKCE protein kinase C, epsilon 
PRKCG protein kinase C, gamma 
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Gene Gene description 
PRKCH protein kinase C, eta 
PRKCI protein kinase C, iota 
PRKCQ protein kinase C, theta 
PRKCZ protein kinase C, zeta 
RAC1 
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP 
binding protein Rac1) 
RHEB Ras homolog enriched in brain 
RHO rhodopsin 
RICTOR RPTOR independent companion of MTOR, complex 2 
RPS6 ribosomal protein S6 
RPS6KB2 ribosomal protein S6 kinase, 70kDa, polypeptide 2 
TSC1 tuberous sclerosis 1 
TSC2 tuberous sclerosis 2 
VEGFA vascular endothelial growth factor A 
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APPENDIX 7 
 
ALTERED RAPAMYCIN RESPONSE ELEMENTS AS A RESULT OF MILD AD 
 
Table 59  Differentially expressed transcripts in brain from mild AD patient (limbic stage: ApoE 3/3) compared to brain from 
control subjects (entorhinal stage: ApoE 3/3) 
Gene  Gene description Location Type Possible 
drug 
target 
Possible 
biomarker 
Drugs 
 CCL2 chemokine ligand 2 
Extracellular 
Space cytokine  x 
 
 IL6 interleukin 6 (interferon, beta 2) 
Extracellular 
Space cytokine  x 
tocilizumab 
 
 ENTPD8 
ectonucleoside triphosphate 
diphosphohydrolase 8 unknown enzyme x  
 
 LOXL4 lysyl oxidase-like 4 Extracellular enzyme x x  
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
biomarker 
Drugs 
Space 
 MOXD1 monooxygenase, DBH-like 1 Cytoplasm enzyme x   
 PLD4 phospholipase D family, member 4 unknown enzyme x   
 PRODH2 proline dehydrogenase (oxidase) 2 Cytoplasm enzyme x   
 TGM4 transglutaminase 4 (prostate) 
Extracellular 
Space enzyme x x 
 
 FN3K fructosamine 3 kinase unknown kinase x   
 FAM64A 
family with sequence similarity 64, 
member A unknown other   
 
 FCGBP  Fc fragment of IgG binding protein 
Extracellular 
Space other  x 
 
 SEMA4C 
sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 
4C 
Plasma 
Membrane other   
 
 DQ249310 urothelial cancer associated 1 (non- unknown other    
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
biomarker 
Drugs 
protein coding) 
 
ADAMTS2 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
Extracellular 
Space peptidase x x 
 
 HDAC5  histone deacetylase 5 Nucleus transcription regulator   
tributyrin, 
belinostat, 
pyroxamide, 
vorinostat, 
romidepsin 
 
 POU4F2  POU class 4 homeobox 2 Nucleus transcription regulator    
 RUNX1T1 
 runt-related transcription factor 1; 
translocated to, 1 (cyclin D-related) Nucleus transcription regulator   
 
 
SLC22A18  solute carrier family 22, member 18 
Plasma 
Membrane transporter x  
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APPENDIX 8 
 
ALTERED RAPAMYCIN RESPONSE ELEMENTS AS A RESULTS OF ADVANCED AD  
 
To identify rapamycin-regulated genes whose transcription is altered in advanced AD, gene transcripts in the frontal lobe of neocortical stage 
AD patients (ApoE 3/3) were compared to gene transcriptions in frontal lobe of elderly control patients (ApoE 3/3).  Only ApoE 3/3 
patients were included in the analysis to eliminate any effect of the ApoE genotype.   
 
Out of the 1172 rapamycin-regulated genes, SAM analysis identified 203 that were differentially expressed at RNA level in frontal lobe of 
advanced AD patients (neocortical stage) compared to controls (see Table 60).  Genes for enzymes, growth factors, ion channels, receptors and 
transporters were marked as possible therapeutic targets; whereas genes for cytokines and proteins located in the extracellular space were 
marked as possible biomarkers of disease.  Of the 203 genes: 79 were identified as possible drug targets, and 27 identified as possible 
biomarkers of disease (see Table 60).  Existing drugs that target the possible drug targets are shown in Table 61. 
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The differentially expressed genes (Table 60) were further analysed with IPA to identify molecular and cellular functions (Table 62), diseases 
and disorders (Table 63) and physiological systems (Table 64) that were significantly associated with the different expressed genes.   
 
 IPA also identified a number of networks (Table 65) and pathways (Table 66) significantly associated with the differentially expressed genes 
Note that the score (x) in Table 65  is based on the right-tailed Fisher’s exact test and represents a 1x10x chance of the network having been 
randomly identified.  The altered genes were strongly associated with all of the networks shown.  
 
The differentially expressed genes included twelve (12) of the 159 genes that are known to be part of the mTOR signalling pathway, as 
identified by IPA Ingenuity (Table 67). 
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Table 60 Differentially expressed transcripts in brain from advanced AD patient (Neocortical stage: ApoE 3/3) relative to control 
(entorhinal stage: ApoE 3/3) 
Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 LOX  lysyl oxidase  Extracellular Space  enzyme x X 
 LOXL3  lysyl oxidase-like 3  Extracellular Space  enzyme x X 
 TGM4  transglutaminase 4 (prostate)  Extracellular Space  enzyme x X 
 BMP7  bone morphogenetic protein 7  Extracellular Space  growth factor x X 
 FGF11  fibroblast growth factor 11  Extracellular Space  growth factor x X 
 FGF7  fibroblast growth factor 7  Extracellular Space  growth factor x X 
 VEGFA  vascular endothelial growth factor A  Extracellular Space  growth factor x X 
 CSN2  casein beta  Extracellular Space  kinase x X 
 ADAMTS2 
 ADAM metallopeptidase with thrombospondin type 1 
motif, 2  Extracellular Space  peptidase x X 
 CPXM2  carboxypeptidase X (M14 family), member 2  Extracellular Space  peptidase x X 
 MMP16  matrix metallopeptidase 16 (membrane-inserted)  Extracellular Space  peptidase x X 
 PLAT  plasminogen activator, tissue  Extracellular Space  peptidase x X 
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 ACPP  acid phosphatase, prostate  Extracellular Space  phosphatase x X 
 CCL11  chemokine (C-C motif) ligand 11  Extracellular Space  cytokine  X 
 CCL2  chemokine (C-C motif) ligand 2  Extracellular Space  cytokine  X 
 IL18  interleukin 18 (interferon-gamma-inducing factor)  Extracellular Space  cytokine  X 
 IL1B  interleukin 1, beta  Extracellular Space  cytokine  X 
 IL6  interleukin 6 (interferon, beta 2)  Extracellular Space  cytokine  X 
 SPRED2  sprouty-related, EVH1 domain containing 2  Extracellular Space  cytokine  X 
 CARD14  caspase recruitment domain family, member 14  Cytoplasm  other   
 CCNB2  cyclin B2  Cytoplasm  other   
 CEP68  centrosomal protein 68kDa  Cytoplasm  other   
 DAOA  D-amino acid oxidase activator  Cytoplasm  other   
 DYNC2LI1  dynein, cytoplasmic 2, light intermediate chain 1  Cytoplasm  other   
 ELAVL4 
 ELAV (embryonic lethal, abnormal vision, Drosophila)-
like 4 (Hu antigen D)  Cytoplasm  other   
 GAB1  GRB2-associated binding protein 1  Cytoplasm  other   
 IRS2  insulin receptor substrate 2  Cytoplasm  other   
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 MACF1  microtubule-actin crosslinking factor 1  Cytoplasm  other   
 PEX5L  peroxisomal biogenesis factor 5-like  Cytoplasm  other   
 PLN  phospholamban  Cytoplasm  other   
 RPTOR  regulatory associated protein of MTOR, complex 1  Cytoplasm  other   
 SGTA 
 small glutamine-rich tetratricopeptide repeat (TPR)-
containing, alpha  Cytoplasm  other   
 STARD13 
 StAR-related lipid transfer (START) domain containing 
13  Cytoplasm  other   
 SYNPO2  synaptopodin 2  Cytoplasm  other   
 TSC2  tuberous sclerosis 2  Cytoplasm  other   
 
ADAMTSL5  ADAMTS-like 5  Extracellular Space  other  X 
 CGA  glycoprotein hormones, alpha polypeptide  Extracellular Space  other  X 
 CLU  clusterin  Extracellular Space  other  X 
 CRP  C-reactive protein, pentraxin-related  Extracellular Space  other  X 
 DCD  dermcidin  Extracellular Space  other  X 
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 FAM12B  epididymal protein 3B  Extracellular Space  other  X 
 FBLN1  fibulin 1  Extracellular Space  other  X 
 FCGBP  Fc fragment of IgG binding protein  Extracellular Space  other   
 FJX1  four jointed box 1 (Drosophila)  Extracellular Space  other   
 MFAP5  microfibrillar associated protein 5  Extracellular Space  other   
 SERPIND1 
 serpin peptidase inhibitor, clade D (heparin cofactor), 
member 1  Extracellular Space  other   
 SERPINE1 
 serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1  Extracellular Space  other   
 THBS1  thrombospondin 1  Extracellular Space  other   
 TIMP2  TIMP metallopeptidase inhibitor 2  Extracellular Space  other   
 TNFAIP6  tumor necrosis factor, alpha-induced protein 6  Extracellular Space  other   
 WFDC11  WAP four-disulfide core domain 11  Extracellular Space  other   
 ATAD3B  ATPase family, AAA domain containing 3B  Nucleus  other   
 BCCIP  BRCA2 and CDKN1A interacting protein  Nucleus  other   
 MIER1  mesoderm induction early response 1 homolog (Xenopus  Nucleus  other   
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
laevis) 
 NAV2  neuron navigator 2  Nucleus  other   
 NIPBL  Nipped-B homolog (Drosophila)  Nucleus  other   
 SORBS2  sorbin and SH3 domain containing 2  Nucleus  other   
 ZNF385B  zinc finger protein 385B  Nucleus  other   
 ZNF711  zinc finger protein 711  Nucleus  other   
 CEACAM6 
 carcinoembryonic antigen-related cell adhesion molecule 
6 (non-specific cross reacting antigen)  Plasma Membrane  other   
 COL13A1  collagen, type XIII, alpha 1  Plasma Membrane  other   
 DRP2  dystrophin related protein 2  Plasma Membrane  other   
 HHIP  hedgehog interacting protein  Plasma Membrane  other   
 LILRB2 
 leukocyte immunoglobulin-like receptor, subfamily B 
(with TM and ITIM domains), member 2  Plasma Membrane  other   
 SEMA4C 
 sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4C  Plasma Membrane  other   
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 SNTB1 
 syntrophin, beta 1 (dystrophin-associated protein A1, 
59kDa, basic component 1)  Plasma Membrane  other   
 TACSTD2  tumor-associated calcium signal transducer 2  Plasma Membrane  other   
 TSPAN8  tetraspanin 8  Plasma Membrane  other   
 AHNAK2  AHNAK nucleoprotein 2  unknown  other   
 
ANKRD36B  ankyrin repeat domain 36B  unknown  other   
 ATRNL1  attractin-like 1  unknown  other   
 AUTS2  autism susceptibility candidate 2  unknown  other   
 BTNL9  butyrophilin-like 9  unknown  other   
 C11orf67  chromosome 11 open reading frame 67  unknown  other   
 C16orf75  chromosome 16 open reading frame 75  unknown  other   
 C18orf26  chromosome 18 open reading frame 26  unknown  other   
 C1orf127  chromosome 1 open reading frame 127  unknown  other   
 C3orf70  chromosome 3 open reading frame 70  unknown  other   
 C4orf22  chromosome 4 open reading frame 22  unknown  other   
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 C4orf26  chromosome 4 open reading frame 26  unknown  other   
 C7orf41  chromosome 7 open reading frame 41  unknown  other   
 CC2D2A  coiled-coil and C2 domain containing 2A  unknown  other   
 WDR40B  DDB1 and CUL4 associated factor 12-like 1  unknown  other   
 DNAH6  dynein, axonemal, heavy chain 6  unknown  other   
 FAM155A  family with sequence similarity 155, member A  unknown  other   
 FAM177A1  family with sequence similarity 177, member A1  unknown  other   
 FAM64A  family with sequence similarity 64, member A  unknown  other   
 FAT3  FAT tumor suppressor homolog 3 (Drosophila)  unknown  other   
 GSG1L  GSG1-like  unknown  other   
 HHIPL1  HHIP-like 1  unknown  other   
 HIST1H4E  histone cluster 1, H4e  unknown  other   
 HRASLS5  HRAS-like suppressor family, member 5  unknown  other   
 HYDIN  hydrocephalus inducing homolog (mouse)  unknown  other   
 IFFO1  intermediate filament family orphan 1  unknown  other   
 KCTD19  potassium channel tetramerisation domain containing 19  unknown  other   
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 KLHL24  kelch-like 24 (Drosophila)  unknown  other   
 KRT72  keratin 72  unknown  other   
 KRTAP9-2  keratin associated protein 9-2  unknown  other   
 LYPD2  LY6/PLAUR domain containing 2  unknown  other   
 MBD3L2  methyl-CpG binding domain protein 3-like 2  unknown  other   
 MCTP1  multiple C2 domains, transmembrane 1  unknown  other   
 NBR1  neighbor of BRCA1 gene 1  unknown  other   
 OLFML2A  olfactomedin-like 2A  unknown  other   
 PCDHGA9  protocadherin gamma subfamily A, 9  unknown  other   
 PHLDA3  pleckstrin homology-like domain, family A, member 3  unknown  other   
 PSORS1C1  psoriasis susceptibility 1 candidate 1  unknown  other   
 SLITRK1  SLIT and NTRK-like family, member 1  unknown  other   
 SLITRK5  SLIT and NTRK-like family, member 5  unknown  other   
 SPRYD5  SPRY domain containing 5  unknown  other   
 SSX8  synovial sarcoma, X breakpoint 8  unknown  other   
 STAG3L1  stromal antigen 3-like 1  unknown  other   
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 TM4SF18  transmembrane 4 L six family member 18  unknown  other   
 TMEM56  transmembrane protein 56  unknown  other   
 UBN2  ubinuclein 2  unknown  other   
 ZC3H6  zinc finger CCCH-type containing 6  unknown  other   
 DHRS3  dehydrogenase/reductase (SDR family) member 3  Cytoplasm  enzyme x  
 DZIP3  DAZ interacting protein 3, zinc finger  Cytoplasm  enzyme x  
 EGLN3  egl nine homolog 3 (C. elegans)  Cytoplasm  enzyme x  
 FKBP1A  FK506 binding protein 1A, 12kDa  Cytoplasm  enzyme x  
 GBP3  guanylate binding protein 3  Cytoplasm  enzyme x  
 MOXD1  monooxygenase, DBH-like 1  Cytoplasm  enzyme x  
 PLCH1  phospholipase C, eta 1  Cytoplasm  enzyme x  
 PRODH2  proline dehydrogenase (oxidase) 2  Cytoplasm  enzyme x  
 RAB3C  RAB3C, member RAS oncogene family  Cytoplasm  enzyme x  
 RAC1 
 ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein Rac1)  Cytoplasm  enzyme x  
 RND3  Rho family GTPase 3  Cytoplasm  enzyme x  
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 RNF128  ring finger protein 128  Cytoplasm  enzyme x  
 STS  steroid sulfatase (microsomal), isozyme S  Cytoplasm  enzyme x  
 TXNRD2  thioredoxin reductase 2  Cytoplasm  enzyme x  
 POLK  polymerase (DNA directed) kappa  Nucleus  enzyme x  
 YPEL1  yippee-like 1 (Drosophila)  Nucleus  enzyme x  
 AASDH  aminoadipate-semialdehyde dehydrogenase  unknown  enzyme x  
 DSEL  dermatan sulfate epimerase-like  unknown  enzyme x  
 ENTPD8  ectonucleoside triphosphate diphosphohydrolase 8  unknown  enzyme x  
 PLD4  phospholipase D family, member 4  unknown  enzyme x  
 CCR1  chemokine (C-C motif) receptor 1  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 CCR2  chemokine (C-C motif) receptor 2  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 GABBR2  gamma-aminobutyric acid (GABA) B receptor, 2  Plasma Membrane  G-protein x  
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
coupled 
receptor 
 GLP1R  glucagon-like peptide 1 receptor  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 GPR34  G protein-coupled receptor 34  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 NTSR1  neurotensin receptor 1 (high affinity)  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 OR51E2  olfactory receptor, family 51, subfamily E, member 2  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 RHO  rhodopsin  Plasma Membrane 
 G-protein 
coupled x  
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
receptor 
 CACNA1D 
 calcium channel, voltage-dependent, L type, alpha 1D 
subunit  Plasma Membrane  ion channel x  
 CFTR 
 cystic fibrosis transmembrane conductance regulator 
(ATP-binding cassette sub-family C, member 7)  Plasma Membrane  ion channel x  
 GLRA1  glycine receptor, alpha 1  Plasma Membrane  ion channel x  
 GRIK2  glutamate receptor, ionotropic, kainate 2  Plasma Membrane  ion channel x  
 KCNAB1 
 potassium voltage-gated channel, shaker-related 
subfamily, beta member 1  Plasma Membrane  ion channel x  
 KCND2 
 potassium voltage-gated channel, Shal-related subfamily, 
member 2  Plasma Membrane  ion channel x  
 KCNG4  potassium voltage-gated channel, subfamily G, member 4  Plasma Membrane  ion channel x  
 KCNIP2  Kv channel interacting protein 2  Plasma Membrane  ion channel x  
 SCN8A  sodium channel, voltage gated, type VIII, alpha subunit  Plasma Membrane  ion channel x  
 STX1B  syntaxin 1B  Plasma Membrane  ion channel x  
 DCLK1  doublecortin-like kinase 1  Cytoplasm  kinase x  
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 MAPK1  mitogen-activated protein kinase 1  Cytoplasm  kinase x  
 MAPK4  mitogen-activated protein kinase 4  Cytoplasm  kinase x  
 MARK1  MAP/microtubule affinity-regulating kinase 1  Cytoplasm  kinase x  
 PIM1  pim-1 oncogene  Cytoplasm  kinase x  
 PRKCH  protein kinase C, eta  Cytoplasm  kinase x  
 RPS6KB2  ribosomal protein S6 kinase, 70kDa, polypeptide 2  Cytoplasm  kinase x  
 SMG1 
 SMG1 homolog, phosphatidylinositol 3-kinase-related 
kinase (C. elegans)  Cytoplasm  kinase x  
 TAOK1  TAO kinase 1  Cytoplasm  kinase x  
 TRIB1  tribbles homolog 1 (Drosophila)  Cytoplasm  kinase x  
 FGR 
 Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene 
homolog  Nucleus  kinase x  
 DLG2  discs, large homolog 2 (Drosophila)  Plasma Membrane  kinase x  
 FGFR1  fibroblast growth factor receptor 1  Plasma Membrane  kinase x  
 FN3K  fructosamine 3 kinase  unknown  kinase x  
 FBP2  fructose-1,6-bisphosphatase 2  Cytoplasm  phosphatase x  
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
 CTDSP1 
 CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase 1  Nucleus  phosphatase x  
 CD69  CD69 molecule  Plasma Membrane 
 transmembrane 
receptor x  
 CHRNA9  cholinergic receptor, nicotinic, alpha 9  Plasma Membrane 
 transmembrane 
receptor x  
 SEMA5A 
 sema domain, seven thrombospondin repeats (type 1 and 
type 1-like), transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 5A  Plasma Membrane 
 transmembrane 
receptor x  
 AP1S1  adaptor-related protein complex 1, sigma 1 subunit  Cytoplasm  transporter x  
 ATP8B3 
 ATPase, aminophospholipid transporter, class I, type 8B, 
member 3  Cytoplasm  transporter x  
 SLC25A27  solute carrier family 25, member 27  Cytoplasm  transporter x  
 ZFYVE16  zinc finger, FYVE domain containing 16  Nucleus  transporter x  
 BPI  bactericidal/permeability-increasing protein  Plasma Membrane  transporter x  
 SLC18A3  solute carrier family 18 (vesicular acetylcholine), member  Plasma Membrane  transporter x  
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drug 
target 
Possible 
bio-
marker 
3 
 SLC22A18  solute carrier family 22, member 18  Plasma Membrane  transporter x  
 SLC38A3  solute carrier family 38, member 3  Plasma Membrane  transporter x  
 SLC4A2 
 solute carrier family 4, anion exchanger, member 2 
(erythrocyte membrane protein band 3-like 1)  Plasma Membrane  transporter x  
 ATF7IP  activating transcription factor 7 interacting protein  Nucleus 
 transcription 
regulator   
 BARX2  BARX homeobox 2  Nucleus 
 transcription 
regulator   
 BCOR  BCL6 corepressor  Nucleus 
 transcription 
regulator   
 BNC1  basonuclin 1  Nucleus 
 transcription 
regulator   
 CREB3L4  cAMP responsive element binding protein 3-like 4  Nucleus 
 transcription 
regulator   
 GLI2  GLI family zinc finger 2  Nucleus  transcription   
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drug 
target 
Possible 
bio-
marker 
regulator 
 HDAC5  histone deacetylase 5  Nucleus 
 transcription 
regulator   
 HDAC9  histone deacetylase 9  Nucleus 
 transcription 
regulator   
 HOXD10  homeobox D10  Nucleus 
 transcription 
regulator   
 IRX4  iroquois homeobox 4  Nucleus 
 transcription 
regulator   
 KANK2  KN motif and ankyrin repeat domains 2  Nucleus 
 transcription 
regulator   
 KLF2  Kruppel-like factor 2 (lung)  Nucleus 
 transcription 
regulator   
 MNT  MAX binding protein  Nucleus 
 transcription 
regulator   
 MYF6  myogenic factor 6 (herculin)  Nucleus  transcription   
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Gene Gene description Location Type Possible 
drug 
target 
Possible 
bio-
marker 
regulator 
 NFIB  nuclear factor I/B  Nucleus 
 transcription 
regulator   
 NKX3-2  NK3 homeobox 2  Nucleus 
 transcription 
regulator   
 POU4F2  POU class 4 homeobox 2  Nucleus 
 transcription 
regulator   
 RUNX1T1 
 runt-related transcription factor 1; translocated to, 1 
(cyclin D-related)  Nucleus 
 transcription 
regulator   
 SMAD3  SMAD family member 3  Nucleus 
 transcription 
regulator   
 SOX21  SRY (sex determining region Y)-box 21  Nucleus 
 transcription 
regulator   
 EIF4A1  eukaryotic translation initiation factor 4A1  Cytoplasm 
 translation 
regulator   
 EIF4E  eukaryotic translation initiation factor 4E  Cytoplasm  translation   
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drug 
target 
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Table 61 Existing drugs that target the genes identified as possible drug targets for advanced AD (neocortical stage: ApoE 3/3) 
relative to control (entorhinal stage: ApoE 3/3)  
Gene symbol Drugs 
 CHRNA9 
 ABT-089, isoflurane, mecamylamine, succinylcholine, rocuronium, doxacurium, amobarbital, mivacurium, pipecuronium, 
rapacuronium, metocurine, atracurium, cisatracurium, acetylcholine, nicotine, D-tubocurarine, arecoline, enflurane, 
pancuronium, vecuronium 
 VEGFA  bevacizumab, ranibizumab, aflibercept, pegaptanib 
 NTSR1  contulakin-G 
 FKBP1A  everolimus 
 GLP1R  liraglutide, T-0632, GLP-1 (7-36) amide, exenatide 
 CACNA1D  MEM-1003, clevidipine butyrate, mibefradil, bepridil, nisoldipine, isradipine, nicardipine 
 FGFR1  pazopanib 
 SCN8A  riluzole 
 CFTR  SP 303 
 STS  STX 64 
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Table 62 Molecular and cellular functions significantly associated with the differentially expressed transcripts in advanced AD 
brain (neocortical stage: ApoE 3/3 genotype) relative to control (entorhinal stage: ApoE 3/3 genotype)  
Molecular and cellular functions p-value Number of Genes 
Cellular Movement  <0.05 28 
Cellular Growth and Proliferation  <0.05 29 
Cell Signaling  <0.05 17 
Small Molecule Biochemistry  <0.05 30 
Vitamin and Mineral Metabolism  <0.05 14 
 
Table 63 Diseases and disorders significantly associated with the differentially expressed transcripts in advanced AD brain 
(neocortical stage: ApoE 3/3 genotype) relative to control (entorhinal stage: ApoE 3/3 genotype) 
Diseases and disorders p-value Number of genes 
Cardiovascular Disease  <0.05 56 
Inflammatory Response  <0.05 23 
Hematological Disease  <0.05 21 
Infectious Disease  <0.05 26 
Inflammatory Disease  <0.05 57 
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Table 64 Physiological systems significantly associated with the differentially expressed transcripts in advanced AD brain 
(neocortical stage: ApoE 3/3 genotype) relative to control (entorhinal stage: ApoE 3/3 genotype) 
Physiological system development and function p-value Number of genes 
Tissue development <0.05 22 
Cardiovascular system development and function <0.05 17 
Organismal development <0.05 19 
Tumour morphology <0.05 7 
Immune cell trafficking <0.05 15 
 
 
Table 65 Networks significantly associated with the differentially expressed transcripts in advanced AD brain (neocortical stage: 
ApoE 3/3 genotype) relative to control (entorhinal stage: ApoE 3/3 genotype)  
Network Number of 
molecules 
Score Top functions 
 1  18  30  Cancer, Tissue Morphology, Carbohydrate Metabolism 
 2  17  26  Cancer, Renal and Urological Disease, Gastrointestinal Disease 
 3  14  21  Gene Expression, Cellular Development, Connective Tissue Development and Function 
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Network Number of 
molecules 
Score Top functions 
 4  15  21 
 Cellular Movement, Skeletal and Muscular System Development and Function, Hematological System 
Development and Function 
 5  13  19  Cell Morphology, Cellular Development, Cardiovascular System Development and Function 
 6  12  17  Inflammatory Response, Cellular Movement, Hematological System Development and Function 
 7  11  16 
 DNA Replication, Recombination, and Repair, Nucleic Acid Metabolism, Small Molecule 
Biochemistry 
 8  11  15 
 Cell Morphology, Cellular Function and Maintenance, Reproductive System Development and 
Function 
 9  12  15  Cellular Assembly and Organization, Cell Morphology, Cellular Development 
 10  10  14  Amino Acid Metabolism, Increased Levels of AST, Increased Levels of Alkaline Phosphatase 
 11  10  13  Gene Expression, Endocrine System Development and Function, Tissue Morphology 
 12  9  12  Cellular Development, Cellular Growth and Proliferation, Hair and Skin Development and Function 
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Table 66 Canonical pathways associated with the differentially expressed transcripts in advanced AD brain (neocortical stage:  
ApoE 3/3 genotype) relative to control (entorhinal stage: ApoE 3/3 genotype) 
Canonical pathway p-value 
 mTOR Signaling <0.001 
 TREM1 Signaling <0.001 
 FGF Signaling <0.001 
 Insulin Receptor Signaling <0.001 
 Role of Hypercytokinemia/ hyperchemokinemia in the Pathogenesis of Influenza <0.001 
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Table 67 Differentially expressed genes that are established members of the mTOR signalling pathway as defined by IPA 
Ingenuity (differentially expressed in advanced AD brain (neocortical: ApoE 3/3) relative to control (entorhinal: ApoE 
3/3)). 
Symbol Entrez Gene Name Location Type(s) 
EIF4A1 eukaryotic translation initiation factor 4A1 Cytoplasm translation regulator 
EIF4E eukaryotic translation initiation factor 4E Cytoplasm translation regulator 
FKBP1A FK506 binding protein 1A, 12kDa Cytoplasm enzyme 
MAPK1 mitogen-activated protein kinase 1 Cytoplasm kinase 
PLD4 phospholipase D family, member 4 unknown enzyme 
PRKCH protein kinase C, eta Cytoplasm kinase 
RAC1 
ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein Rac1) Cytoplasm enzyme 
RND3 Rho family GTPase 3 Cytoplasm enzyme 
RPS6KB2 ribosomal protein S6 kinase, 70kDa, polypeptide 2 Cytoplasm kinase 
RPTOR regulatory associated protein of MTOR, complex 1 Cytoplasm other 
TSC2 tuberous sclerosis 2 Cytoplasm other 
VEGFA vascular endothelial growth factor A Extracellular Space growth factor 
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APPENDIX 9 
 
ALTERED RAPAMYCIN RESPONSE ELEMENTS AS A 
RESULT OF ADVANCED AD AND APOE 4 
 
To identify rapamycin-regulated genes whose transcription is altered as a result of advanced 
AD (AD neocortical stage) and ApoE 4, gene transcripts in the frontal lobe of advanced AD 
patients (neocortical stage: ApoE 3/4) were compared to gene transcripts in the frontal 
lobe of control subjects (ApoE 3/3).   
 
Of the 1172 identified rapamycin-regulated genes, SAM analysis identified 168 that were 
differentially expressed in advanced AD (neocortical stage: ApoE 3/4) compared to 
control (ApoE 3/3) (Table 68).  Genes for enzymes, growth factors, ion channels, 
receptors and transporters were marked as possible drug targets; whereas genes for 
cytokines, and proteins located in the extracellular space were marked as possible 
biomarkers of disease. Of the 168 differentially expressed genes, 69 were identified as 
possible drug targets, and 27 identified as possible biomarkers of disease (Table 68).  Eleven 
(11) drugs target the identified possible drug targets (Table 69).   
 
The differentially expressed genes were further analysed with IPA to identify molecular and 
cellular functions (Table 70), diseases and disorders (Table 71), and physiological systems 
(Table 72) that are significantly associated with the differentially expressed genes.  A 
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number of networks (Table 73) and pathways (Table 74) were also significantly associated 
with the differentially expressed genes.  Note that the score (x) in Table 73 is based on the 
right-tailed Fisher’s exact test and represents a 1x10x chance of the network having been 
randomly identified.       
 
The differentially expressed genes included 10 of the 159 well established genes of the 
mTOR signalling pathway (as identified by IPA Ingenuity) (Table 75).
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Table 68 Differentially expressed transcripts in frontal lobe of advanced AD patients (neocortical stage: ApoE 3/4) compared to 
control (ApoE 3/3) 
Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
TGM4  transglutaminase 4 (prostate)  Extracellular Space  enzyme x X 
 LOXL4  lysyl oxidase-like 4  Extracellular Space  enzyme x X 
 VEGFA  vascular endothelial growth factor A  Extracellular Space  growth factor x X 
 FGF11  fibroblast growth factor 11  Extracellular Space  growth factor x X 
 BMP7  bone morphogenetic protein 7  Extracellular Space  growth factor x X 
 CSN2  casein beta  Extracellular Space  kinase x X 
 PCSK2  proprotein convertase subtilisin/kexin type 2  Extracellular Space  peptidase x X 
 MMP16  matrix metallopeptidase 16 (membrane-inserted)  Extracellular Space  peptidase x X 
 CPXM2  carboxypeptidase X (M14 family), member 2  Extracellular Space  peptidase x X 
 ADAMTS2 
 ADAM metallopeptidase with thrombospondin 
type 1 motif, 2  Extracellular Space  peptidase x X 
 SPRED2  sprouty-related, EVH1 domain containing 2  Extracellular Space  cytokine  X 
 IL6  interleukin 6 (interferon, beta 2)  Extracellular Space  cytokine  X 
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 CCL2  chemokine (C-C motif) ligand 2  Extracellular Space  cytokine  X 
 CCL1  chemokine (C-C motif) ligand 1  Extracellular Space  cytokine  X 
 VSNL1  visinin-like 1  Cytoplasm  other   
 TSC2  tuberous sclerosis 2  Cytoplasm  other   
 STARD13 
 StAR-related lipid transfer (START) domain 
containing 13  Cytoplasm  other   
 SGTA 
 small glutamine-rich tetratricopeptide repeat 
(TPR)-containing, alpha  Cytoplasm  other   
 SCGN  secretagogin, EF-hand calcium binding protein  Cytoplasm  other   
 RIMS2  regulating synaptic membrane exocytosis 2  Cytoplasm  other   
 PEX5L  peroxisomal biogenesis factor 5-like  Cytoplasm  other   
 KIAA1683  KIAA1683  Cytoplasm  other   
 IRS2  insulin receptor substrate 2  Cytoplasm  other   
 GFAP  glial fibrillary acidic protein  Cytoplasm  other   
 ELAVL4 
 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D)  Cytoplasm  other   
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 DYNC2LI1  dynein, cytoplasmic 2, light intermediate chain 1  Cytoplasm  other   
 CPLX2  complexin 2  Cytoplasm  other   
 CEP68  centrosomal protein 68kDa  Cytoplasm  other   
 ABLIM2  actin binding LIM protein family, member 2  Cytoplasm  other   
 WFDC6  WAP four-disulfide core domain 6  Extracellular Space  other  X 
 SERPINE1 
 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1  Extracellular Space  other  X 
 SERPIND1 
 serpin peptidase inhibitor, clade D (heparin 
cofactor), member 1  Extracellular Space  other  X 
 NPTX1  neuronal pentraxin I  Extracellular Space  other  X 
 NEGR1  neuronal growth regulator 1  Extracellular Space  other  X 
 LECT1  leukocyte cell derived chemotaxin 1  Extracellular Space  other  X 
 FJX1  four jointed box 1 (Drosophila)  Extracellular Space  other  X 
 DEFB119  defensin, beta 119  Extracellular Space  other  X 
 DCD  dermcidin  Extracellular Space  other  X 
 CYR61  cysteine-rich, angiogenic inducer, 61  Extracellular Space  other  X 
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 CRP  C-reactive protein, pentraxin-related  Extracellular Space  other  X 
 CLU  clusterin  Extracellular Space  other  X 
 ADAMTSL5  ADAMTS-like 5  Extracellular Space  other  X 
 ZBTB20  zinc finger and BTB domain containing 20  Nucleus  other   
 SORBS2  sorbin and SH3 domain containing 2  Nucleus  other   
 PNRC1  proline-rich nuclear receptor coactivator 1  Nucleus  other   
 ELAVL3 
 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 3 (Hu antigen C)  Nucleus  other   
 ATAD3B  ATPase family, AAA domain containing 3B  Nucleus  other   
 SEMA4C 
 sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4C  Plasma Membrane  other   
 DRP2  dystrophin related protein 2  Plasma Membrane  other   
 CEACAM6 
 carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen)  Plasma Membrane  other   
 CDH13  cadherin 13, H-cadherin (heart)  Plasma Membrane  other   
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 ZCCHC12  zinc finger, CCHC domain containing 12  unknown  other   
 ZC3H6  zinc finger CCCH-type containing 6  unknown  other   
 YPEL5  yippee-like 5 (Drosophila)  unknown  other   
 DQ249310  urothelial cancer associated 1 (non-protein coding)  unknown  other   
 TMEM56  transmembrane protein 56  unknown  other   
 TM4SF18  transmembrane 4 L six family member 18  unknown  other   
 STAG3L1  stromal antigen 3-like 1  unknown  other   
 SLITRK1  SLIT and NTRK-like family, member 1  unknown  other   
 SLC35F3  solute carrier family 35, member F3  unknown  other   
 PHYHD1  phytanoyl-CoA dioxygenase domain containing 1  unknown  other   
 PHLDA3 
 pleckstrin homology-like domain, family A, 
member 3  unknown  other   
 PCDHGA9  protocadherin gamma subfamily A, 9  unknown  other   
 MEG3  maternally expressed 3 (non-protein coding)  unknown  other   
 MCTP1  multiple C2 domains, transmembrane 1  unknown  other   
 LYPD2  LY6/PLAUR domain containing 2  unknown  other   
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 KLHL24  kelch-like 24 (Drosophila)  unknown  other   
 ITGBL1 
 integrin, beta-like 1 (with EGF-like repeat 
domains)  unknown  other   
 HYDIN  hydrocephalus inducing homolog (mouse)  unknown  other   
 HIST1H4E  histone cluster 1, H4e  unknown  other   
 HHIPL1  HHIP-like 1  unknown  other   
 GIGYF1  GRB10 interacting GYF protein 1  unknown  other   
 LRRC37A4 
 leucine rich repeat containing 37, member A4 
(pseudogene)  unknown  other   
 FBXL16  F-box and leucine-rich repeat protein 16  unknown  other   
 FAT3  FAT tumor suppressor homolog 3 (Drosophila)  unknown  other   
 FAM64A  family with sequence similarity 64, member A  unknown  other   
 FAM171B  family with sequence similarity 171, member B  unknown  other   
 FAM155A  family with sequence similarity 155, member A  unknown  other   
 DNAH6  dynein, axonemal, heavy chain 6  unknown  other   
 WDR40B  DDB1 and CUL4 associated factor 12-like 1  unknown  other   
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 CCDC85A  coiled-coil domain containing 85A  unknown  other   
 CCDC28A  coiled-coil domain containing 28A  unknown  other   
 CC2D2A  coiled-coil and C2 domain containing 2A  unknown  other   
 C1orf127  chromosome 1 open reading frame 127  unknown  other   
 C18orf26  chromosome 18 open reading frame 26  unknown  other   
 C17orf99  chromosome 17 open reading frame 99  unknown  other   
 C16orf75  chromosome 16 open reading frame 75  unknown  other   
 BTNL9  butyrophilin-like 9  unknown  other   
 ATRNL1  attractin-like 1  unknown  other   
 ANKRD36B  ankyrin repeat domain 36B  unknown  other   
 KIAA1641  ankyrin repeat domain 36B  unknown  other   
 AHNAK2  AHNAK nucleoprotein 2  unknown  other   
 ACTRT1  actin-related protein T1  unknown  other   
 UBE2M 
 ubiquitin-conjugating enzyme E2M (UBC12 
homolog, yeast)  Cytoplasm  enzyme x  
 RNF128  ring finger protein 128  Cytoplasm  enzyme x  
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drug 
target 
Possible 
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 RAB3C  RAB3C, member RAS oncogene family  Cytoplasm  enzyme x  
 PTGS2 
 prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase)  Cytoplasm  enzyme x  
 PRODH2  proline dehydrogenase (oxidase) 2  Cytoplasm  enzyme x  
 PAOX  polyamine oxidase (exo-N4-amino)  Cytoplasm  enzyme x  
 NMNAT2  nicotinamide nucleotide adenylyltransferase 2  Cytoplasm  enzyme x  
 MOXD1  monooxygenase, DBH-like 1  Cytoplasm  enzyme x  
 HMGCS2 
 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial)  Cytoplasm  enzyme x  
 GALNT10 
 UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 10 (GalNAc-
T10)  Cytoplasm  enzyme x  
 FKBP1A  FK506 binding protein 1A, 12kDa  Cytoplasm  enzyme x  
 DZIP3  DAZ interacting protein 3, zinc finger  Cytoplasm  enzyme x  
 ACSL6  acyl-CoA synthetase long-chain family member 6  Cytoplasm  enzyme x  
 YPEL1  yippee-like 1 (Drosophila)  Nucleus  enzyme x  
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 GNG8 
 guanine nucleotide binding protein (G protein), 
gamma 8  Plasma Membrane  enzyme x  
 PLD4  phospholipase D family, member 4  unknown  enzyme x  
 PDE8B  phosphodiesterase 8B  unknown  enzyme x  
 ENTPD8  ectonucleoside triphosphate diphosphohydrolase 8  unknown  enzyme x  
 SSTR1  somatostatin receptor 1  Plasma Membrane 
 G-protein 
coupled receptor x  
 OR52B2 
 olfactory receptor, family 52, subfamily B, 
member 2  Plasma Membrane 
 G-protein 
coupled receptor x  
 NTSR1  neurotensin receptor 1 (high affinity)  Plasma Membrane 
 G-protein 
coupled receptor x  
 GPR176  G protein-coupled receptor 176  Plasma Membrane 
 G-protein 
coupled receptor x  
 GPR109B  G protein-coupled receptor 109B  Plasma Membrane 
 G-protein 
coupled receptor x  
 GABBR2  gamma-aminobutyric acid (GABA) B receptor, 2  Plasma Membrane  G-protein x  
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drug 
target 
Possible 
bio-marker 
coupled receptor 
 CCR1  chemokine (C-C motif) receptor 1  Plasma Membrane 
 G-protein 
coupled receptor x  
 KCNG4 
 potassium voltage-gated channel, subfamily G, 
member 4  Cytoplasm  ion channel x  
 TRPV1 
 transient receptor potential cation channel, 
subfamily V, member 1  Plasma Membrane  ion channel x  
 STX1B  syntaxin 1B  Plasma Membrane  ion channel x  
 SCN8A 
 sodium channel, voltage gated, type VIII, alpha 
subunit  Plasma Membrane  ion channel x  
 KCND2 
 potassium voltage-gated channel, Shal-related 
subfamily, member 2  Plasma Membrane  ion channel x  
 KCNAB1 
 potassium voltage-gated channel, shaker-related 
subfamily, beta member 1  Plasma Membrane  ion channel x  
 GRIA2  glutamate receptor, ionotropic, AMPA 2  Plasma Membrane  ion channel x  
 CACNA1D  calcium channel, voltage-dependent, L type, alpha  Plasma Membrane  ion channel x  
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
1D subunit 
 TAOK1  TAO kinase 1  Cytoplasm  kinase x  
RPS6KB2 ribosomal protein S6 kinase, 70kDa, polypeptide 2  Cytoplasm  kinase x  
 PRKCI  protein kinase C, iota  Cytoplasm  kinase x  
 PRKCH  protein kinase C, eta  Cytoplasm  kinase x  
 PRKCA  protein kinase C, alpha  Cytoplasm  kinase x  
 PIM1  pim-1 oncogene  Cytoplasm  kinase x  
 MAPK4  mitogen-activated protein kinase 4  Cytoplasm  kinase x  
 MAPK1  mitogen-activated protein kinase 1  Cytoplasm  kinase x  
 DCLK1  doublecortin-like kinase 1  Cytoplasm  kinase x  
 DLG2  discs, large homolog 2 (Drosophila)  Plasma Membrane  kinase x  
 ACVR2B  activin A receptor, type IIB  Plasma Membrane  kinase x  
 FN3K  fructosamine 3 kinase  unknown  kinase x  
 RORB  RAR-related orphan receptor B  Nucleus 
 ligand-dependent 
nuclear receptor x  
 CTDSP1  CTD (carboxy-terminal domain, RNA polymerase  Nucleus  phosphatase x  
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drug 
target 
Possible 
bio-marker 
II, polypeptide A) small phosphatase 1 
 TNFRSF10C 
 tumor necrosis factor receptor superfamily, 
member 10c, decoy without an intracellular domain  Plasma Membrane 
 transmembrane 
receptor x  
 SEMA5A 
 sema domain, seven thrombospondin repeats (type 
1 and type 1-like), transmembrane domain (TM) 
and short cytoplasmic domain, (semaphorin) 5A  Plasma Membrane 
 transmembrane 
receptor x  
 TIMM17B 
 translocase of inner mitochondrial membrane 17 
homolog B (yeast)  Cytoplasm  transporter x  
 SLC25A27  solute carrier family 25, member 27  Cytoplasm  transporter x  
AP1S1 adaptor-related protein complex 1, sigma 1 subunit Cytoplasm transporter x  
 SLC6A15 
 solute carrier family 6 (neutral amino acid 
transporter), member 15  Plasma Membrane transporter x  
 SLC6A11 
 solute carrier family 6 (neurotransmitter 
transporter, GABA), member 11  Plasma Membrane  transporter x  
SLC38A3  solute carrier family 38, member 3 Plasma Membrane transporter x  
SLC22A18  solute carrier family 22, member 18  Plasma Membrane transporter x  
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drug 
target 
Possible 
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 SLC18A3 
 solute carrier family 18 (vesicular acetylcholine), 
member 3  Plasma Membrane  transporter x  
 BPI  bactericidal/permeability-increasing protein  Plasma Membrane  transporter x  
 CDCP2  CUB domain containing protein 2  unknown  transporter x  
 SMAD3  SMAD family member 3  Nucleus 
transcription 
regulator   
 RUNX1T1 
 runt-related transcription factor 1; translocated to, 
1 (cyclin D-related)  Nucleus 
transcription 
regulator   
 POU4F2  POU class 4 homeobox 2  Nucleus 
transcription 
regulator   
 MYF6  myogenic factor 6 (herculin)  Nucleus 
transcription 
regulator   
 EVI1  MDS1 and EVI1 complex locus  Nucleus 
transcription 
regulator   
 KLF2  Kruppel-like factor 2 (lung)  Nucleus 
transcription 
regulator   
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Gene  Gene description Location Type Possible 
drug 
target 
Possible 
bio-marker 
 HDAC5  histone deacetylase 5  Nucleus 
 transcription 
regulator   
 GLI2  GLI family zinc finger 2  Nucleus 
transcription 
regulator   
 EGR1  early growth response 1  Nucleus 
transcription 
regulator   
 CREB3L4  cAMP responsive element binding protein 3-like 4  Nucleus 
transcription 
regulator   
 BCOR  BCL6 co-repressor  Nucleus 
transcription 
regulator   
 BARX2  BARX homeobox 2  Nucleus 
transcription 
regulator   
 ATF7IP  activating transcription factor 7 interacting protein  Nucleus 
transcription 
regulator   
 EIF4E  eukaryotic translation initiation factor 4E  Cytoplasm 
translation 
regulator   
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drug 
target 
Possible 
bio-marker 
 ABTB1 
 ankyrin repeat and BTB (POZ) domain containing 
1  Cytoplasm 
translation 
regulator   
BRUNOL4  CUGBP, Elav-like family member 4  Nucleus 
translation 
regulator   
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Table 69 Existing drugs that target the genes identified as possible drug targets for advanced AD (neocortical stage: ApoE 3/4) 
compared to control (entorhinal stage: ApoE 3/3) 
Gene 
symbol 
Drugs 
 PTGS2 
5-aminosalicylic acid, acetaminophen, aspirin, balsalazide, bromfenac, butalbital, caffeine, carisoprodol, celecoxib, 
chlorpheniramine, clemastine, codeine, dexbrompheniramine, diclofenac, diflunisal, dihydrocodeine, dipyridamole, dipyrone, 
etodolac, fenoprofen, GW406381X, hydrocodone, ibuprofen, indomethacin, ketoprofen, ketorolac, licofelone, meclofenamic 
acid, mefenamic acid, meloxicam, menatetrenone, meprobamate, methocarbamol, misoprostol, nabumetone, naproxen, 
nitroaspirin, orphenadrine, oxycodone, pentazocine, phenacetin, phenylephrine, piroxicam, pravastatin, propoxyphene, 
propoxyphene, pseudoephedrine, racemic flurbiprofen, rofecoxib, salicylic acid, sulfasalazine, sulindac, sumatriptan, tolmetin, 
tramadol, valdecoxib, zomepirac 
 VEGFA  bevacizumab, ranibizumab, aflibercept, pegaptanib 
 NTSR1  contulakin-G 
 FKBP1A  everolimus 
 PRKCA  L-threo-safingol 
 
CACNA1D  MEM-1003, clevidipine butyrate, mibefradil, bepridil, nisoldipine, isradipine, nicardipine 
 SSTR1  pasireotide, octreotide 
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Gene 
symbol 
Drugs 
 SCN8A  riluzole 
 TRPV1  SB-705498, capsaicin 
 GRIA2  talampanel, Org 24448, LY451395, tezampanel 
 SLC6A11  tiagabine 
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Table 70 Molecular and cellular functions significantly associated with the genes identified to be differentially expressed in 
advanced AD brain (neocortical stage: ApoE 3/4) compared to control (ApoE 3/3) 
Molecular and Cellular Functions p-value Number of Genes 
Cellular Growth and Proliferation  <0.05 40 
Cellular Movement  <0.05 29 
Cellular Development  <0.05 27 
Cell-To-Cell Signalling and Interaction  <0.05 33 
Cell Death  <0.05 33 
 
 
Table 71 Diseases and disorders significantly associated with the genes identified to be differentially expressed in advanced AD 
brain (neocortical stage: ApoE 3/4) compared to control (ApoE 3/3) 
Diseases and Disorders p-value Number of Genes 
Neurological Disease  <0.05 68 
Genetic Disorder  <0.05 95 
Cancer  <0.05 53 
Cardiovascular Disease  <0.05 45 
Endocrine System Disorders  <0.05 42 
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Table 72 Physiological systems significantly associated with the genes identified to be differentially expressed in advanced AD 
brain (neocortical stage: ApoE 3/4) compared to control (ApoE 3/3) 
Physiological system development and function p-value Number of Genes 
Organismal development <0.05 13 
Lymphoid tissue structure and function <0.05 7 
Cardiovascular system development and function <0.05 15 
Skeletal and muscular system development and function <0.05 12 
Tissue development <0.05 24 
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Table 73 Top networks associated with the genes identified to be differentially expressed in advanced AD brain (ApoE 3/4)   
  compared to control (ApoE3/3) 
Network Score Focus 
Molecules 
Top Functions 
 1  27  16  Organismal Development, Tissue Development, Cell Morphology 
 2  25  15  Cell Signaling, Cellular Function and Maintenance, Molecular Transport 
 3  25  15  Renal and Urological Disease, Embryonic Development, Tissue Development 
 4  24  16  Cell Cycle, Hair and Skin Development and Function, Cell-To-Cell Signaling and Interaction 
 5  19  12  Cellular Development, Nervous System Development and Function, Inflammatory Response 
 6  19  12  Cell Signaling, DNA Replication, Recombination, and Repair, Nucleic Acid Metabolism 
 7  17  11  Auditory and Vestibular System Development and Function, Organ Development, Organ Morphology 
 8  15  10  Cellular Function and Maintenance, Skeletal and Muscular System Development and Function, Cell Cycle 
 9  11  9  Gene Expression, Cancer, Cell Cycle 
 10  7  6  Lipid Metabolism, Small Molecule Biochemistry, Cell Signaling 
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Table 74 Canonical pathways significantly associated with the genes identified to be differentially expressed in advanced AD brain  
(ApoE 3/4) compared to control (ApoE3/3) 
Canonical pathway p-value 
 mTOR Signaling <0.001 
 Corticotropin Releasing Hormone Signaling <0.001 
 Thrombopoietin Signaling <0.001 
 Insulin Receptor Signaling <0.001 
 Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes <0.001 
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Table 75 Established mTOR signalling genes that were differentially expressed in advanced AD brain (ApoE 3/4) compared to 
 control (ApoE 3/3) 
Symbol Entrez Gene Name Location Type(s) 
EIF4E 
eukaryotic translation initiation 
factor 4E Cytoplasm translation regulator 
FKBP1A 
FK506 binding protein 1A, 
12kDa Cytoplasm enzyme 
MAPK1 
mitogen-activated protein kinase 
1 Cytoplasm kinase 
PLD4 
phospholipase D family, member 
4 unknown enzyme 
PRKCA protein kinase C, alpha Cytoplasm kinase 
PRKCH protein kinase C, eta Cytoplasm kinase 
PRKCI protein kinase C, iota Cytoplasm kinase 
RPS6KB2 
ribosomal protein S6 kinase, 
70kDa, polypeptide 2 Cytoplasm kinase 
TSC2 tuberous sclerosis 2 Cytoplasm other 
VEGFA vascular endothelial growth factor Extracellular Space growth factor 
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Symbol Entrez Gene Name Location Type(s) 
A 
EIF4E 
eukaryotic translation initiation 
factor 4E Cytoplasm translation regulator 
FKBP1A 
FK506 binding protein 1A, 
12kDa Cytoplasm enzyme 
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APPENDIX 10 
 
ALTERED RAPAMYCIN RESPONSE ELEMENTS AS A RESULT OF ADVANCED AD ONLY 
 
Table 76 Genes that were differentially expressed as a result of advanced AD only  
(genes that were differentially expressed in advanced AD (ApoE 3/4) compared to control (ApoE 3/3) AND 
differentially expressed in advanced AD (ApoE 3/3) compared to control (ApoE 3/3)) 
Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
 ADAMTS2 
 ADAM metallopeptidase with thrombospondin type 1 
motif, 2  Extracellular Space  peptidase x x 
 
ADAMTSL5  ADAMTS-like 5  Extracellular Space  other  x 
 AHNAK2  AHNAK nucleoprotein 2  unknown  other   
  ankyrin repeat domain 36B  unknown  other   
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
ANKRD36B 
 AP1S1  adaptor-related protein complex 1, sigma 1 subunit  Cytoplasm  transporter x  
 ATAD3B  ATPase family, AAA domain containing 3B  Nucleus  other   
 ATF7IP  activating transcription factor 7 interacting protein  Nucleus 
 transcription 
regulator   
 ATRNL1  attractin-like 1  unknown  other  x 
 BARX2  BARX homeobox 2  Nucleus 
 transcription 
regulator   
 BCOR  BCL6 corepressor  Nucleus 
 transcription 
regulator   
 BMP7  bone morphogenetic protein 7  Extracellular Space  growth factor x x 
 BPI  bactericidal/permeability-increasing protein  Plasma Membrane  transporter x  
 BTNL9  butyrophilin-like 9  unknown  other   
 C16orf75  chromosome 16 open reading frame 75  unknown  other   
 C18orf26  chromosome 18 open reading frame 26  unknown  other   
 C1orf127  chromosome 1 open reading frame 127  unknown  other   
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
 CACNA1D 
 calcium channel, voltage-dependent, L type, alpha 1D 
subunit  Plasma Membrane  ion channel x  
 CC2D2A  coiled-coil and C2 domain containing 2A  unknown  other   
 CCL2  chemokine (C-C motif) ligand 2  Extracellular Space  cytokine  x 
 CCR1  chemokine (C-C motif) receptor 1  Plasma Membrane 
 G-protein coupled 
receptor x  
 CEACAM6 
 carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen)  Plasma Membrane  other   
 CEP68  centrosomal protein 68kDa  Cytoplasm  other   
 CLU  clusterin  Extracellular Space  other  X 
 CPXM2  carboxypeptidase X (M14 family), member 2 Extracellular Space  peptidase x X 
 CREB3L4  cAMP responsive element binding protein 3-like 4  Nucleus 
 transcription 
regulator   
 CRP  C-reactive protein, pentraxin-related  Extracellular Space  other  x 
 CSN2  casein beta  Extracellular Space  kinase x x 
 CTDSP1  CTD (carboxy-terminal domain, RNA polymerase II,  Nucleus  phosphatase x  
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
polypeptide A) small phosphatase 1 
 DCD  dermcidin  Extracellular Space  other  x 
 DCLK1  doublecortin-like kinase 1  Cytoplasm  kinase x  
 DLG2  discs, large homolog 2 (Drosophila)  Plasma Membrane  kinase x  
 DNAH6  dynein, axonemal, heavy chain 6  unknown  other   
 DRP2  dystrophin related protein 2  Plasma Membrane  other   
 DYNC2LI1  dynein, cytoplasmic 2, light intermediate chain 1  Cytoplasm  other   
 DZIP3  DAZ interacting protein 3, zinc finger  Cytoplasm  enzyme x  
 EIF4E  eukaryotic translation initiation factor 4E  Cytoplasm 
 translation 
regulator   
 ELAVL4 
 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D)  Cytoplasm  other   
 ENTPD8  ectonucleoside triphosphate diphosphohydrolase 8  unknown  enzyme x  
 FAM155A  family with sequence similarity 155, member A  unknown  other   
 FAM64A  family with sequence similarity 64, member A  unknown  other   
 FAT3  FAT tumor suppressor homolog 3 (Drosophila)  unknown  other   
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
 FGF11  fibroblast growth factor 11  Extracellular Space  growth factor x x 
 FJX1  four jointed box 1 (Drosophila)  Extracellular Space  other  x 
 FKBP1A  FK506 binding protein 1A, 12kDa  Cytoplasm  enzyme x  
 FN3K  fructosamine 3 kinase  unknown  kinase x  
 GABBR2  gamma-aminobutyric acid (GABA) B receptor, 2  Plasma Membrane 
 G-protein coupled 
receptor x  
 GLI2  GLI family zinc finger 2  Nucleus 
 transcription 
regulator   
 HDAC5  histone deacetylase 5  Nucleus 
 transcription 
regulator   
 HHIPL1  HHIP-like 1  unknown  other   
 HIST1H4E  histone cluster 1, H4e  unknown  other   
 HYDIN  hydrocephalus inducing homolog (mouse)  unknown  other   
 IL6  interleukin 6 (interferon, beta 2)  Extracellular Space  cytokine  x 
 IRS2  insulin receptor substrate 2  Cytoplasm  other   
 KCNAB1  potassium voltage-gated channel, shaker-related  Plasma Membrane  ion channel x  
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
subfamily, beta member 1 
 KCND2 
 potassium voltage-gated channel, Shal-related 
subfamily, member 2  Plasma Membrane  ion channel x  
 KCNG4 
 potassium voltage-gated channel, subfamily G, 
member 4  Plasma Membrane  ion channel x  
 KLF2  Kruppel-like factor 2 (lung)  Nucleus 
 transcription 
regulator   
 KLHL24  kelch-like 24 (Drosophila)  unknown  other   
 LYPD2  LY6/PLAUR domain containing 2  unknown  other   
 MAPK1  mitogen-activated protein kinase 1  Cytoplasm  kinase x  
 MAPK4  mitogen-activated protein kinase 4  Cytoplasm  kinase x  
 MCTP1  multiple C2 domains, transmembrane 1  unknown  other   
 MMP16  matrix metallopeptidase 16 (membrane-inserted)  Extracellular Space  peptidase x x 
 MOXD1  monooxygenase, DBH-like 1  Cytoplasm  enzyme x  
 MYF6  myogenic factor 6 (herculin)  Nucleus 
 transcription 
regulator   
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
 NTSR1  neurotensin receptor 1 (high affinity)  Plasma Membrane 
 G-protein coupled 
receptor x  
 PCDHGA9  protocadherin gamma subfamily A, 9  unknown  other   
 PEX5L  peroxisomal biogenesis factor 5-like  Cytoplasm  other   
 PHLDA3  pleckstrin homology-like domain, family A, member 3  unknown  other   
 PIM1  pim-1 oncogene  Cytoplasm  kinase x  
 PLD4  phospholipase D family, member 4  unknown  enzyme x  
 POU4F2  POU class 4 homeobox 2  Nucleus 
 transcription 
regulator   
 PRKCH  protein kinase C, eta  Cytoplasm  kinase x  
 PRODH2  proline dehydrogenase (oxidase) 2  Cytoplasm  enzyme x  
 RAB3C  RAB3C, member RAS oncogene family  Cytoplasm  enzyme x  
 RNF128  ring finger protein 128  Cytoplasm  enzyme x  
 RPS6KB2  ribosomal protein S6 kinase, 70kDa, polypeptide 2  Cytoplasm  kinase x  
 RUNX1T1 
 runt-related transcription factor 1; translocated to, 1 
(cyclin D-related)  Nucleus 
 transcription 
regulator   
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
 SCN8A  sodium channel, voltage gated, type VIII, alpha subunit  Plasma Membrane  ion channel x  
 SEMA4C 
 sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 4C  Plasma Membrane  other   
 SEMA5A 
 sema domain, seven thrombospondin repeats (type 1 
and type 1-like), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 5A  Plasma Membrane 
 transmembrane 
receptor x  
 SERPIND1 
 serpin peptidase inhibitor, clade D (heparin cofactor), 
member 1  Extracellular Space  other  x 
 SERPINE1 
 serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1  Extracellular Space  other  x 
 SGTA 
 small glutamine-rich tetratricopeptide repeat (TPR)-
containing, alpha  Cytoplasm  other   
 SLC18A3 
 solute carrier family 18 (vesicular acetylcholine), 
member 3  Plasma Membrane  transporter x  
 SLC22A18  solute carrier family 22, member 18  Plasma Membrane  transporter x  
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
 SLC25A27  solute carrier family 25, member 27  Cytoplasm  transporter x  
 SLC38A3  solute carrier family 38, member 3  Plasma Membrane  transporter x  
 SLITRK1  SLIT and NTRK-like family, member 1  unknown  other   
 SMAD3  SMAD family member 3  Nucleus 
 transcription 
regulator   
 SORBS2  sorbin and SH3 domain containing 2  Nucleus  other   
 SPRED2  sprouty-related, EVH1 domain containing 2  Extracellular Space  cytokine  x 
 STAG3L1  stromal antigen 3-like 1  unknown  other   
 STARD13 
 StAR-related lipid transfer (START) domain 
containing 13  Cytoplasm  other   
 STX1B  syntaxin 1B  Plasma Membrane  ion channel x  
 TAOK1  TAO kinase 1  Cytoplasm  kinase x  
 TGM4  transglutaminase 4 (prostate)  Extracellular Space  enzyme x x 
 TM4SF18  transmembrane 4 L six family member 18  unknown  other   
 TMEM56  transmembrane protein 56  unknown  other   
 TSC2  tuberous sclerosis 2  Cytoplasm  other   
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Gene ID Full name Location Type Possible 
drug 
targets 
Possible 
bio-
markers 
 VEGFA  vascular endothelial growth factor A  Extracellular Space  growth factor x x 
 WDR40B  DDB1 and CUL4 associated factor 12-like 1  unknown  other   
 YPEL1  yippee-like 1 (Drosophila)  Nucleus  enzyme x  
 ZC3H6  zinc finger CCCH-type containing 6  unknown  other   
 
 
Table 77  Drugs that target the genes identified as differentially expressed as a result of advanced AD only 
Gene symbol Drugs 
 VEGFA  bevacizumab, ranibizumab, aflibercept, pegaptanib 
 NTSR1  contulakin-G 
 FKBP1A  everolimus 
 CACNA1D  MEM-1003, clevidipine butyrate, mibefradil, bepridil, nisoldipine, isradipine, nicardipine 
 SCN8A  riluzole 
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APPENDIX 11 
 
ALTERED RAPAMYCIN RESPONSE ELEMENTS AS A RESULT OF THE APOE ALLELE 
 
Table 78 Transcripts that were differentially expressed as a result of the ApoE 4 allele only (transcripts that were differentially 
expressed in advanced AD (ApoE 3/4) compared to control (ApoE 3/3) but NOT differentially expressed in advanced AD 
(ApoE 3/3) compared to control (ApoE 3/3)) 
Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
 LOXL4  lysyl oxidase-like 4 Extracellular Space  enzyme x x 
 PCSK2  proprotein convertase subtilisin/kexin type 2 Extracellular Space  peptidase x x 
 CCL1  chemokine (C-C motif) ligand 1 Extracellular Space  cytokine  x 
 VSNL1  visinin-like 1  Cytoplasm  other  x 
 SCGN  secretagogin, EF-hand calcium binding protein  Cytoplasm  other  x 
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Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
 RIMS2  regulating synaptic membrane exocytosis 2  Cytoplasm  other  x 
KIAA168
3  KIAA1683  Cytoplasm  other  x 
 GFAP  glial fibrillary acidic protein  Cytoplasm  other  x 
 CPLX2  complexin 2  Cytoplasm  other  x 
 ABLIM2  actin binding LIM protein family, member 2  Cytoplasm  other  x 
 WFDC6  WAP four-disulfide core domain 6 Extracellular Space  other  x 
 NPTX1  neuronal pentraxin I Extracellular Space  other  x 
 NEGR1  neuronal growth regulator 1 Extracellular Space  other  x 
 LECT1  leukocyte cell derived chemotaxin 1 Extracellular Space  other  x 
 DEFB119  defensin, beta 119 Extracellular Space  other  x 
 CYR61  cysteine-rich, angiogenic inducer, 61 Extracellular Space  other  x 
 ZBTB20  zinc finger and BTB domain containing 20 Nucleus  other  x 
 PNRC1  proline-rich nuclear receptor coactivator 1 Nucleus  other  x 
 ELAVL3 
 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 3 (Hu antigen C) Nucleus  other  x 
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Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
 CDH13  cadherin 13, H-cadherin (heart) Plasma Membrane  other  x 
 
ZCCHC12  zinc finger, CCHC domain containing 12 unknown  other  x 
 YPEL5  yippee-like 5 (Drosophila)  unknown  other  x 
 
DQ24931
0  urothelial cancer associated 1 (non-protein coding)  unknown  other  x 
 SLC35F3  solute carrier family 35, member F3  unknown  other  x 
 PHYHD1  phytanoyl-CoA dioxygenase domain containing 1  unknown  other  x 
 MEG3  maternally expressed 3 (non-protein coding)  unknown  other  x 
 ITGBL1  integrin, beta-like 1 (with EGF-like repeat domains)  unknown  other  x 
 GIGYF1  GRB10 interacting GYF protein 1  unknown  other  x 
 
LRRC37A
4 
 leucine rich repeat containing 37, member A4 
(pseudogene)  unknown  other  x 
 FBXL16  F-box and leucine-rich repeat protein 16  unknown  other  x 
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Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
FAM171B family with sequence similarity 171, member B  unknown  other  x 
CCDC85
A  coiled-coil domain containing 85A  unknown  other  x 
CCDC28
A  coiled-coil domain containing 28A  unknown  other  x 
 C17orf99  chromosome 17 open reading frame 99  unknown  other  x 
KIAA164
1  ankyrin repeat domain 36B  unknown  other  x 
 ACTRT1  actin-related protein T1  unknown  other  x 
 UBE2M 
 ubiquitin-conjugating enzyme E2M (UBC12 
homolog, yeast)  Cytoplasm  enzyme x  
 PTGS2 
 prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase)  Cytoplasm  enzyme x  
 PAOX  polyamine oxidase (exo-N4-amino)  Cytoplasm  enzyme x  
 
NMNAT2  nicotinamide nucleotide adenylyltransferase 2  Cytoplasm  enzyme x  
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Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
 HMGCS2 
 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial)  Cytoplasm  enzyme x  
 
GALNT1
0 
 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10 (GalNAc-T10)  Cytoplasm  enzyme x  
 ACSL6  acyl-CoA synthetase long-chain family member 6  Cytoplasm  enzyme x  
 GNG8 
 guanine nucleotide binding protein (G protein), 
gamma 8  Plasma Membrane  enzyme x  
 PDE8B  phosphodiesterase 8B  unknown  enzyme x  
 SSTR1  somatostatin receptor 1  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 OR52B2  olfactory receptor, family 52, subfamily B, member 2  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 GPR176  G protein-coupled receptor 176  Plasma Membrane  G-protein x  
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Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
coupled 
receptor 
 GPR109B  G protein-coupled receptor 109B  Plasma Membrane 
 G-protein 
coupled 
receptor x  
 TRPV1 
 transient receptor potential cation channel, subfamily 
V, member 1  Plasma Membrane  ion channel x  
 GRIA2  glutamate receptor, ionotropic, AMPA 2  Plasma Membrane  ion channel x  
 PRKCI  protein kinase C, iota  Cytoplasm  kinase x  
 PRKCA  protein kinase C, alpha  Cytoplasm  kinase x  
 ACVR2B  activin A receptor, type IIB  Plasma Membrane  kinase x  
 RORB  RAR-related orphan receptor B  Nucleus 
 ligand-
dependent 
nuclear 
receptor x  
  tumor necrosis factor receptor superfamily, member  Plasma Membrane  x  
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Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
TNFRSF1
0C 
10c, decoy without an intracellular domain transmembran
e receptor 
 
TIMM17
B 
 translocase of inner mitochondrial membrane 17 
homolog B (yeast)  Cytoplasm  transporter x  
 SLC6A15 
 solute carrier family 6 (neutral amino acid 
transporter), member 15  Plasma Membrane  transporter x  
 SLC6A11 
 solute carrier family 6 (neurotransmitter transporter, 
GABA), member 11  Plasma Membrane  transporter x  
 CDCP2  CUB domain containing protein 2  unknown  transporter x  
 EVI1  MDS1 and EVI1 complex locus  Nucleus 
transcription 
regulator   
 EGR1  early growth response 1  Nucleus 
transcription 
regulator   
 ABTB1  ankyrin repeat and BTB (POZ) domain containing 1  Cytoplasm 
translation 
regulator   
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Gene 
symbol 
Full name Location Type Possible drug 
targets 
Possible 
biomarker
s 
 
BRUNOL
4  CUGBP, Elav-like family member 4  Nucleus 
 translation 
regulator   
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APPENDIX 12 
 
Table 79 Transcripts that were differentially expressed in brain affected by AD, irrespective of disease severity  
(Overlap in differentially expressed transcripts in mild AD and advanced AD). 
Gene ID Full name Location Type Possible 
drug targets 
Possible 
biomarker
s 
 
ADAMTS2 
 ADAM metallopeptidase with 
thrombospondin type 1 motif, 2  Extracellular Space  peptidase 
X X 
 CCL2  chemokine (C-C motif) ligand 2  Extracellular Space  cytokine  X 
 ENTPD8 
 ectonucleoside triphosphate 
diphosphohydrolase 8  unknown  enzyme 
X  
 FAM64A  family with sequence similarity 64, member A  unknown  other   
 FN3K  fructosamine 3 kinase  unknown  kinase X  
 HDAC5  histone deacetylase 5  Nucleus  transcription regulator   
 IL6  interleukin 6 (interferon, beta 2)  Extracellular Space  cytokine  X 
 MOXD1  monooxygenase, DBH-like 1  Cytoplasm  enzyme X  
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Gene ID Full name Location Type Possible 
drug targets 
Possible 
biomarker
s 
 PLD4  phospholipase D family, member 4  unknown  enzyme X  
 POU4F2  POU class 4 homeobox 2  Nucleus  transcription regulator   
 PRODH2  proline dehydrogenase (oxidase) 2  Cytoplasm  enzyme X  
 RUNX1T1 
 runt-related transcription factor 1; translocated 
to, 1 (cyclin D-related)  Nucleus  transcription regulator 
  
 SEMA4C 
 sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4C  Plasma Membrane  other 
  
 
SLC22A18  solute carrier family 22, member 18  Plasma Membrane  transporter 
X  
 TGM4  transglutaminase 4 (prostate)  Extracellular Space  enzyme X  
 
 
                APPENDIX 12 
326 
 
Table 80   Transcripts that were differentially expressed in advanced AD, but not in mild AD (transcripts that were differentially 
expressed in advanced AD compared to control but not differentially expressed in mild AD compared to control). 
Gene Full name Location Type Possible drug 
target 
Possible 
biomarker 
ADAMTSL5 ADAMTS-like 5 Extracellular Space  other  x 
 AHNAK2  AHNAK nucleoprotein 2 unknown  other   
 
ANKRD36B  ankyrin repeat domain 36B unknown  other   
 AP1S1  adaptor-related protein complex 1, sigma 1 subunit Cytoplasm  transporter x  
 ATAD3B  ATPase family, AAA domain containing 3B Nucleus  other   
 ATF7IP  activating transcription factor 7 interacting protein Nucleus 
 transcription 
regulator    
 ATRNL1  attractin-like 1 unknown  other   
 BARX2  BARX homeobox 2 Nucleus 
 transcription 
regulator    
 BCOR  BCL6 corepressor Nucleus 
 transcription 
regulator    
 BMP7  bone morphogenetic protein 7 Extracellular Space  growth factor x x 
 BPI  bactericidal/permeability-increasing protein  Plasma Membrane  transporter x   
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Gene Full name Location Type Possible drug 
target 
Possible 
biomarker 
 BTNL9  butyrophilin-like 9  unknown  other   
 C16orf75  chromosome 16 open reading frame 75  unknown  other   
 C18orf26  chromosome 18 open reading frame 26  unknown  other   
 C1orf127  chromosome 1 open reading frame 127  unknown  other   
 CACNA1D 
 calcium channel, voltage-dependent, L type, alpha 
1D subunit  Plasma Membrane  ion channel x   
 CC2D2A  coiled-coil and C2 domain containing 2A  unknown  other   
 CCR1  chemokine (C-C motif) receptor 1  Plasma Membrane 
 G-protein 
coupled 
receptor x   
 CEACAM6 
 carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen)  Plasma Membrane  other   
 CEP68  centrosomal protein 68kDa  Cytoplasm  other   
 CLU  clusterin Extracellular Space  other  x 
 CPXM2  carboxypeptidase X (M14 family), member 2 Extracellular Space  peptidase x x 
 CREB3L4  cAMP responsive element binding protein 3-like 4  Nucleus 
 transcription 
regulator     
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Gene Full name Location Type Possible drug 
target 
Possible 
biomarker 
 CRP  C-reactive protein, pentraxin-related Extracellular Space  other   x 
 CSN2  casein beta Extracellular Space  kinase x x 
 CTDSP1 
 CTD (carboxy-terminal domain, RNA polymerase 
II, polypeptide A) small phosphatase 1  Nucleus  phosphatase x   
 WDR40B  DDB1 and CUL4 associated factor 12-like 1  unknown  other    
 DCD  dermcidin 
 Extracellular 
Space  other   x 
 DCLK1  doublecortin-like kinase 1  Cytoplasm  kinase x   
 DLG2  discs, large homolog 2 (Drosophila)  Plasma Membrane  kinase x   
 DNAH6  dynein, axonemal, heavy chain 6  unknown  other    
 DRP2  dystrophin related protein 2  Plasma Membrane  other    
 DYNC2LI1  dynein, cytoplasmic 2, light intermediate chain 1  Cytoplasm  other    
 DZIP3  DAZ interacting protein 3, zinc finger  Cytoplasm  enzyme x   
 EIF4E  eukaryotic translation initiation factor 4E  Cytoplasm 
 translation 
regulator     
 ELAVL4 
 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D)  Cytoplasm  other    
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 FAM155A  family with sequence similarity 155, member A  unknown  other    
 FAT3  FAT tumor suppressor homolog 3 (Drosophila)  unknown  other    
 FGF11  fibroblast growth factor 11 Extracellular Space  growth factor x x 
 FJX1  four jointed box 1 (Drosophila) Extracellular Space  other   x 
 FKBP1A  FK506 binding protein 1A, 12kDa  Cytoplasm  enzyme x   
 GABBR2  gamma-aminobutyric acid (GABA) B receptor, 2  Plasma Membrane 
 G-protein 
coupled 
receptor x   
 GLI2  GLI family zinc finger 2  Nucleus 
 transcription 
regulator     
 HHIPL1  HHIP-like 1  unknown  other    
 HIST1H4E  histone cluster 1, H4e  unknown  other    
 HYDIN  hydrocephalus inducing homolog (mouse)  unknown  other    
 IRS2  insulin receptor substrate 2  Cytoplasm  other    
 KCNAB1 
 potassium voltage-gated channel, shaker-related 
subfamily, beta member 1 Plasma Membrane  ion channel x  
 KCND2  potassium voltage-gated channel, Shal-related Plasma Membrane  ion channel x   
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subfamily, member 2 
 KCNG4 
 potassium voltage-gated channel, subfamily G, 
member 4  Plasma Membrane  ion channel x   
 KLF2  Kruppel-like factor 2 (lung) Nucleus 
 transcription 
regulator     
 KLHL24  kelch-like 24 (Drosophila)  unknown  other    
 LYPD2  LY6/PLAUR domain containing 2  unknown  other    
 MAPK1  mitogen-activated protein kinase 1  Cytoplasm  kinase x   
 MAPK4  mitogen-activated protein kinase 4  Cytoplasm  kinase x   
 MCTP1  multiple C2 domains, transmembrane 1  unknown  other    
 MMP16  matrix metallopeptidase 16 (membrane-inserted) Extracellular Space  peptidase x x 
 MYF6  myogenic factor 6 (herculin)  Nucleus 
 transcription 
regulator     
 NTSR1  neurotensin receptor 1 (high affinity)  Plasma Membrane 
 G-protein 
coupled 
receptor x   
 PCDHGA9  protocadherin gamma subfamily A, 9  unknown  other    
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 PEX5L  peroxisomal biogenesis factor 5-like  Cytoplasm  other    
 PHLDA3 
 pleckstrin homology-like domain, family A, 
member 3  unknown  other    
 PIM1  pim-1 oncogene  Cytoplasm  kinase x   
 PRKCH  protein kinase C, eta  Cytoplasm  kinase x   
 RAB3C  RAB3C, member RAS oncogene family  Cytoplasm  enzyme x   
 RNF128  ring finger protein 128  Cytoplasm  enzyme x   
 RPS6KB2  ribosomal protein S6 kinase, 70kDa, polypeptide 2  Cytoplasm  kinase x   
 SCN8A 
 sodium channel, voltage gated, type VIII, alpha 
subunit  Plasma Membrane  ion channel x   
 SEMA5A 
 sema domain, seven thrombospondin repeats (type 1 
and type 1-like), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 5A  Plasma Membrane 
 transmembrane 
receptor x   
 SERPIND1 
 serpin peptidase inhibitor, clade D (heparin 
cofactor), member 1 
 Extracellular 
Space  other   x 
 SERPINE1 
 serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 
 Extracellular 
Space  other   x 
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 SGTA 
 small glutamine-rich tetratricopeptide repeat (TPR)-
containing, alpha  Cytoplasm  other    
 SLC18A3 
 solute carrier family 18 (vesicular acetylcholine), 
member 3  Plasma Membrane  transporter x   
 SLC25A27  solute carrier family 25, member 27  Cytoplasm  transporter x   
 SLC38A3  solute carrier family 38, member 3  Plasma Membrane  transporter x   
 SLITRK1  SLIT and NTRK-like family, member 1  unknown  other    
 SMAD3  SMAD family member 3  Nucleus 
 transcription 
regulator     
 SORBS2  sorbin and SH3 domain containing 2  Nucleus  other    
 SPRED2  sprouty-related, EVH1 domain containing 2 
 Extracellular 
Space  cytokine   x 
 STAG3L1  stromal antigen 3-like 1  unknown  other    
 STARD13 
 StAR-related lipid transfer (START) domain 
containing 13  Cytoplasm  other    
 STX1B  syntaxin 1B  Plasma Membrane  ion channel x   
 TAOK1  TAO kinase 1  Cytoplasm  kinase x   
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 TM4SF18  transmembrane 4 L six family member 18  unknown  other    
 TMEM56  transmembrane protein 56  unknown  other    
 TSC2  tuberous sclerosis 2  Cytoplasm  other    
 VEGFA  vascular endothelial growth factor A 
 Extracellular 
Space  growth factor x x 
 YPEL1  yippee-like 1 (Drosophila)  Nucleus  enzyme x   
ZC3H6 
  zinc finger CCCH-type containing 6  unknown  other    
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